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Abstract 
 
Beta-endorphin (BE 1-31) is a prominent endogenous opioid peptide that plays an 
important role in pain and inflammation. Inflammation is characterised by the 
infiltration of leukocytes, these cells migrating specifically to inflamed tissue and 
producing opioid peptides such as BE 1-31. Stimulation of these opioid peptide-
containing leukocytes by local factors results in receptor specific release within 
inflamed tissue and subsequent activation of opioid receptors to reduce pain. BE 1-
31 is highly susceptible to enzymatic degradation in the harsh conditions within 
inflamed tissue, leading to the generation of a number of peptide fragments, some 
possessing opioid activity, whilst others may affect other molecular mechanisms 
relevant to inflammation. The central hypothesis of this thesis is that BE 1-31 is 
rapidly biotransformed into bioactive fragments that possess activity at opioid 
receptors and/or modulate inflammatory processes. This thesis firstly studies the 
biotransformation of BE 1-31 in inflamed tissue homogenates at the acidic pH found 
in the inflammatory milieu. Secondly, the role of identified major N-terminal 
fragments of BE 1-31 in the modulation of cell signals associated with pain and 
inflammation is examined. 
 
In inflamed tissue homogenates at pH 5.5, BE 1-31 was found to undergo rapid 
biotransformation into a small number of N-terminal fragments as well as an array of 
C-terminal and intermediate fragments. Only a small number of N-terminal fragments 
were detectable over a two-hour period of incubation within inflamed tissue. From 
these studies BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20 were seen to exhibit 
higher mean residence time (MRT) values when compared to other N-terminal 
fragments.  Moreover, BE 1-11 was detected in early fractions of biotransformed BE 
1-17 and BE 1-13, indicating the importance of BE 1-11 as a major fragment in the 
biotransformation of BE 1-31.  
 
N-terminal biotransformed fragments, like the parent molecule, BE 1-31, may 
activate opioid receptors located on the peripheral terminals of sensory neurons to 
produce peripheral analgesia during inflammation. Characterisation of the activity of 
opioid receptor agonist action was determined by the assessment of the inhibition of 
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forskolin (FSK)-stimulated adenylyl cyclase activity; this opioid agonist action 
resulted in decreased measurable levels of cAMP production. This study 
demonstrated that fragments of BE 1-31 (BE 1-11, BE 1-13, BE 1-17, and BE 1-20) 
inhibited FSK-stimulated cAMP in HEK-MOP cells (HEK cells transfected with μ-
opioid receptors) and HEK-DOP cells (HEK cells transfected with δ-opioid 
receptors). The potency of BE 1-11, BE 1-13, BE 1-17 and BE 1-20 in cAMP 
inhibition was not significantly different from that of the inhibitory action of BE 1-31 in 
HEK-MOP and HEK-DOP cells. However, BE 1-9 displayed partial agonist activity at 
MOP, whilst full agonist activity was observed at DOP. BE 1-31 and all fragments 
studied (BE 1-11, BE 1-13, BE 1-17, and BE 1-20) displayed limited potency at κ-
opioid receptors (KOP).  
 
The ability of BE 1-31 and selected fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, 
and BE 1-20) to modulate cell signals associated with inflammation such as 
modulation of interleukin-1beta (IL-1β) release and modulation of nuclear factor-
kappaB (NF-κB) translocation was also investigated. BE 1-31 and selected 
fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20) were incubated with 
differentiated THP-1 cells induced by LPS to study their modulation of IL-1β release. 
A significant decrease in IL-1β release was observed when shorter fragments of BE 
1-31 (BE 1-9, BE 1-11, and BE 1-13) at concentrations of 0.1 μM were added to 
differentiated THP-1 cells-induced by LPS. In contrast, at the same concentration BE 
1-17, BE 1-20, and BE 1-31 increased IL-1β release from differentiated THP-1 cells. 
To determine the mechanism underlying the effect of BE 1-31 and its selected 
fragments on release of IL-1β, naloxone was used. Naloxone could not block the 
effect of BE 1-13, BE 1-17, and BE 1-20. However, the effect of naloxone on the 
modulation of IL-1β releases with BE 1-9, BE 1-11, and BE 1-31 was indistinct. 
 
One of the major components in inflammatory signalling is the activation NF-κB 
translocation resulting in the transcription of pro-inflammatory genes such as IL-1β. 
The modulation of NF-κB translocation by BE 1-31 and selected fragments was 
assessed in differentiated THP-1 cells and differentiated SHSY5Y cells. BE 1-13, BE 
1-17, and BE 1-20 did not display significant modulation of NF-κB translocation in 
differentiated THP-1 cells. However, these fragments increased NF-κB translocation 
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in differentiated SHSY5Y cells. Fragments BE 1-9 and BE 1-11 significantly reduced 
NF-κB translocation in differentiated THP-1 cells, indicating not only a differential role 
of fragments from their effects on IL-1β but also a differential activity of the 
biotransformed fragments on NF-κB translocation. 
 
Overall this thesis details the in vitro biotransformation of BE1-31 in inflammation 
and demonstrates the effect of the biotransformed fragments on the modulation of 
inflammatory signals. Consequently, the effects of BE 1-31 may not be attributable to 
BE 1-31 alone in peripheral analgesia in inflammation. Biotransformed fragments of 
BE 1-31 (BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20) that reside in inflamed 
tissue for extended periods, may produce a range of effects on inflammatory signals 
and contribute to the role played by BE 1-31 in disease states that involve 
inflammation. 
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 :Literature review Chapter 1
 
 
 
1.1. Introduction 
 
Peripheral analgesia during inflammation results from the activation of opioid 
receptors located on sensory neurons by endogenous opioid peptides (1-3). Three 
major opioid receptor families have been characterised, namely:  µ, κ and δ opioid 
receptors (MOP, KOP, and DOP respectively). Opioid receptors belong to the G 
protein-coupled receptor (GPCR) family (4), and are expressed not only within the 
central nervous system (CNS) but also on peripheral sensory nerve terminals (5).  
Endogenous opioid peptides have differential affinities for the major classes of opioid 
receptors. One of the most abundant opioid peptides, beta-endorphin (BE 1-31), has 
been shown to play a crucial role in pain (6). ΒE 1-31 is a non-selective endogenous 
peptide with highest affinity for MOP and DOP (3). Endogenous opioid peptides are 
synthesised in the CNS, peripheral nervous system and within the immune system. 
These peptides have a crucial role in the reward pathway and analgesia pathways, 
when released in the CNS, however more recently they have been shown to be 
released by leukocytes at sites of inflammation thus mediating pain peripherally (2, 
7-10). During inflammation, the production of endogenous opioid peptides is 
increased and subsequently more endogenous opioid peptides are available for 
release within the inflamed tissue (2). In addition, evidence suggests that BE 1-31 
modulate the immune response in inflammation including the production of pro-
inflammatory cytokines such as interleukin-1beta (IL-1β), Interleukin-6 (IL-6), and 
Tumour necrosis factor (TNF-α). In addition, nuclear factor-kappaB transcription 
factor (NF-κB) is a major component in the inflammatory signalling pathway and is 
responsible for the transcription of mentioned pro-inflammatory genes (11, 12). 
 
Endogenous opioid peptides are degraded by a variety of enzymes. The metabolism 
of BE 1-31 has been studied in different biological fluids and tissue, however, there 
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is limited information on the contribution of BE 1-31 fragments to analgesia and 
modulation of inflammatory signals (13, 14). Thus, the assessment of the effect of 
BE 1-31 fragments on modulation of cAMP, modulation of IL-1β release and 
modulation of NF-κB form the objectives of this thesis. 
 
1.2. Endogenous Opioid peptides 
  
Four families of endogenous opioid peptides are distinguished in the CNS and 
neuroendocrine system. Each peptide family is derived from the four precursor 
proteins (Proopiomelanocortin (POMC), Proenkephalin (PENK), Prodynorphin 
(ProDYN), and Pronociceptin/orphanin FQ. These precursors are expressed in the 
CNS and also in peripheral tissue (15). The resultant opioid peptides arising from 
these precursors are the groups of peptides called Endorphins, Enkephalins, 
Dynorphins and Nociceptins (Table 1.1). POMC is the 241 amino acid precursor 
polypeptide of BE 1-31. The POMC gene is expressed in both the anterior and 
intermediate lobes of the pituitary gland (16). POMC expression by leukocytes was 
first demonstrated by Blalock and Smith (17). Immune cells are able to synthesise 
full-length POMC transcripts and the release of various immune and inflammatory 
mediators induces this production (18).  POMC and PENK-mRNAs were detected in 
immune cells of inflamed, but not in non-inflamed tissue (19). Sun et al. showed that 
PDYN mRNA can be expressed in U-937 macrophage cells, but not in human T and 
B lymphocytes (20) alluding to the potential for different roles of opioid peptides in 
immune modulation based on cell type.  
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Table 1.1. Opioid peptides derived from the three known opioid precursor in man adopted from 
(18, 21). 
 
 
Opioid peptides are expressed as a component of larger precursor peptides, and are 
released by peptidases and other post-translational processing enzymes (21, 22). 
This enzymatic processing occurs in the endoplasmic reticulum, Golgi, and secretory 
vesicles (21). Signal peptidases remove the signal peptide, usually 20-25 amino 
Precursor  Opioid peptide      Amino acid sequence       
Pro-opiomelanocortin  
        
 
BE 1–31 
 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr- 
    
Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu 
 
 
BE 1-27  
 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr- 
    
Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr 
  
 
BE 1-26  
 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr- 
    
Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala 
  
 
γ-Endorphin  
 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu 
 
ɑ-Endorphin  
 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr 
Pro-enkephalin  
        
 
peptide F 
  
Glu-Gln-Leu-Leu-Lys-Ala-Leu-GluPhe-Leu-Leu-Lys-Glu-Leu-Leu-Glu- 
    
Lys-Leu 
     
 
Peptide E  
  
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp- 
    
Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu 
   
 
BAM 22 
  
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Phe-Glu-Trp-Trp-Met-Asp- 
    
Tyr-Gln-Lys-Arg-Tyr-Gly 
    
 
BAM 20  
  
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Phe-Glu-Trp-Trp-Met-Asp- 
    
Tyr-Gln-Lys-Arg 
    
 
BAM 18  
  
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Phe-Glu-Trp-Trp-Met-Asp- 
    
Tyr-Gln 
     
 
BAM 12  
  
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Phe-Glu 
  
 
Metorphamide 
 
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2 
   
 
Met-enkephalin-Arg-Gly-Leu  Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu 
   
 
Met-enkephalin-Arg-Phe  
 
Tyr-Gly-Gly-Phe-Met-Arg-Phe 
   
 
Met-enkephalin  
 
Tyr-Gly-Gly-Phe-Met 
    
 
Leu-enkephalin  
 
Tyr-Gly-Gly-Phe-Leu 
    Pro-Dyn  
        
 
Dyn A (1–7)  
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg 
   
 
Dyn A (1–8)  
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile 
   
 
Dyn A (1–9)  
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg 
   
 
Dyn A (1–13)  
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Phe-Lys-Leu-Lys 
 
 
Dyn A (1–17)  
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Phe-Lys-Leu-Lys-Trp-Asp-Asn- 
    
Gln 
     
 
Dyn B (1–13)  
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr 
 
 
Leumorphin 
  
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-Arg-Ser-Gln- 
    
Glu-Asp-Pro-Asn-Ala-Tyr-Ser-Gly-Glu-Leu-Phe-Asp-Ala 
 
 
ɑ-Neo-endorphin  
 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Phe-Lys 
    β-Neo-endorphin    Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Phe       
Pronociceptin/orphanin 
FQ 
Nociceptin/Orphanin  Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln 
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acids from the N-terminus of precursor, in the endoplasmic reticulum (23). The 
addition of a sugar side chain, O-linked glycosylation of proenkephalin and POMC, is 
performed in the Golgi. Phosphorylation on some proenkephalin and POMC-derived 
peptides also occurs in the Golgi by casein kinase 1 (24). Prohormone convertases 
or proprotein convertases (PCs) including PACE4, a PC-like enzyme. PC5 and PC7 
are responsible for the cleavage of prohormones at the C-terminal site of Lys and 
Arg residues in the trans-Golgi network (25). Following the action of the 
endopeptidase, the C-terminal basic residues are separated by carboxypeptidases 
(CP). Carboxypeptidase E (CPE) is the major CP enzyme which is also called CP H 
and enkephalin convertase ((21); Table 1.2). Post-translational processing takes 
place after proteolytic processing. For example, after proteolytic processing, C-
terminal amidation of peptide hormones is performed by peptidylglycine-ɑ-amidating 
monooxygenase (PAM) in secretory vesicles (21). In addition to amidation, N-
terminal acetylation of POMC has been observed in the intermediate pituitary and 
several brain regions.  The PAM has been well characterized, whereas the enzyme 
responsible for acetylation is unknown (21). Enzymes involved in the post-
translational processing of neuropeptide precursors are listed in Table 1.2 (21). 
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Table 1.2. Enzymes involved in the post-translational processing of neuropeptide precursors 
 adopted from (21). 
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1.3. Βeta-endorphin 
 
ΒE 1-31 is an endogenous opioid peptide with 31 amino acid residues. The 
sequence of amino acids of BE 1-31 isolated from the pituitary gland has been 
identified in various mammals including human (26, 27), rat (28), camel (29), porcine 
(30), bovine (31), ovine (32), ostrich (33), and mouse (34). The amino acid 
sequences of the species variants in BE 1-31 are illustrated in Figure 1.1 (35). 
 
 
Figure 1.1. Amino acid sequences of BE 1-31 from human, rat, camel, bovine, ovine, mouse, 
porcine, ostrich and horse pituitary glands. The variations in amino acid sequences in different 
mammals are shown in red (35). 
 
BE 1-31 is synthesised by the pituitary, the brain, the lungs, the gastro-intestinal 
tract, the placenta and the immune cells, but is primarily produced in the pituitary 
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gland and the brain (36, 37). Cleavage sites of POMC have sequences of Arg-Lys, 
Lys-Arg or Lys-Lys. POMC is cleaved by prohormone convertase to 
adrenocorticotropic hormone (ACTH) and β-lipotropin in the corticotrophic cells of the 
anterior pituitary under the control of corticotropin releasing hormone (CRH) (16, 24). 
Alpha-melanocyte stimulating hormone (α-MSH), corticotropin-like intermediate lobe 
peptide (CLIP), γ-lipotropin and BE 1-31 are products produced in the intermediate 
lobe of the pituitary and their production is regulated by dopamine (16, 24). The 
expression of the POMC gene is also enhanced by β-adrenergic agonists. In 
addition, Kavelaars et al. demonstrated in vitro β-adrenergic stimulation of 
lymphocytes induces the release of immune-reactive beta-endorphin (38). ΒE 1-31 is 
also produced and released by immune cells within inflamed tissue. This 
endogenous opioid peptide produces peripheral and central analgesia through the 
activation of opioid receptors (36). BE 1-31 not only has opioid activity but also has 
been shown to have non-opioid biological activities (39); this will be discussed further 
in section 1.4. A number of studies have identified differential roles for BE 1-31, 
some of these are displayed below: 
 
 Regulation of human epidermal melanocyte biology (40, 41) 
 Promoting a feeling of well-being Pathophysiology of major depression (42, 
43). 
 Slowing the growth of the cancer cells and migration of tumour cells (44). 
 Stress-related Psychiatric disorders (45, 46). 
 Induced feeding (47). 
 Energy homeostasis (48). 
 Pathophysiology of self-injuries and suicidal behaviour (49). 
 Obesity (adrenocortical function) (50). 
 Polycystic ovary syndrome (51). 
 Euphoria and drug-induced reward (52). 
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1.3.1. Βeta-endorphin pharmacokinetics and stability  
 
There is limited information regarding the pharmacokinetic and pharmacodynamic 
characteristics of BE 1-31 due to changes in BE 1-31 levels in pathological, 
psychological and physiological cases (53). Houghten et al. found that the 
distribution time and clearance time of BE 1-31 were 2-5 min and 1-8 h respectively 
after intravenous administration in rats and rabbits (54).  The half-life of BE 1-31 (5-
10 mg) after intravenous administration was approximately 37 min, whereas its half-
life after intra-cerebroventricular administration was 93 minutes in cancer patients. 
This highlights the potential for enzymatic variation dependent on different sites of 
injection and disease state(55). Intrastriatal microinjection of rat BE 1-31 showed a 
rapid distribution of BE 1-31 from brain parenchyma into the cerebrospinal fluid 
(CSF) compartment. An increase was observed in the presence of intact BE 1-31 
with a peak at 30-45 min post-injection in the CSF (56). The tissue distribution of BE 
1-31 was studied by delivering an intravenous injection of radioiodinated BE 1-31 to 
rats and it was found that BE 1-31 had a 7.5 h half-life in plasma and a 4 h half-life in 
blood. However, utilising isotopically labelled BE 1-31 did not permit these 
investigators to differentiate between BE 1-31 and many of its probable fragments 
(14, 53). 
 
    
1.3.2. Biotransformation of beta-endorphin  
 
Opioid peptides such as BE 1-31 are susceptible to rapid enzymatic degradation 
(57). Peptidases are involved in the degradation of opioid peptides include 
aminopeptidases (58), dipeptidyl peptidase III, dipeptidyl peptidase IV (DPP III, DPP 
IV) (59), insulin degrading enzyme (14), and angiotensin-converting enzyme (ACE) 
(60). Peptidases are found in capillary endothelial cells, serum, and the blood-brain 
barrier (60). DPP III has also been identified in human neutrophils (61). The 
proposed pathway for in vitro conversion of BE 1-31 by peptidases and the 
subsequent identified fragments are depicted in Figure 1.2. DPP IV is a serine 
protease which is found in the liver, the placenta, the kidney, circumventricular 
organs and leptomeningeal cells (62). BE 1-31, DYN, ENK, SP, endomorphins, and 
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bradykinin are substrates for DPP IV. This enzyme selectively cleaves opioid 
peptides from amino acid, proline (63).  ACE is found in many cells with broad 
peptide cleavage functions (60).   
 
 
Figure 1.2. Proposed pathway for biotransformation of BE 1-31 by peptidases. The vertical 
arrows mark cleavage sites in BE 1-31 and BE 1-17 and possible types of proteolytic enzymes are 
depicted (EP: endopeptidase; AP: aminopeptidases; CP:Carboxypeptidase) adopted from (64). 
 
 
Peptidases that are involved in enzymatic cleavage of opioid peptides can be 
inhibited by a number of compounds (65). Di-isopropyl fluorophosphate and 
phenylmethanesulphony fluoride, and diprotin A are inhibitors for DPP IV (66). 
Spinorphin, which is an endogenous factor derived from bovine spinal cord and its 
truncated fragment, tynorphin, are inhibitors of DPP III (67). Leupeptin, an organic 
compound produced by Gram- negative bacteria, blocks cysteine-containing 
enzymes (68) and EDTA and phenanthroline inhibit metalloproteases (69). 
Aminopeptidase B and cytosolic alanine aminopeptidase are inhibited by bestatin (an 
antibiotic), but are not blocked by DPP IV (70). Phosphoramidon is a peptidase 
inhibitor derived from cultures of Streptomyces tanashiensis and this compound 
together with two other peptidase inhibitors (captopril, amastatin) can prevent the 
degradation of endogenous opioid peptide and potentiate the antinociceptive effects 
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of endogenous opioid peptides depending on the structure of initial opioid peptide 
and also the fragments produced (71, 72). Inhibiting the enzymes that are involved in 
the biotransformation of endogenous opioid peptides results in an increased duration 
of analgesic effect of active biotransformed fragments (71, 72). 
 
1.4. Opioid receptors 
 
BE 1-31 binds to opioid receptors in the peripheral (PNS) and central nervous 
system (CNS) to produce antinociceptive effects (73). Opioid receptors are 
expressed not only within the CNS but also on peripheral sensory nerve terminals. 
Opioid receptors belong to the GPCR family and contain seven hydrophobic 
transmembrane domains which share a large number of amino acid sequence 
homology with the angiotensin and somatostatin receptors (74). 
 
Opioid receptors have three cytoplasmic and three extracellular loops and a 
cytoplasmic carboxyl-terminal segment (Figure 1.3) (15). GPCRs are composed of 
heterotrimeric G proteins with three subunits ɑ, β and γ. Binding of agonists to a 
GPCR induces the exchange of guanosine diphosphate  (GDP) (attached to the Gɑ 
subunit) for guanosine triphosphate (GTP); this leads to separation of Gɑ-GTP 
complex from the βγ heterodimer (75). The free βγ subunits and Gɑ-GTP can 
interact with other proteins to induce different signals including activation of 
phosphoinositide 3-kinase (PI3K) (76) which is necessary for Gβγ-mediated mitogen-
activated protein kinase (MAPK) signalling. Gβγ also activates a number of kinases 
such as the Raf1 protein kinase (77). In addition, the ɑβγ complex may be 
constructed of different subunits. There are four classes of Gɑ proteins, designated 
Gi, Gs, Gq and G12. Each Gɑ protein is responsible for a specific set of signalling 
events. Gi proteins are responsible for inhibition of adenylyl cyclase, high voltage 
calcium channels and also tetrodotoxin-resistant sodium channels. However, Gi 
proteins activate phospholipase C-β (PLCβ) and G protein activated inwardly 
rectifying K+ channel (GIRK) (78). Gs proteins are responsible for stimulation of 
adenylyl cyclase and calcium channels and the inhibition of PLCβ and GIRK. Gq 
proteins are responsible for activation of PLCβ. The role of G12 proteins has not 
been fully characterised, but they were found to be involved in the activation of Rho 
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family of GTPases (79, 80). Hydrolysis of GTP to GDP and reattachment of the ɑβγ 
complex results in the termination of the signal (81). 
 
 
 
Figure 1.3. Structure of opioid receptors with numbered trans-membrane loops. The white 
empty circles represent non-conserved amino acids among the MOP, DOP, KOP. White circles with a 
letter represent identical amino acids among all four opioid receptors. Violet circles indicate points of 
difference between the MOP, DOP and KOP. Green circles highlight the highly conserved fingerprint 
residues. Yellow circles depict the two conserved cysteine bonds in EL loops 1 and 2, likely forming a 
disulphide-bridge. IL= intracellular loop and EL=extracellular loop taken with permission from (15). 
 
Activation of opioid receptors (MOP, DOP, and KOP) results in the inhibition of 
adenylyl cyclase and a decrease in the level of cAMP. In addition, it causes 
suppression of tertrodoxin-resistant Na+ channel and transient receptor potential 
vanilloid subtype-1 (TRPV1) responses. These effects are regulated by 
Ca2+/calmodulin-dependent protein kinases and PKA (82, 83).  Activation of opioid 
receptors also activates MAP kinases including extracellular signal-regulated 
kinases-1 (ERK-1) and extracellular signal-regulated kinases-2 (ERK-2) in 
downstream signalling and several phosphorylation events targeting various 
transcription factors such as nuclear transcription factor activator protein 1 (AP-1) 
(83, 84).   
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1.4.1. Opioid receptor activity based around amino acid sequences  
 
Endogenous opioids peptides, excluding pronociceptin, contain message peptides 
with the amino acid sequence of Tyr-Gly-Gly-Phe-Met/Leu (YGGFM/L) at their N-
terminal.  Strict amino acid sequences are required in the message sequence of 
endogenous opioid peptides for binding to opioid receptors (85). However, 
endomorphin 1 and 2 (EM-1 and EM-2), which are highly selective MOP ligands, are 
structurally different from other endogenous peptides. EM-1, Tyr-Pro-Trp-Phe, and 
EM-2, Tyr-Pro-Phe-Phe, isolated from the human cortex and from bovine brain, are 
known to be selective agonists for MOP and also possess a high selectivity for MOP 
over DOP (86, 87). The aromatic groups at amino acid 1 and 3 of endomorphins 
have been identified as essential in determining MOP affinity. Proline is considered 
to be a spacer amino acid that joins the two-pharmacophore amino acids (Tyr and 
Trp/Phe) (88). DYN A and DYN B both contain the amino acid sequences of Tyr-Gly-
Gly-Phe-Leu and are selective ligands for the KOP. However, DYN A has been 
shown to be more selective for KOP than DYN B (89, 90). Different metabolites of 
DYN have been shown to differ in their affinity for KOP, MOP and DOP. For 
example, lLeucine-enkephalin (Leu-ENK) and (Leu-ENK)-Arg are possible 
metabolites of DYN and possess high affinity for DOP (91). Furthermore, it has been 
demonstrated that the length of the peptide has an effect on the affinity of DYN 
peptide for KOP. DYN A 1-17 shows higher specificity for KOP than DYN A 1-8 
peptide (92). The lysine-11 and lysine-13 in DYN also play crucial roles in KOP 
binding affinity and selectivity (93, 94). Lateral intraventricular and cerebral aqueduct 
administration of DYN 1-13 produced analgesia and catalepsy induction in rats (95). 
Goldstein et al. found that DYN A 1-6 is selective ligand for MOP rather than KOP 
(96). ΒE 1-31 possesses high affinity for MOP and DOP (4, 97).   
 
The more recently discovered opioid peptide class- Nociceptin/Orphanin FQ is a 17 
amino acid peptide FQ comprised of phenylalanine (F) in place of the N-terminal Tyr. 
Nociceptin/Orphanin FQ binds to opioid- like receptors called orphanin receptors or 
nociceptin receptor (NOP). NOP is a member of the family of opioid receptors on the 
basis of its structural homology with the classical opioid receptors (98). Selective 
agonists for orphanin have been shown to produce both analgesia (99) and 
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nociception in separate studies (100, 101). Interestingly, this appears to be largely a 
consequence of action of the specific agonist to the site of delivery (principally spinal 
compared to supraspinal). Some of the selective opioid receptor ligands are listed in 
Table 1.3 (15).  
 
1.4.2. Opioid receptor agonist activity 
 
Selective MOP agonists such as morphine, fentanyl, and BE 1-31 produce 
analgesia. Activation of MOP regulates neuronal excitability as it stops neurons from 
firing and inhibits neurotransmitter release in the nervous system (102). Binding of 
MOP agonists to opioid receptors on the terminal of primary afferent neurons, 
causes conformational changes in the opioid receptor that inhibit the presynaptic 
release of Substance P (SP), resulting no pain signal being propagated to the brain 
(103).  In addition, these agonists activate MOP on the cell body of second order 
neurons at the spinal dorsal horn to induce postsynaptic hyperpolarisation of 
excitatory neurons. MOP agonists can also bring about the progress of physical 
dependence in analgesic doses due to down-regulation and desensitisation of MOP 
(104). DOP agonists are responsible for the regulation of analgesia, the function of 
the neuroendocrine system, the function of the autonomic system, and mood driven 
behaviours (105). KOP agonists regulate spinal analgesia (106). Since, selective 
opioid agonists can produce a variety of side effects, targeting opioid agonists to 
specific opioid receptors could be of therapeutic value for specific clinical 
pathologies. 
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Table 1.3. Selective opioid receptor ligands adopted from (15). 
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1.4.3. Opioid receptor subtypes  
 
Different subtypes of MOP (μ1, μ2, μ3), DOP (δ1, δ2), and KOP (κ1, κ2, κ3) have 
been proposed whilst molecular biology describes only a single receptor at the gene 
level.  The opioid receptor subtypes have been characterised based on the range of 
pharmacological effects elicited using different antagonist. For example, β-
funaltexamine, which binds to all of the known MOP subtypes, can antagonise the 
effects of morphine such as; analgesia, inhibition of gastrointestinal transit, and 
respiratory depression. Whereas naloxonazine, which binds specifically to μ1, can 
only reverse the analgesic activity of morphine. Since this antagonist does not bind 
to μ2, it does not block the respiratory depression and the inhibitory effects on 
gastrointestinal transit associated with morphine binding to μ2 (107, 108).  Opioid 
receptors can form heteromers with different opioid receptors, for example 
MOP/DOP or DOP/KOP heteromers. There is some evidence that the δ1 and κ2 
could in fact be the pharmacological characterisation of a DOP/KOP heteromer (109) 
and δ2 could be a DOP/MOP heteromer (110). Moreover, opioid receptors may not 
only form heteromers with different opioid receptors but evidence also suggests the 
formation of heteromers with different GPCR’s such as with the CC chemokine 
receptor type 5 (CCR5 receptor) (111), neurokinin-1 (NK-1) (112), and α2A-
adrenergic receptor (113). These heteromers exhibit differences in signalling, 
receptor trafficking and ligand affinities. 
 
It is postulated that each of the opioid receptor subtypes has more than one splice 
variant (114). This is a regulated process whereby multiple proteins is coded for by a 
single gene. In this process, particular exons may be excluded or included in the final 
gene transcript. As a consequence, different μ1 can be translated from alternatively 
spliced mRNAs. Splice variants have been identified for μ1. An active metabolite of 
morphine, morphine 6-glucuronide, has been shown to produce a higher analgesic 
effect than morphine; however this metabolite showed a lower binding affinity to the 
μ1 receptor than that of morphine (114). In addition, the 3-O-methylnaltrexone can 
block the analgesic effect of morphine 6-glucuronide, however this antagonist cannot 
reverse the analgesia produced by morphine (114). However, the analgesic actions 
of morphine 6-glucuronide are antagonised by naloxonazine in a manner similar to 
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morphine. These observations indicate that there may be more than one μ1 variant 
(114). The cloning of MOP has assisted in better understanding these differences at 
the molecular level and has suggested the existence of multiple MOP spliced 
variants that may go some way to explaining the pharmacological variants (114).   
 
 
1.4.4. Orthosteric and allosteric modulation in opioid receptors 
 
When MOP agonists are used for clinical analgesia; they produce a variety of side 
effects such as tolerance and dependence. Discovery of positive allosteric 
modulators (PAMs) can be considered as a new strategy for the treatment of severe 
pain with fewer side effects through the altered signal process in allosteric 
modulation. 
 
Opioid receptors are proposed to have more than one binding site on a receptor; an 
orthosteric site, which is the primary site for binding of the endogenous ligand, and 
an allosteric site (115). An allosteric modulator is a ligand that does not bind to the 
orthosteric sites but can inhibit or potentiate the action of the receptor.  PAMs have 
little or no activity in the absence of an orthosteric agonist; however, they can 
potentiate the efficacy and potency of an orthosteric agonist. A number of allosteric 
modulators of opioid receptors have been identified. For example, cannabidiol (a CB-
1 agonist) is a negative allosteric modulator for MOP and DOP (116). Salvinorin-A is 
a KOP agonist (117), but acts as a negative allosteric modulator for MOP (118). 
MOP-PAMs were examined in a high-throughput screen using a β-arrestin 
recruitment assay in human osterosarcoma cells (119). BMS-986121 and BMS-
986122 displayed no agonist activity for MOP; however they produced a 7-fold 
increase in the potency of endomorphin, a MOP agonist (119). These PAM were 
also examined in an inhibition of forskolin–stimulated cAMP assay in Chinese 
hamster ovary cells-expressing MOP. The result was the leftward shift in the potency 
of endomorphin as well as morphine. 
 
Ligand binding studies were used for further confirmation of PAM activity of BMS-
986121 and BMS-986122.  In these studies, only endomorphin as endogenous 
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opioid agonist for MOP was evaluated. Additional studies on the activity of PAM 
should evaluate on different opioid receptor types and different orthosteric and 
endogenous agonists, and potentially their active metabolites (120, 121).    
 
 1.4.5. Opioid receptors in inflammation 
 
Opioid receptors are produced in the cell bodies of dorsal root ganglia (DRG) and 
are distributed to nerve terminals by axonal transport (122, 123). During 
inflammation, increased receptor binding and increased immune-reactivity for opioid 
receptors has been identified on peripheral nerve terminals. The acidic environment 
in peripheral inflammation changes the interaction of opioid receptors with G-proteins 
in neuronal membranes and enhances opioid agonist efficacy (2, 124, 125). 
Furthermore, MOP G-protein coupling increases at peripheral nerve terminals 
causing the production of pro-inflammatory cytokines (e.g. IL-1β, IL-6, TNF-ɑ) and 
nerve growth factor (NGF) (126-128). NGF is enhanced in peripheral inflammation 
and acts on nociceptive neurons via tyrosine kinase receptors (TrkA) (129). It is 
possible that NGF is the major effector for the up-regulation of MOPs in sensory 
neurons (128). 
  
1.5. Inflammation  
 
Inflammation is the body’s adaptive response to foreign stimuli; these inflammatory 
responses can be the result of tissue injury, infection or stress. Pain, swelling, heat 
and redness are the four hallmarks of inflammation (130). The inflammatory 
response is characterised by infiltration of leukocytes and a concomitant increase in 
the production of mediators such as chemokines and cytokines (131).  
 
Immune responses during inflammation can be divided into innate (non-specific) and 
acquired (specific) immunity. The number of opioid-containing leukocytes increases 
in the site of inflammation. In innate immunity, neutrophils and macrophages migrate 
to the inflamed site. These migrated immune cells are activated through a number of 
pathways:  pattern-recognition receptors including Toll-like receptors (TLR);, 
nucleotide-binding oligomerisation domain receptors; (NOD)- like receptors (NLR);, 
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retinoic acid-inducible gene 1( RIG)- like helicases (RLH);, and C-type lectin 
receptors (CLR) (132).   
 
In the case of bacterial infection, lipopolysaccharide (LPS), consisting of a lipid and a 
polysaccharide, found in Gram-negative bacterial cell walls, activates the immune 
system through activation of TLR and induces inflammatory responses such as the 
activation of NF-κB and the production of pro-inflammatory cytokines such as IL-1β 
and TNF-α (133). The pivotal role of NF-κB and IL-1β in inflammation will be 
discussed further in sections 1.5.1 and 1.5.2 and are a focus of this thesis.  
 
Chemokines attract more immune cells including T and B lymphocytes by 
chemotaxis. The Recruitment of lymphocytes into the inflamed site is mediated by an 
array of adhesion molecules (134); the homing of leukocytes begins with their 
tethering and rolling along the vascular endothelial cell line mediated by L, P, E 
selectins (135). Leukocytes are then activated by chemokines resulting in the up-
regulation of integrins on their surfaces. These integrins are CD49d/CD29 and CD18 
that mediate the adhesion of leukocytes to endothelial cells through an Intracellular 
Adhesion Molecule (ICAM) (135 449). Under inflammation, the expression of ICAM-1 
is increased by sympathetic nerve fibres and peripheral nerves resulting in the 
migration of opioid-containing leukocytes to neurons in peripheral inflamed tissue 
(136); BE 1-31 can modulate the adherence of immune cells to the endothelium, for 
instance, BE 1-31 at concentration of 1 µM increases the expression of CD11b and 
CD18 on the neutrophils (137). Leukocytes then migrate through the endothelium by 
interacting with the platelet endothelial cell adhesion molecule-1 (PECAM-1) (135). 
Opioid-containing immune cells release opioid peptides within inflamed tissue, which 
will be discussed in section 1.5.5. 
 
Anti-inflammatory pathways are also triggered, particularly upon resolving infection, 
resulting in release of anti-inflammatory cytokines, including IL-1 receptor antagonist, 
IL-4, IL-10, IL-13, transforming growth factor (TGF)-β, and suppressor of cytokine 
signal inhibitor-1. These anti-inflammatory cytokines help the body to resolve 
inflammation (138). An overview of the inflammatory response is depicted in Figure 
1.4 (139). 
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Figure 1.4. Inflammation is a component of several diseases such as cancer, diabetes, 
cardiovascular diseases, infection, auto-immune diseases.  The above diagram represents an 
overview of inflammatory responses in those diseases and describes the involvement of immune cells 
and the activation of several pathways resulting in the release of endogenous opioid peptides. 
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1.5.1. Nuclear factor-kappa B proteins in the inflammatory response 
 
NF-κB proteins are activated during the inflammatory response by a range of 
mechanisms, either directly by the binding of bacterial cell surface sugars or proteins 
to pathogen associated molecular recognition pattern receptors (for example LPS 
activates TLR-4), or by endogenous pro-inflammatory cytokines (TNF-α and IL-1β) 
binding to their relevant receptors (140). Activation of NF-κB plays a fundamental 
role in the regulation of transcription of pro-inflammatory mediators such as; IL-1β, 
adhesion molecules (141), chemokines, growth factors, inducible enzymes 
(cyclooxygenase 2), and inducible nitric oxide synthase (iNOS). NOS is involved in 
many physiological process in the brain. It can be found mostly in neurons and 
astrocytes (142). The major source of nitric oxide is via NOS (143). Production of 
nitric oxide causes an increase in vascular permeability and chemotaxis of immune 
cells to the inflamed site in order to eliminate the foreign stimuli. NF-κB transcription 
factor exists as homodimeric or heterodimeric proteins (144). Eight proteins in the 
NF-κB  family have been cloned including Rel A (p65), Rel B, C-Rel, p50, p52; the 
predominant form of NF-κB is the heterodimer of the proteins p65 and p50 (145). 
 
NF-κB binds to the inhibitory protein κB (IκB), which inhibits the translocation of NF-
κB from the cytoplasm to the nucleus. Bacterial products such as LPS induce the 
phosphorylation of IκB kinase (IKK) resulting in phosphorylation of IκBs (146). IκB is 
degraded after phosphorylation and this process induces translocation of NF-κB from 
the cytoplasm to the nucleus. Phosphorylation at serine 32 and 36 in IκB causes the 
degradation of IκB by the proteasome (146).  NF-κB transcription factor binds to 
specific promoters to induce inflammatory gene transcription. NF-κB and IKKβ are 
important for initiating the inflammatory response and inhibition of these pathways 
results in the resolution of inflammation. However, Lawrence et al. demonstrated that 
activation of NF-κB pathway during the onset on inflammation can cause the 
recruitment of leukocytes, whereas activation of the NF-κB pathway during the 
resolution of inflammation, induces the expression of anti-inflammatory genes and 
the induction of apoptosis of inflammatory cells (147) (Figure 1.5).  
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Figure 1.5. The NF-kB pathway. LPS or TNF-α induces the phosphorylation of IKK resulting in 
phosphorylation (P) of IκB. IκB is degraded after phosphorylation and this process induces 
translocation of NF-κB from the cytoplasm to the nucleus. Activation of NF-κB results in transcription 
of pro-inflammatory mediators such as: IL-1β and TNF-α, adhesion molecules such as VCAM-1, 
chemokines, growth factors, inducible enzymes (cyclooxygenase 2), and iNOS. 
 
1.5.2. Interleukin-1β in the inflammatory response  
 
IL-1β plays a key role in the host’s response to a primary cause of inflammation or 
infection (148).  IL-1β production is increased in infections and chronic inflammatory 
diseases such as sepsis, arthritis, scleroderma, and in atherosclerotic lesions 
resulting in myocardial infarction (149). IL-1β is produced in the form of an inactive 
pro-cytokine with a molecular mass of 31 kDa.  IL-1β is released from the cytosol in 
an active form with a molecular mass of 17 kDa (150).   
 
The activated form of IL-1β is released after processing of pro-IL-1β by several 
proteases during inflammation, with the most important enzyme in the process being 
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caspase-1 (casp-1). Casp-1 is necessary for the secretion and proteolytic cleavage 
of IL-1β and this processing enzyme is present in resting cells in its inactive form 
with a molecular mass of 45 kDa (procasp-1) (151, 152). Pro-IL-1β is cleaved to an 
N-terminal 14-kDa inactive pro-piece and the C-terminal 17 kDa biologically mature 
and active form of IL-1β (153). Studies have demonstrated that pre-treatment with 
LPS is required for substantial activation of casp-1 in mouse macrophages (154, 
155).  One of the most important pathways involved in IL-1 release is mediated 
through activation of the ion channel P2X7R. This ion channel has more diversity in 
terms of pharmacology, function and structure compared to other members of this 
family (156, 157).   
 
There are two suggested pathways for P2X7R-stimulated IL-1β cleavage and 
release. Andrei et al. suggested that, with the activation of P2X7R, K+ efflux is 
triggered, and pro-IL-1β is accumulated into secretory lysosomes together with casp-
1 (158). Pro-IL-1β is converted into mature IL-1β during this process. P2X7R-
induced loss of intracellular K+ stimulates phosphatidylcholine-specific 
phospholipase and increases cytosolic Ca2+ and consequently activates Ca2+-
dependent phospholipase A2 to induce the secretion of the IL-1β containing 
lysosomes (158). It has been proposed that after activation of macrophages, Pro-IL-
1β is accumulated below the inner part of the plasma membrane (159). Activation of 
P2X7R stimulates budding of micro-vesicles containing pro-IL-1β. K+ loss drives 
cleavage of pro-casp-1 to casp-1 and consequently cleavage of pro-IL-1β to IL-1β 
(159). 
 
Apart from macrophages, a variety of cells in the skin and underlying tissue can 
produce pro-inflammatory cytokines. Fibroblasts and keratinocytes in the skin can 
produce an inactive pro-IL-1β. Mast cells migrate to the inflamed site to release TNF-
α, IL-1, IL-6 and chymase, which converts fibroblast and keratinocyte-derived IL-1β 
precursor to its active form, the latter to be released within inflamed tissue (150). 
Released IL-1β stimulates the liberation of endogenous opioid peptides from 
leukocytes, which migrate to the inflamed site; this will be discussed further in 
section 1.5.5. 
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1.5.3. Pain in the inflammatory response 
 
Released IL-1β from immune cells binds to peripheral nerve terminals to activate 
neurons and liberate SP (126, 160). Released SP produces a positive feedback loop 
that induces activation of macrophage and mast cells thus resulting in an augmented 
release of pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6 (161).  
 
The sensation of pain during inflammation results from the excitation of primary 
afferent neurons (PANs) induced mainly by activation of TRPA1 and TRPV1. In 
addition, neuro-inflammatory factors such as SP and glutamate that are released 
during inflammation induce pain (130). These two transmitters bind and activate NK-
1 and N-methyl-D-aspartate (NMDA) receptors, respectively. PANs possess 
unmyelinated or lightly myelinated axons and their cell bodies are located in the 
DRG. Nociceptive signals are transmitted to the superficial lamina within the dorsal 
horn of the spinal cord and these signals are relayed via second-order neurons in the 
dorsal horn to the brainstem, midbrain and thalamus, terminating in the limbic 
system and cortex (162). The threshold of activation and the sensitivity of 
nociceptors to stimulus, differentiate them from other sensory nerve fibres (163). The 
sensitivity of the peripheral terminals of Aδ and C fibres is enhanced at the inflamed 
site. Numerous diseases such as invading cancer, arthritis, irritable bowel syndrome 
(IBS), and neuropathic diseases can cause chronic pain (164). Damage to peripheral 
nerves, the DRG neuron or the dorsal root nerves can cause neuropathic pain and 
may be characterised by hyperalgesia and allodynia. Hyperalgesia is an extreme 
response to stimuli and is characterised by an enhanced sensitivity to pain. It can be 
caused by the production of cytokines and chemokines from immune cells, or due to 
peripheral nerve damage or nociceptor damage (165). Allodynia is a painful 
response evoked by stimuli that does not normally induce pain, and can be the result 
of some disease such as neuropathy (163, 165, 166).  
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1.5.4. Release of BE 1-31 from immune cells in the inflammatory response 
 
Inflammatory processes have been shown to be involved both in promoting pain 
through the production of inflammatory mediators and by producing antinociceptive 
effects through the release of opioid peptides. These opioid peptides are produced in 
immune cells that have migrated to injured tissue under pathological conditions 
(167). BE 1-31 is an effective peripheral analgesic in conditions of hyperalgesia 
produced by inflammation (168).    
 
Among the large number of inflammatory mediators released in the inflamed site, IL-
1β, corticotropin-releasing factor (CRF) and noradrenaline have been shown to 
induce the release of endogenous opioid peptides from immune cells resulting in 
analgesia (148, 169). During inflammation, the production of CRF and IL-1β is 
increased in inflamed tissue. Furthermore, the expression of CRF and IL-1β 
receptors on leukocytes is increased (170, 171). Adrenergic α1, β2 are expressed on 
BE 1-31-containing inflammatory cells located in close proximity to sympathetic 
nerve fibres (172). All these factors induce a release of endogenous opioid peptides 
including BE 1-31 from immune cells. 
 
Leukocytes migrate to the site of inflammation and secrete opioid peptides such as 
BE 1-31 within inflamed tissue (5, 8). Opioid peptides including BE 1-31 can be 
produced by leukocyte subpopulations such as monocytes, lymphocytes, and 
granulocytes in the peripheral blood and lymph nodes (2, 10). BE 1-31 and POMC 
mRNA were present in lesser amounts in circulating lymphocytes than those in 
lymph nodes. In the early stages of inflammation, granulocytes (neutrophils, 
basophils and eosinophils) are the most common source of endogenous opioid 
peptides (173). Monocytes and macrophages are a major source of endogenous 
opioid peptides within inflamed tissue after the development of the inflammatory 
response (5, 10, 173).  
 
A greater number of activated/memory T cells (CD4+ cells) containing opioid 
peptides are found in peripheral inflamed tissue, whereas a lower number of naive 
CD4 cells (CD45RC+) are observed in peripheral inflamed tissues (2). Granulocytes 
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have a number of different types of granules, including azurophilic granules (primary 
granules), specific granules (secondary), gelatinase granules (tertiary) and secretory 
granules.  
 
Each granule type can be identified by different marker proteins. Myeloperoxidase 
and CD63 are marker proteins for primary granules; lactoferrin is a marker protein for 
secondary granules; gelatinase is a marker protein for tertiary granules and albumin 
is marker protein for secretory vesicles (10). It has been demonstrated that BE 1-31 
and met-enkephalin are released from primary granules by myeloperoxidase and 
CD63-cell-surface protein (174). Various factors, including chemokines binding to 
CXCR1/2 receptors, can induce the release of opioid peptides from granulocytes 
(174).  
 
CXCR1/2 receptors are chemokine G1 protein- coupled receptors. Activation of the 
heterotrimeric G-proteins, Gβγ subunits, causes activation of phosphoinositol-3-
kinase-γ, p38 mitogen-activated kinase and the transfer of calcium from the 
endoplasmatic reticulum (175, 176). This results in translocation of primary granules 
and the subsequent release of opioid peptides. Opioid peptide release depends on 
intracellular calcium and is unrelated to extracellular calcium (10) (Figure 1.5). The 
above illustrates that the release of CXCR2-mediated opioid peptides from 
granulocytes is dependent on intracellular calcium, phosphoinositol-3-kinase-γ, and 
p38 mitogen-activated kinase (10). However, the release of peptide opioids from 
leukocytes is regulated not only by chemokines but also by other mediators such as 
SP which binds to neurokinin 1(NK1) receptors and adrenergic neurotransmitters 
(177).  
 
Opioid peptides bind to peripheral opioid receptors within the inflamed tissue 
resulting in peripheral mediated analgesia (178). The pH and temperature of the 
environment that the BE 1-31 is released into can also have an effect on the binding 
of BE 1-31 to the opioid receptors (179). The migration of immune cells containing 
opioids to inflamed tissue is fundamental to peripheral analgesic activity (10, 131).  
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Figure 1.6. Granulocytes containing opioid peptides migrate to the site of inflammation. Opioid 
peptides are released from granulocytes in response to chemokines binding their receptors and 
released opioids bind to opioid receptors eliciting analgesia. Opioid peptide release depends on 
increasing intracellular Ca
2+
 via flux from the endoplasmic reticulum. Taken with permission from (10). 
1.6. Modulatory effect of BE 1-31 and its biotransformed fragments 
on immune cells and inflammatory signals 
 
BE 1-31 released from leukocytes within inflamed tissue can modulate immune cells 
and displays a dual effect, both inhibitory and stimulatory, depending on the type of 
immune cells and experimental environment.  
 
BE 1-31 suppresses the phagocytosis of macrophages, mediated through opioid 
receptors (180). This peptide also shows an inhibitory effect on proliferation of donor 
T-lymphocytes (181). In vitro studies showed that BE 1-31 suppresses the 
proliferation of T lymphocytes activated by haemaglutinin via non-opioid receptor 
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mechanisms (182). Furthermore, Borner et al. demonstrated the inhibitory effect of 
BE 1-31 on the transcription of IL-2 and the transcription factors such as NF-κB in a 
Jurkat activated human T cell line, the incubation of T cells with the opioids caused a 
significant inhibition of NF-κB   protein, which is responsible for transcription of IL-2 
(183).  
 
A stimulatory effect of BE 1-31 was also observed in several studies on T-
lymphocytes (184) and on macrophages (185, 186).   For example, the effect of BE 
1-31 was examined on different stages of phagocytic function of peritoneal 
macrophages. BE 1-31 at a concentration of 0.5 ng/mL induces phagocytosis of 
Candida albicans by macrophages (185). BE 1-31 also enhanced the production of 
IL-4 in purified CD4+ T cells (184).  
 
BE 1-31 is unstable and is cleaved into different fragments in a hostile inflamed 
environment by peptidases secreted from immune and neuronal cells (187). These 
biotransformed fragments may also modulate immune system and inflammatory 
signals as observed with BE 1-31.  
 
BE 1-17, which is one of the main fragments identified in several studies of BE 1-31 
biotransformation, displayed modulatory effects on high affinity IL-2 receptor 
expression on human T cells (188), BE 1-17 does not compete with IL-2, however, 
can stimulate the binding of IL-2 to the high affinity IL-2 receptor in a dose-
dependent manner (188). In addition, the structure-related activities of BE 1-31 
fragments (BE 1-16, BE 1-17, BE 1-27, BE 6-31, and BE 28-31) were evaluated on 
human monocyte chemotaxis. The results presented evidence for the involvement of 
non-opioid receptors in the chemotaxis of opioid peptides, since all the fragments, 
except BE 28-31, displayed a chemotactic effect (189). BE 1-31 induces T-cell 
proliferation via the activation of non-opioid receptors. BE 6-31 and BE 18-31, which 
are both devoid of the N-terminal sequence of BE 1-31, stimulate T-cell proliferation 
(190).  
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In conclusion, biotransformed fragments of BE 1-31 may modulate inflammatory 
signals through opioid and non-opioid receptors in a similar manner to the parent 
peptide, BE 1-31. 
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1.7. Summary  
 
Four families of endogenous opioid peptides have been identified in the CNS and 
neuroendocrine system. BE 1-31 is a prominent endogenous opioid peptide which is 
derived from POMC. BE 1-31 is involved in inhibition of inflammatory pain through 
activation of the antinociceptive receptors MOP and DOP. In addition, it is apparent 
from the literature that opioids modulate both the immune system and inflammatory 
signals during inflammation. During inflammation, leukocytes migrate to the site of 
inflammation to release endogenous opioid peptides including BE 1-31. BE 1-31 is 
unstable and several fragments may be formed due to its degradation by enzymes in 
body tissues. Therefore, the biotransformed fragments may also activate one or 
multiple important antinociceptive receptors to produce peripheral analgesia during 
inflammation.  
 
1.8. Research hypotheses and aims 
 
1.8.1. Hypotheses 
 
The analgesic activity of BE 1-31, an important endogenous opioid peptide, has 
been demonstrated in inflammatory pain; BE 1-31 is not stable and is degraded by a 
variety of enzymes in biological fluid and tissue especially under pathological 
conditions such as inflammation. The effect of BE 1-31 may not be attributable to BE 
1-31 alone and major N-terminal biotransformed fragments of BE 1-31 may reside in 
tissues for a longer period than the parent molecule and produce a range of effects 
on analgesia and on inflammatory signals. 
 
 
1.8.2. Aims 
 
Aim 1: Investigate the biotransformation of BE 1-31 and three major N-terminal 
fragments in an inflammatory tissue extract. 
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Aim 2: Characterise the potency of BE1-31 and selected fragments at MOP, DOP 
and KOP receptors expressed in HEK cells using cAMP assay. 
 
Aim 3: Examine the effects of BE 1-31 and selected fragments on the modulation of 
IL-1β release in macrophages.  
 
Aim 4: Examine the effects of BE 1-31 and selected fragments on the modulation of 
NF-κB translocation in macrophages and neuronal cells. 
 
 
1.8.2.1. Context of aims 
 
The aims of this thesis are centred on the identification of BE 1-31 biotransformed 
fragments and the improving our understanding of their role in the modulation of 
inflammatory signals (cAMP accumulation, the release of IL-1β and the translocation 
of NF-κB) in in vitro model. These findings may help to reveal the mechanism of 
peripheral analgesia by endogenous opioid peptides during inflammation. It can also 
provide novel insight into the effect of tissue biotransformation in managing pain 
during inflammation. 
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 : Biotransformation of BE 1-31 and three major Chapter 2
N-terminal fragments in homogenised inflamed tissue 
 
 
2.1. Foreword 
 
The biotransformation of BE 1-31 was performed in homogenised rat inflamed 
tissue. In addition, the biotransformation of three major N-terminal fragments of BE 
1-31 (BE 1-11, BE 1-13, BE 1-17) were performed in homogenised inflamed tissue to 
elucidate the biotransformation pathway of BE 1-31.  
 
2.2. Introduction 
 
BE 1-31 is derived from its precursor POMC by an enzymatic process (18, 21). It 
plays an important role in the modulation of many biological processes such as pain, 
inflammation, immune system, award, and stress. BE 1-31 is a unique endogenous 
polypeptide, which primarily has opioid activity but also has been shown to have 
non-opioid biological activities. It is released from immune cells within inflamed 
tissue to provide analgesia (191). It is susceptible to increased enzymatic 
degradation within the inflamed tissues (192). Therefore, the pharmacological effects 
of BE 1-31 may not just be produced by intact BE 1-31 but also by its fragments. 
There is limited information on the relative contributions of BE 1-31 fragments to 
analgesia in inflammatory pain (13, 14). The metabolism of BE 1-31 has previously 
been examined in rat brain (64, 193, 194), cultured aortic endothelial cells (195), 
human T cells, thymoma cell line (39, 196), human plasma (13), and human pituitary 
(197). A recent study in our laboratory has identified biotransformed fragments of BE 
1-31 in rat serum, rat inflamed tissue, and following Tyr hydrolysis in media (192). 
Herath et al. found that BE 1-31 is unstable and was degraded to several major 
fragments including BE 19-31, BE 20-31, BE 1-9, BE 1-17, and BE 1-20 (192). In 
Herath’s study, Trichloroacetic acid (TCA) was used for sample preparation. The 
  
57 
 
Mean Residence time (MRT) values were not calculated and the biotransformation of 
BE 1-11, BE 1-13, and BE 1-17 in homogenised, inflamed tissue were not examined 
in the previous studies. Further investigation of biotransformation of BE 1–31 and its 
major fragments in inflamed site may elucidate the biotransformation pathway of BE 
1-31 and also provide an insight into key fragments with unique pharmacological 
actions. 
 
Traditional methods for the quantification of neuropeptides are immunoassays such 
as enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA) 
(198). DYN A 1-17, DYN A 1-8, DYN B, ɑ-neo-endorphin, β-neo-endorphin, Leu-ENK 
and (Met-ENK)-Arg6-Gly7-Leu8 were measured by RIA in homogenized rat brain 
tissue (199). Measurement of BE 1-31 by RIA is more difficult than that of other 
neuropeptides due to its relatively large size (31 amino acids). There is a need for 
the development of analytical methods with no cross reactivity that is observed with 
immunoassays, allowing for the accurate measurements of both the concentrations 
of parent peptide and its fragments. Recent advances have led to the use of a 
capillary liquid chromatography column to analyse Met-ENK. High-performance 
liquid chromatography (HPLC) with electrochemical detector (EC) has been used for 
analysing Met-ENK, Leu-ENK, endomorphin 1 and 2 (200). Moreover, Met-ENK and 
Leu-ENK have been detected by Capillary liquid chromatography (LC) with MS2 and 
MS3 detection modes (201). Some techniques have been used to avoid degradation 
of peptides such as adding 5% acetic acid, adding protease inhibitors and same day 
detection (202). More recently, LC-MS has been used as an effective method for 
analysis of several neuropeptides such as enkephalins, endorphins, and DYN. 
Detection of DYN A 1-8 together with Met-ENK and Leu-ENK in rat brain was carried 
out by liquid chromatography/mass spectrometry (LC-MS) (203). HPLC-fast atom 
bombardment (FAB) MS was used to measure BE1-31 in human pituitary extracts 
(204). In another study, the quantification of ɑ- and γ- endorphins in homogenised rat 
brain tissue were performed by LC/tandem mass spectrometry (MS/MS) through 
electrospray ionization (ESI) (205). LC-MS is a technique to detect and quantify low 
levels of opioid peptides and other peptides in biological fluid (206). In summary, the 
LC-MS is robust technique for accurate identification of endogenous opioid peptide 
fragments. 
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This chapter examined the biotransformation of BE 1-31 in homogenised inflamed 
tissue at pH 7.4 and pH 5.5 by LC-MS analysis. Two reagents (acetonitrile and TCA) 
were compared for their efficiency in removing proteins from the collected samples. 
In this study, Acetonitrile is used for terminating the fragmentation of opioid peptides 
by enzyme action at different time points as well as protein removal. Acetonitrile was 
selected as the solvent of choice for studying fragmentation at different time points 
due to producing better samples. The MRT values were calculated for each fragment 
representing the average time that a produced fragment resides in the homogenised 
inflamed tissue. Based on the mean residence times, three major N-terminal 
fragments (BE 1-17, BE 1-3, and BE 1-11) were selected for further study. These 
fragments were also incubated in homogenised inflamed tissue to elucidate their 
biotransformation profiles providing an insight into the enzyme processing steps.  
 
2.3. Materials  
 
Standard compounds BE 1-31, BE 1-17, BE 1-13, and BE 1-11 were obtained from 
Mimotopes Pty. Ltd, Australia. MES buffer (pH 5.5, 2-(N-morpholino) ethanesulfonic 
acid) and Sucrose 99+% were purchased from Sigma (St. Louis, MO, USA). 
Phosphate buffer Saline (PBS) tablets were supplied by Astral Scientific Company, 
NSW, Australia.  HPLC grade solvents and buffers were used for chromatography: 
acetonitrile (Merck KGaA, Darmstadt, Germany), formic acid (Nuplex industries 
(Aus) Pty Ltd., NSW, Australia), Milli-Q water (Elix 5 UV analytical grade type 1 
ultrapure water purification system with dual-wavelength UV lamp for the photo-
oxidation of organics, Millipore Corporation, Bedford, MA). TCA was purchased from 
Nuplex industries Pty Ltd. (NSW, Australia). 
 
 2.3.1. Inflamed rat paw preparation 
 
To obtain inflamed paw tissues, animal ethics was obtained from the University of 
Queensland ethics committee. Male Wistar rats were obtained from an institutional 
breeding colony at the University of Queensland. Animals were housed on a 12 h 
dark/light cycle with access to water and food ad libitum. Rats were briefly 
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anaesthetised isoflurane 5% in oxygen.  Freund’s Complete Adjuvant (FCA, 0.15ml; 
Sigma, St. Louis, MO, USA) was administered to a hind paw. After 6 days, rats were 
euthanised and inflamed paw tissues were immediately surgically removed and 
frozen at -80 °C for later use. 
 
 2.3.2. Liquid chromatography  
 
 An Agilent binary HPLC system comprising of an Agilent 1100 LC pump, an Agilent 
1100 well plate auto-sampler (Agilent Technologies, Santa Clara, CA, USA) and a 
Jupiter 5 µ (C4, 300 A, 150x2.00 mm, 5 µ) RP HPLC column (Phenomenex, 
Torrance, CA, USA) were used for separations. The mobile phase flow rate was 200 
µL/min and the volume of injection was 20 µL. The separations were performed 
using a binary solvent gradient; water containing 0.1% v/v formic acid was used as 
the solvent A and acetonitrile containing 0.1% v/v formic acid was used as the 
solvent B. The chromatographic separation was achieved using the following 
gradient (table 2.1): 
 
Table 2.1. Chromatographic gradient used for the separation of BE 1-31 fragments 
 
Time 
(min) 
A% B% 
0 100 0 
3 100 0 
33 50 50 
38 0 100 
40 0 100 
43 100 0 
53 100 0 
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2.3.3. Mass spectrometry  
 
An API 3000 tandem mass spectrometer equipped with a turbo ion spray was used 
as the HPLC detector. Detection was performed in total ion current (TIC) mode 
(MS1/Q1), in positive mode, within the range 200-3000 amu. The data were acquired 
and processed by Analyst 1.5 software (Applied Biosystems, Foster city, CA, USA). 
Mass spectra were obtained using: declustering potential (DF) of 16V, focusing 
potential (FP) of 120V, Entrance potential (EP) of 10V, and Ion spray voltage (IS) of 
5000V. Structure identity of fragments was based on the respective mass/charge 
(m/z) values of each peptide metabolite.  
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2.4. Methods 
 
2.4.1. Comparison of two reagents trichloroacetic acid and acetonitrile for 
sample preparation  
 
There are several reagents available for protein precipitation such as TCA, Acetone, 
Chloroform/methanol, Ammonium sulphate, Acetonitrile, and Zinc sulphate (207). 
Precipitation of proteins with TCA, Acetonitrile, and acetone, and ultrafiltration have 
shown to be efficient (207). In this study, TCA and acetonitrile were compared in 
terms of LC-MS chromatograms obtained. The homogenised inflamed rat paw 
tissues in MES buffer (pH 5.5) were used for this experiment as described in section 
2.3.1.  
 
2.4.1.1. Acetonitrile method 
 
A sample (100 μL) was removed at different incubation periods ranging from 0 to 120 
min. The enzymatic biotransformation process was terminated at these specific time 
points when the proteins (including enzymes) were precipitated by the addition of 
acetonitrile (200 µL) and vortex mixing for 1 min. Samples were incubated for 20 min 
at room temperature followed by 15 min centrifugation at 12 500 relative centrifugal 
force (g) at room temperature. The supernatant was transferred to a fresh 
microcentrifuge tube and dried under nitrogen on a heating block at 37 ͦ C. Milli-Q 
water (75µL) was used to reconstitute each dried sample. Samples were then 
transferred to LC-MS vial inserts for subsequent analysis.  
 
2.4.1.2. TCA method 
 
A sample (100 μL) was removed at different incubation periods ranging from 0 to 120 
min, and TCA was added to a final concentration in the supernatant of 3% (w/v) 
TCA, to precipitate proteins. Samples were then incubated at room temperature for 
20 min to complete the protein precipitation and then centrifuged at 25 °C at 12 500 
g for 10 min. The resultant supernatants were analysed using LC-MS.  
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 2.4.2. Fragmentation of BE 1-31 in homogenised inflamed tissue at pH 5.5 and 
7.4 
 
Inflamed tissue was homogenised in phosphate buffer solution (PBS) pH=7.4 or 
isotonic MES buffer (pH=5.5) at a ratio of 1 g tissue /10ml buffer. The tissue 
homogenate was then centrifuged for 10 min (4ºC) at 1600 g and the supernatant 
collected. BE 1-31 was added to the tissue homogenate supernatant to a resultant 
final concentration of 115 µM of peptide, which is a optimal concentration of BE 1-31 
reported in Herath’s study. Samples (100 µL) of the peptide/tissue homogenate 
mixture were collected at intervals (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, and 120 min) 
during 120 min incubation. The protein removal with acetonitrile was carried out on 
each sample as described in section 2.4.1.1. 
 
2.4.3. Evaluation of the effect of acidic pH on degradation of BE 1-31 without 
using homogenised inflamed tissue 
 
BE 1-31 was added to MES buffer (pH: 5.5) to a resultant final concentration of 115 
µM of peptide. Samples (100 µL) of the peptide in MES buffer were collected at 
intervals (0, 5, 15, 30, 60, and 120) during 120 min incubation. The sample 
extraction was performed as described in section 2.4.1.1. 
 
 2.4.4. Fragmentation of BE 1-17, BE 1-13, BE 1-11 in homogenised inflamed 
tissue in MES buffer 
 
Each peptide was added separately to the tissue homogenate to a resultant final 
concentration of 115 µM of peptide. Samples (100 µL) of the peptide/tissue 
homogenate mixture were collected at intervals (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 
and 120) during a 120 min incubation. Subsequent sample treatment has been 
performed as per section 2.4.1. 
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 2.4.5. Mean Residence Time (MRT) Calculations for Identified Fragments   
 
MRT represents the average time that a molecule resides in a particular environment 
and can be calculated as follows: 
𝑀𝑅𝑇 =
𝐴𝑈𝑀𝐶
𝐴𝑈𝐶
 
Where the AUMC is area under the first moment curve and AUC is area under the 
concentration-time curve. The areas can be expressed in the following manner 
where C (t) is compound concentration at time t [32, 33].  In the following 
calculations chromatographic peptide peak intensity was taken to represent the 
respective peptide concentration. 
𝐴𝑈𝑀𝐶
𝐴𝑈𝐶
=
∫ 𝑡 𝐶(𝑡)𝑑𝑡
𝑡2
𝑡1
∫ 𝐶(𝑡)𝑑𝑡
𝑡2
𝑡1
 
Relative MRT values were calculated from the ratio of the respective MRT of each 
fragment to the MRT of BE 1-31. 
 
Note: Results are displayed from a single analysis and repeated for confirmation of 
findings.  
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2.5. Results 
 
 2.5.1. Comparison of two reagents TCA and acetonitrile for sample 
preparation  
 
BE 1-31 was incubated in homogenised inflamed tissue at pH 5.5 for 120 min. 
Protein precipitation/ sample clean-up was carried out using TCA and acetonitrile. 
The resultant solutions were analysed by LC-MS. In total, 30 fragments were 
identified after incubation of BE 1-31in inflamed tissue at pH 5.5.  BE 19-31, BE 20-
31, BE 5-18, BE 10-31, BE 10-28, and BE 10-16 were major metabolites identified 
with both methods of sample preparation. However, fragments BE 16-30 and BE 5-
24 were identified only with acetonitrile extraction. In addition, the chromatograms 
were cleaner and the peak areas larger with acetonitrile extraction (after allowing for 
changes in dilution). Some of the impurities that cause ion suppression in TCA 
extracts may be lacking in acetonitrile extracts to produce larger peptide peaks. 
Using acetonitrile for sample preparation was therefore found to be superior to TCA 
method. 
 
 2.5.2. Fragmentation of BE 1-31 in homogenised inflamed tissue at pH 7.4 
 
To determine bio-transformed products of BE 1-31, it was incubated, for various 
lengths of time, in an inflamed tissue homogenate at pH 7.4; pH 7.4 representing the 
pH of normal body tissue. Samples were cleaned and analysed by LC-MS and the 
results are shown in table 2.2: The cleavage pattern of identified fragments, their 
observed mass/charge values and MRT are shown. Single, double and triple 
charged ion states were observed for most of the fragments. Intact BE 1-31 was 
detected at a retention time of 25.8. The following mass/charge values were 
observed for BE (1-31):  
Charge state    +2           +3             +4           +5            +6 
M/Z                   1734        1156.3     868        694.2       578.8 
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the mass spectra of water, homogenised inflamed tissue, BE 1-31 in homogenised 
inflamed tissue at zero time were shown in appendix 1, I, II, III.
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Table 2.2. List of fragments produced after incubation of BE 1-31 in homogenised tissue at pH 7.4. MRT and MRT ratio were calculated for fragments 
and retention time and mass/charge values for each fragment are listed. a: not detected and b: not calculated. 
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The rate of metabolism of BE 1-31 in inflamed rat paw tissue incubation at pH 7.4 is 
shown in Figure 2.1. A total of 29 BE 1-31 fragments with amino acid sequences: BE 
29-31, BE 19-31, BE 21-31, BE 19-30, BE 20-31, BE 18-31, BE 20-24, BE 6-16 (see 
appendix 1, v), BE 2-14, BE 3-16, BE 5-18 (Figure 2.1, A) (see appendix 1, vi), BE1-
16, BE 7-16, BE 6-17 (Figure 2.1, B) (see appendix 1, vii), BE 7-17, BE 8-17 (see 
appendix 1, viii), BE 9-17, BE12-17, BE 2-16, BE 10-31, BE1-17, BE 6-18, BE 7-18, 
BE 8-18 (see appendix 1, viii), 1-18, 2-18 (Figure 2.1, C), were detected at pH 7.4. 
C-terminal fragments (BE 20-31, BE 21-31, BE 19-31, and BE 29-31) and 
intermediate fragments (BE 6-16, BE 3-16, and BE 5-18) resided in inflamed tissue 
at pH 7.4 for a longer time compared to N-terminal fragments. BE 1-16 remained in 
inflamed tissue for nearly 59 min displaying higher MRT compared to other N-
terminal fragments. BE 1-16 (ɑ-endorphin), BE 1-17 (γ-endorphin), BE 20-31, and 
BE 21-31 were observed earlier than other fragments (within 5 min) (Figure 2.1, A).  
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Figure 2.1. Biotransformation of BE 1-31 in inflamed tissue homogenate at pH 7.4 at 37°C over 
180 min.  Fragments BE 3-16, BE 2-14, BE 20-24, BE 20-31, BE 6-16 and BE 21-31 (A), Fragments 
BE 16-30, BE 6-22, BE 2-17, BE 6-18, and BE 2-18, and BE 1-31 (B), Fragments BE 5-18, BE 1-16, 
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BE 6-17,  BE 7-17, BE 9-17, BE 12-17, and BE 1-17  (C). The peak area of each fragment was 
determined at each time point and plotted. 
 
2.5.3. Fragmentation of BE 1-31 in homogenised inflamed tissue at pH 5.5 
 
BE 1-31 was incubated in an inflamed tissue homogenate at pH 5.5; representing 
the localised acidic environment seen in inflammation. Samples were analysed by 
LC-MS and the biotransformation pattern of BE1-31 in inflamed tissue is depicted in 
Table 3. MRT and relative MRT for BE 1-31 and produced fragments are listed in 
table 3. C-terminal fragments BE 19-31 and BE 20-31, and intermediate fragments 
BE 10-16, BE 20-24, BE 20-27, and BE 20-28 possess higher MRT compared to N-
terminal fragments (Table 2.3).  
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Table 2.3. List of fragments produced after incubation of BE 1-31 in homogenised tissue at pH 5.5. MRT and MRT ratio were calculated for fragments 
and retention time and mass/charge values for each fragment were listed. a: not detected and b: not calculated. 
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The peak intensity of BE 1-31 reduced rapidly such that only 7.5% of parent peptide 
was detected at 15 min (Figure 2.2). The following BE 1-31 fragments were detected 
: BE19-31, BE 21-31, BE 19-30, BE 20-31, BE 20-29 (see appendix 2, iii), BE 11-18, 
BE 18-31, BE 20-28, BE 20-24 (see appendix 2, iv), BE 20-27, BE 6-16 (see 
appendix 2, v), BE 5-24, BE 10-16, BE 2-13, BE 1-9, BE 2-14, BE 5-18, BE 15-24, 
BE 1-16, BE1-15 (see appendix 2, vi), BE 1-20 (see appendix 2, vii), BE 10-31 (see 
appendix 2, viii), BE10-28, BE 10-18, and BE 10-24. The production and degradation 
of fragments BE 5-18, BE 10-16, BE 10-28, and BE 10-31 are shown in Figure 2.2. 
 
 
 
Figure 2.2. Biotransformation of BE 1-31 in inflamed tissue homogenate at pH 5.5 at 37°C over 
60 min. The production and degradation of major intermediate and C-terminal  fragments produced 
after incubation of BE 1-31 in inflamed tissue homogenate at pH 5.5 at 37°C over 60 min. The peak 
area of each fragment was determined at each time point and plotted. 
 
BE 1-16, BE 1-17, BE 1-18, and BE1-20 appeared after 2 min of incubation of BE 1-
31 in homogenised inflamed tissue at pH 5.5 (Figure 2.3). The common cleavage 
area at BE 1-31 was detected between amino acid Leu17 and Phe18. After 5 min 
incubation of BE 1-31, BE 1-13 was detected with higher peak intensity compared to 
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other biotransformed fragments. In addition, BE 1-13 resided in inflamed tissue for 
over 1 h. The time profile of production of N-terminal fragments of BE 1-31 is shown 
in Figure 2.3.  
 
 
Figure 2.3. Biotransformation of BE 1-31 in inflamed tissue homogenate at pH 5.5 at 37°C over 
60 min. The production and degradation of N-terminal fragments produced after incubation of BE 1-
31 in inflamed tissue homogenate at pH 5.5 at 37°C over 60 min. The peak area of each fragment 
was determined at each time point and plotted. 
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2.5.4. Evaluation of the effect of acidic pH on degradation of BE 1-31 without 
using homogenised inflamed tissue 
 
To confirm the cleavage of BE 1-31 was due to enzymes and not due to the acidic 
pH. BE 1-31 was added to MES buffer only and incubated for 120 min. The LC-MS 
results showed no fragments confirming that the acidic pH did not cleave BE 1-31 
and the enzymes present in homogenised inflamed tissue are responsible for 
biotransformation of BE 1-31 into different fragments. 
 
2.5.5. Fragmentation of BE 1-17 in homogenised inflamed tissue at pH 5.5 
 
BE 1-17 was identified as one of the major N-terminal fragments of biotransformation 
of BE 1-31 in inflamed tissue as described in section 2.5.3. As mentioned in Chapter 
1, Tyr at N-terminal side of BE 1-31 is important for opioid receptor binding activity. 
Therefore the biotransformation of other C-terminal or intermediate fragments was 
not evaluated although they displayed a higher MRT. This peptide is known as γ-
endorphin. BE 1-17 was incubated in an inflamed tissue homogenate at pH 5.5 for 
various time periods and the samples were analysed by using LC-MS. The results 
are shown in Table 2.4 and figure 2.4.  
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Table 2.4. List of fragments produced after incubation of BE 1-17 in homogenised tissue at pH 
5.5. MRT and MRT ratio were calculated for fragments and retention time and mass/charge values for 
each fragment were listed. a: not detected and b: not calculated. 
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Figure 2-4. Biotransformation of BE 1-17 in inflamed tissue homogenate at pH 5.5 at 37°C over 
60 min. The peak area of each fragment was determined at each time point and plotted. 
 
BE 1-17 was not detectable after 15 min of incubation (Figure 2.4). Fragments BE 1-
16, BE 1-15, BE 2-17, and BE 3-17 were observed after 2 min of incubation of BE 1-
17, although they disappeared after 5 min. BE 1-13, BE 1-11, BE 2-17, BE 2-13, and 
BE 2-9 were the major fragments produced after incubation of BE 1-17 in an 
inflamed tissue homogenate at pH 5.5. BE 1-13 and BE 2-13 were detected after 2 
min incubation, while BE 2-9 was observed prior to BE 1-9.   
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2.5.6. Fragmentation of BE 1-13 in homogenised inflamed tissue at pH 5.5 
 
BE 1-13 was observed as the major fragment metabolite after incubation of BE 1-17 
and BE 1-31 in the homogenised inflamed rat paw. BE 1-13 was observed at a 
retention time of 18.5 min. To determine bio-transformed products of BE 1-13, BE 1-
13 was incubated in an inflamed tissue homogenate at pH 5.5 and samples taken 
periodically. Samples were analysed by LC-MS and the results shown in table 2.5 
and figure 2.5.  
 
 
 
Table 2.5. List of fragments produced after incubation of BE 1-13 in homogenised tissue at pH 
5.5. MRT and MRT ratio were calculated for fragments and retention time and mass/charge values for 
each fragment are listed. a: not detected. 
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Figure 2.5. Biotransformation of BE 1-13 in inflamed tissue homogenate at pH 5.5 at 37°C over 
60 min. The peak area of each fragment was determined at each time point and plotted. 
 
BE 1-11 and BE 2-13 appeared after 2 min incubation of BE 1-13 in an inflamed 
tissue homogenate at pH 5.5 (Figure 2.5). BE 2-13 was detected as a major 
biotransformed fragment of BE 1-13. BE 3-13, BE 4-13, BE 2-12, and BE 2-11were 
observed following the detection of BE 2-13 and BE 1-11. BE 1-11 reached 
maximum peak intensity after 5 min. However, other fragments reached their 
maximum peak intensities after 15 min and resided in inflamed tissue homogenate 
for 45 min.  
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2.5.7. Fragmentation of BE 1-11 in homogenised inflamed tissue in MES buffer 
 
BE 1-11 was detected after biotransformation of BE 1-31, BE 1-17, and BE 1-13 in 
homogenised tissue at pH 5.5. BE 1-11 was produced after enzymatic hydrolysis 
between Gln-11 and Thr-12 and appeared at a retention time of 17.4 min. To identify 
biotransformed fragments of BE 1-11, BE 1-11 was incubated in an inflamed tissue 
homogenate at pH 5.5 for various time periods. LC-MS was used to analyse the 
samples and the results are shown in Table 2.6 and Figure 2.6. 
 
 
 
Table 2.6. List of fragments produced after incubation of BE 1-11 in homogenised tissue at pH 
5.5. MRT and MRT ratio were calculated for fragments and retention time and mass/charge values for 
each fragment were listed. a: not detected. 
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Figure 2.6. Biotransformation of BE 1-11 in inflamed tissue homogenate at pH 5.5 at 37°C over 
60 min. The peak area of each fragment was determined at each time point and plotted. 
 
BE 2-11, BE 3-11, BE 4-11, and BE 2-9 were major metabolites produced after 
degradation of BE 1-11 in homogenised tissue at pH 5.5 (Figure 2.6). BE 2-11 was 
the major fragment with highest peak intensity compared to other biotransformed 
fragments of BE 1-11. Biotransformed fragments of BE 1-11 reached their maximum 
peak intensities after 15 min incubation. 
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2.6. Discussion 
 
During inflammation, the production of BE 1-31 is increased in leukocytes and it is 
subsequently released in inflamed tissue after which it undergoes rapid 
biotransformation (2, 65, 208). There is variability in the reported literature with 
regards to clearance, distribution and half-life of BE 1-31 (54, 55), which can be 
attributed substantially to the species studied, tissue source and anatomical location 
being examined (13, 39, 64, 193-197). In this study, BE 1-31 incubated in 
homogenised inflamed tissue at physiological pH 7.4 and acidic pH 5.5, produced 29 
fragments at pH 7.4 and 30 fragments at pH 5.5. BE 19-30, BE 20-31, BE 20-24, BE 
2-14, BE 5-18, BE 1-16, BE 10-31 were observed at both pH 7.4 and pH 5.5 
indicating the potential sites for enzymatic cleavage between following amino acid 
pairs: Tyr1-Gly2, Leu14-Val15, Phe18-Lys19, Lys19-Asn20, Lys24-Asn25, Lys28-Lys29. 
However, more potential cleavage sites between the following amino acid pairs: 
Lys9-Ser10, Pro13-Leu14, Leu17-Phe18 were detected when BE 1-31 were incubated in 
homogenised inflamed tissue at pH 5.5. Fragments BE 2-17, BE 6-17, E 7-17, BE 8-
17, BE 9-17, BE 12-17, BE 2-14, BE 2-18, BE 6-18, and BE 8-18 were only detected 
at pH 7.4. The following fragments were detected at both pH: BE 6-16, BE 1-16, BE 
20-24, BE 1-17, BE 19-31, BE 20-31, BE 29-31, BE 10-31. 
 
The pH in inflamed tissue has been found to be as low as 5.2 resulting in an 
increased activity of some enzymes such as serine protease and dipeptidyl 
peptidase (209, 210). The metabolism rate of BE 1-31 in acidic pH (5.5) was greater 
than that in normal pH (pH: 7.4) and may be attributed to the pH increasing the 
activity of select enzymes.  For this reason, more fragments were observed after 5 
min incubation of BE 1-31 at pH 5.5.  
 
The MRT of peptide fragments were estimated by using statistical moment theory 
(211). C-terminal fragments and intermediate fragments displayed higher MRT 
values compared to N-terminal fragments. Furthermore, the C-terminal fragments 
were eluted at a lower retention time, indicative of their higher polarity compared to 
N-terminal fragments. Primary fragments are fragments, which were detected in the 
early time point of sample collection. However, the focus of this study was to explore 
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the presence of N-terminal fragments with higher MRT., As mentioned in Chapter 1, 
tyr amino acid at N-terminal side of BE 1-31 is important for opioid activity. 
 
 
Similar to the current study, BE 1-16, BE 1-17, and BE 1-18 were detected as 
primary metabolites in the extracellular biotransformation of BE 1-31 in rat striatum 
and cerebrospinal fluid (14) implying amino acid sequence Thr16-Leu17-Phe18-Lys19 
has potential sites for enzymatic degradation of BE 1-31. BE 1-31 (1 nM) was 
infused into the striatum of adult male Fischer rat and microinfusion/ micro dialysis 
was used to collect samples and matrix-assisted laser desorption/ionisation mass 
spectrometry was used to detect BE 1-31 fragments (14). BE 1-17, BE 1-18, BE 18-
31 and BE 19-31 have also been detected as major metabolites after metabolism of 
BE 1-31 in T cells, thymoma cells (39)  and cultured aortic endothelial cells (195). 
This confirms that Leu17-Phe18-Lys19 in the structure of BE 1-31 is more susceptible 
to metabolism by enzymes independent of the environment to which BE 1-31 is 
released. The degradation of human BE 1-31 by a human plasma protease was 
investigated by Sandin  et al. (13). BE 1-19 and BE 20-31 were identified as major 
fragments using LC-electrospray mass spectrometry. Metal dependent serine 
protease was identified as the enzyme responsible for this process. Sarada et al. 
showed endopeptidase hydrolysis of BE 1-31 by human peripheral blood CD4+ T 
cells activated with immobilized anti-CD3. BE 1-17 was detected as the primary 
metabolite and BE 1-18, BE 2-18, BE 1-17, BE 2-17, BE 18-31, BE 19-31, BE 1-13, 
BE 2-13, BE 18-26, BE 20-31 were also detected. Except BE 18-26, all other 
fragments were also identified in the current study.  
 
Biotransformation of BE 1-31 in rat brain synaptosomal plasma membrane (SPM) 
produced γ-endorphin (193). γ-endorphin was produced from the activity of 
cathepsin D in acidic pH and from activity of SPM associated peptidase in pH 7.4.  
The activity of SPM associated peptidase was not blocked by the specific cathepsin 
D inhibitor (bestatin). Proteolytic conversion of BE 1-31 by synaptic membrane-
bound peptidase in rat brain was investigated by Burbach et al. (64) using HPLC. 
They showed that fragments BE 1-21 and BE 2-21 were produced at pH 7.4 and 
fragments BE 18-31, BE 1-14, BE 1-13, BE 1-17, BE 1-16, BE 2-17, BE 2-16 were 
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produced at pH 5.0 (64). In addition, BE 1-17 was shown to be degraded to BE 1-16, 
BE 1-15, BE 1-14, BE 1-13 by CP A at pH 5.0 (64). The extracellular 
biotransformation of BE 1-31 was investigated in three different cell lines (CD4+, 
CD8+, and the thymoma cell line, EL4) by Miller et al. (39).  A secreted, metal-
dependent, thiol peptidase was detected as the enzyme responsible for the 
metabolism of BE 1-31 in three different cell lines. BE 1-17, BE 1-18, BE 18-31, BE 
19-31 were produced at approximately equal rates displaying the susceptibility of BE 
1-31 at amino acid sequence of Phe18-Lys19 and Leu17- Phe18 for enzymatic 
cleavage. BE 1-31 is cleaved by endopeptidase enzyme between amino acid Leu17 
and Phe18 to produce BE 1-17 and BE 18-31. This enzyme acted like a thiol 
endopeptidase, since its activity was blocked by using low concentration of N-
ethylmaleimide, p-chloromercuibenzoate, p-chloromercuribenzoyl sulphate, and Hg+2 
(194).  
 
BE 1-17, noted in this chapter and also in other studies was identified as one of the 
N-terminal fragments of BE 1-31 fragments. In this study, further processing of BE 1-
17 was performed to ascertain the biotransformed peptides produced as a 
consequence of the high residence time of BE 1-17 within inflamed tissue 
homogenates. The rate of hydrolysis (assessed using MRT data) at the C-terminus 
of BE 1-17 was greater than that of the enzymatic cleavage at N-terminus of that 
peptide over a 2 h of incubation. BE 1-17 incubation with inflamed tissue 
homogenates yielded BE 1-16, BE 1-15, BE 1-14, and BE 1-13 within the first 5 
minutes of sampling. This demonstrated that BE1-17 undergoes rapid, sequential, C-
terminal metabolism. BE 2-9, BE 2-13, and BE 2-11 were then identified as major 
secondary metabolites of the metabolism of BE 1-17. BE 2-9, one of the major 
hydrolysis products of BE 1-17, was detected prior to the appearance of BE 1-9 with 
a greater peak intensity highlighting its potential formation from longer des-Tyr 
fragments such as BE 2-17, BE 2-16, BE 2-13, and BE 2-11. The conclusion that the 
BE 2-13 peptide was produced principally from BE 1-13 is supported by the 
observation that the production of BE 2-13 increased coinciding with the degradation 
of BE 1-13. BE 2-11 was observed as a significant metabolite of BE 1-17 hydrolysis 
most likely from a BE 1-11 precursor. BE 2-11; however, demonstrated higher peak 
intensity than BE 1-11 indicating that it may be produced from other peptides in 
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addition to BE 1-11. In general, des-Tyr metabolites (BE 2-9, BE 2-11, BE 2-13) had 
greater peak intensities compared to BE 1-9, BE 1-11, and BE 1-13. This study 
emphasises that BE 1-31 and its fragments are sensitive to enzymatic degradation 
between amino acids Tyr1-Gly2. It was shown that substitution of Gly with D-Ala and 
also substitution of Phe with Me-Phe, in Met-enkephalin enhanced the stability of the 
compound (212).  
 
It has previously been demonstrated that a number of the des-Tyr hydrolysis 
metabolites of BE 1-17 may produce a range of biological effects. Wied et al. 
demonstrated that BE 2-17 mimics certain defined effects of neuroleptics (213) and 
in a separate study BE 2-16 and BE 2-17 were reported to increase natural killer cell 
activity. Such non-opioid fragments are known to be more potent in increasing 
lymphocyte natural killer cell activity, via an unknown mechanism (214), in 
comparison to opioid fragments such as BE 1-31 and BE 1-17. The peptides BE 2-
16 and BE 2-9 were also shown to have amphetamine-like activity in rats delaying 
the extinction of pole-jumping avoidance behaviour and facilitating passive 
avoidance behaviours (213). In addition, BE 2-9 can increase the stereotypical 
sniffing response induced by amphetamine injection into nucleus caudatus (213, 
215). BE 10-16, one of the major intermediate hydrolysis metabolites which was 
identified in the biotransformation of BE 1-31 in homogenised inflamed tissue, has 
previously been shown to produce serotonin-like effects, inhibiting the behavioural 
effect of melatonin injected into the nucleus accumbens (213, 216). 
 
In the present study, the helical structure of BE 1-31 and its fragments was not 
evaluated. Depending on structure of peptide, susceptible area to enzyme breakage 
in peptide can be exposed more to be broken down by enzymes and or can be also 
hidden from enzymes. Therefore, the three dimensional structure of peptide can 
affect the rate of biotransformation and also produced fragments. Further 
investigation of BE 1-31 biotransformation in the inflammatory environments may 
provide an insight into key fragments with different pharmacological actions unique 
to the inflammatory environment. Therefore, the identification of BE 1-31 fragments 
and studying their roles in inflammation is of paramount consideration in 
understanding peripheral opioid action. 
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2.7. Conclusion 
 
BE 1-31 is susceptible to increased enzymatic degradation within the inflamed 
milieu. BE 1-20, BE 1-17, BE 1-13 and BE 1-11 were identified as major N-terminal 
fragments after incubation of BE 1-31 in inflamed tissue homogenates. 
Biotransformed fragments were also unstable and degraded to multiple fragments.  
The hydrolysis locus in BE 1-17, 1-13, and BE 1-11 was shown to be between amino 
acids Tyr1-Gly2. BE 2-9, BE 2-13, and BE 2-17 were major fragments after incubation 
of BE 1-17 in inflamed tissue homogenates. BE 1-11 and BE 2-13 were detected in 
early fractions of bio-transformed BE 1-13. BE 2-11, 3-11, 4-11 and 2-9 were 
detected following incubation of BE 1-11 in inflamed tissue.  
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 : Effect of bio-transformed fragments of BE 1-31 Chapter 3
on modulation of cAMP 
 
 
3.1. Foreword 
 
This chapter describes a detailed study of cAMP modulation of five N-terminal 
fragments of BE 1-31 in HEK cells stably expressing MOP, DOP, and KOP 
receptors. The Alphascreen cAMP assay was used for measuring cAMP 
accumulation. Parts of this chapter have been published in my recent publication in 
PLOSone (217). 
 
3.2. Introduction 
       
 Opioids are not only involved in the activation of opioid receptors in the spinal cord 
and brain, but may also be involved in the activation of opioid receptors on peripheral 
sensory neurons (164). Endogenous opioid peptides have varying affinities for the 
MOP, DOP, and KOP receptors. Levine et al. demonstrated that only the agonists of 
MOP produce peripheral analgesia via binding and activating to MOPs on the 
peripheral terminals of primary afferents. Their actions are mediated by blocking the 
production of cAMP (218). MOP receptors have also been suggested to inhibit 
calcium channels via a direct interaction between the beta gamma subunit and the 
calcium channel (219). 
 
BE 1-31 is a non-selective endogenous peptide with the highest affinity at MOP and 
DOP (4). BE 1-31 is degraded by variety of enzymes in inflamed tissue. Therefore, 
other biotransformed fragments may activate opioid receptors and may act as a 
substitution for BE 1-31 with similar potency. BE 1-31 is a potent analgesic peptide 
showing antinociceptive activity in the tail-flick, hot plate, and writhing tests in mice-
test of the pain response in animal model- and in the wet shake test in rats when it is 
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administered directly intracerebrally (IC) (220). BE 1-31 produced antinociceptive 
activity and catalepsy when it was administered at low doses (1.3 to 2.7 μg) into the 
anterior hypothalamus and nucleus accumbens of rat (221). Deakin et al. showed 
that the removal of one, two, or four amino acids from the C-terminal of BE 1-31 
caused a reduction in the affinity and  potency of the BE 1-31 fragments. Moreover, 
the removal of tyrosine amino acid at the N-terminal was shown to remove opioid 
binding and opioid analgesic activity (222). This indicates that the amino acids at the 
N-terminal amino acid of BE 1-31 are necessary for the analgesic properties of the 
ligand. In contrast, amino acid sequences in the C-terminal determine the potency of 
the opioid peptide. In addition, N-acetyl derivatives of BE 1-31 naturally found in the 
pituitary and brain, did not produce opioid activity (222). BE 1-27 and BE 1-26 also 
detected in the brain and pituitary did not display analgesic activity (223, 224). BE1-
27 (intra-cerebroventricularly) blocked the analgesic effect of BE 1-31 in mice (225).  
A parallel shift in the dose-response curve of BE 1-31 in the presence of BE 1-27 
suggests they compete for the same binding site (225). The antagonistic potency of 
BE 1-27 at reducing BE 1-31 analgesia was shown to be 4 times greater than that of 
the potent non selective opioid antagonist, naloxone (225). However, further C-
terminal truncation of the fragment BE 1-27 removed the antagonist effect (223, 
224).  
 
Chapter 2 described that BE 1-31 was unstable in inflamed tissue and was degraded 
to several smaller fragments. As the opioid activity of BE 1-31 is largely indicated by 
the presence of Tyr at position 1, the N-terminal fragments of BE 1-31 are the focus 
of this study, BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20 were the major N-
terminal fragments in biotransformation of BE 1-31. In this chapter, BE 1-9, BE 1-11, 
BE 1-13, and BE 1-17 were selected for investigation of their potential agonist 
activity on HEK cells expressing MOP. The cAMP modulation activity of BE 1-20 on 
HEK-MOP cells was performed previously in our lab by Dr. Dilanthi Herath (217).   
Fragments, BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20 were chosen to 
examine their activity on HEK cells expressing DOP  and also HEK cells expressing 
KOP.  A cAMP Alphascreen assay was selected for evaluating the agonist and 
antagonist activity of opioid fragments on opioid receptors. In addition, the effect of a 
mixture of different concentrations of N-terminal fragments (BE 1-9 or BE 1-17) with 
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C-terminal fragments (BE 19-31, BE 20-31, and BE 29-31) on cAMP accumulation 
were evaluated for possible C-terminal positive or negative modulation of the N-
terminal fragments efficacy; this type of interaction is described by the concept of 
positive and negative allosteric modulator in Chapter 1 section 1.4.2.  
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3.3. Materials 
 
HEK 293 (Human Embryonic Kidney) cells independently and stably expressing 
MOP, DOP, and KOP receptors were used to examine endogenous opioid peptide 
efficacy (a kind gift from Professor Maree Smith, University of Queensland, 
Australia). DMEM (Dulbecco’s Modified Eagle Medium) and FBS (Foetal Bovine 
Serum) were purchased from PAA Laboratories GmbH, Australia. Trypsin-EDTA 
(0.25%), G418  sulfate (Genetecin) and Versene were supplied from Invitrogen, Mt 
Waverly, Australia.   Versene is a tetrasodium ethylenediaminetetraacetate (EDTA 
(Na4)) solution for use as a gentle non-enzymatic cell dissociation reagent. Versene 
solution (0.48 mM) is formulated as 0.2 g EDTA (Na4) per liter of Phosphate Buffered 
Saline (PBS). BE1-31, BE 1-20, BE 1-17, BE 1-13, BE 1-11, BE 1-9, BE 19-31, BE 
20-31, and BE 29-31 were obtained from Mimotopes Company, Melbourne, Australia 
and the purity was greater than 95% for all peptides. 
 
Stimulation buffer (pH 7.4) containing 0.1% bovine serum albumin (BSA), 0.5mM 3-
isobutyl-1-methylxanthine (IBMX) and 5mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES). 
 
Lysis/detection buffer (pH 7.4) containing 0.1% BSA, 0.3% Tween 20 (10%), and 
5mM HEPES in Milli-Q water were freshly prepared prior to use.  
 
BSA and Tween 20 were obtained from Research Organics, Cleveland, OH, USA. 
IBMX, and SNC-80 (4-[(R)-[(2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl](3-
methoxyphenyl)methyl]-N,N-diethylbenzamide) were purchased from Alexis 
Biochemicals, Switzerland. U50, 488, 3-amino-propyltriethoxysilane (APTS) 2-(3,4-
Dichlorophenyl)-N-methyl-N-[(1R,2R)-2-(1-pyrrolidinyl) cyclohexyl]acetamide was 
supplied from Enzo Life Sciences, INC, NY, USA.  Forskolin (FSK) 
((3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6,10,10b-trihydroxy-3,4a,7,7,10a-
pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzo[f]chromen-5-yl acetate) was 
obtained from Enzo Life Sciences, INC, NY, USA. HEPES, Hank’s balanced saline 
solution (HBSS), naloxone and sodium bicarbonate were supplied by Sigma Aldrich, 
St. Louis, MO, USA. The determination of cAMP was performed using an 
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Alphascreen cAMP assay kit (code 6760625M) purchased from Perkin Elmer, 
Massachusetts, USA. 
 
3.4. Methods 
 
3.4.1. HEK cell tissue culture 
 
HEK 293 (Human Embryonic Kidney) cells independently and stably expressing 
MOP, DOP, and KOP were used to examine opioid potency on the accumulation of 
cAMP. Prior to this study, HEK 293 cells were transfected with pcDNA3 containing 
FLAG-MOP using Lipofectamine 2000 (Invitrogen Australia Pty Ltd, Mulgrave, 
Victoria, Australia). Stable FLAG-MOP cells were selected using geneticin. 
Immunohistochemistry and western blotting were used to verify FLAG-MOP 
expression. Plasmids that contain cDNA, encode the murine FLAG-epitope-tagged 
MOP (FLAG-MOP) [32]. A similar process was conducted for HEK-DOP and HEK-
KOP cell lines. Passage numbers for HEK-MOP cells were 38–53. Passage 
numbers for HEK-DOP cells were 15–30, and passage numbers for HEK-KOP cells 
were 25–36. 
 
Stably transfected HEK 293 cells (expressing MOP, KOP, DOP individually) were 
split every 3-4 days, when the cells were approximately 70-80% confluent by adding 
1 mL/75 cm2 of trypsin/EDTA. Cells were then incubated for 1-2 min at 37 °C. Cells 
were detached by tapping the culture flask gently. The detached cells were diluted in 
5 mL DMEM containing 10% w/v FBS and 1% w/v Geneticin. Cells were split in 
ratios of 1:10 into T-75 cm2 tissue culture flasks (Corning life sciences). Cells were 
subcultured into T-75 cm2 tissue culture flask and kept in a 5% humidified CO2 
incubator at 37 °C. Cells were not used beyond passage 55 for experiments. For 
long storage of cells, cells were detached by adding trypsin-EDTA and centrifuged at 
350 g for 2 min and resuspended in freezing media containing 10% DMSO to culture 
media with 50% FBS. The resulting cell suspension was stored at -80 °C up to a few 
weeks or stored in liquid nitrogen for long-term cryopreservation. 
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3.4.2. cAMP Alphascreen assay 
 
Stimulation and lysis buffer were freshly prepared each day as described in section 
3.3. cAMP standards were serially diluted in stimulation buffer to provide a 
concentration range of 1.5x10-9 to 5x10-6 M in half log unit intervals (Appendix 3.i).  
Similarly, FSK was serially diluted with stimulation buffer to provide a concentration 
range of 0 to 2x10-3 M in half log unit intervals. cAMP dilution series (5 µL), FSK 
dilution series (5 µL) or the mixture of FSK (specific concentration) and drug (5 µL) 
were plated in individual wells in half area 96 well micro-plates. Cells grown to 70-
80% confluence (in 75 cm2 flask) were used for the cAMP assay. Cells were washed 
with PBS and detached by incubating at 37 °C for 5 min with Versene. Cells were 
then diluted with PBS (5 mL) and centrifuged at 280 g for 5 min at 23°C. Cells were 
counted and then reconstituted in stimulation buffer. Cells were diluted with the 
acceptor bead working solution and the stimulation buffer containing 0.2 units/µL of 
anti-cAMP acceptor beads. An anti-acceptor bead solution (5 µL, 0.2 units/ µL) 
consisting of the desired number of cells was also added to the 96-well plate.  The 
plate was incubated for 30 min with gentle mixing on an orbital shaker. After this 
incubation, streptavidin donor beads and biotinylated cAMP (15 µL) mixture was 
added to each well. Biotinylated cAMP was prepared by diluting in lysis buffer in ratio 
of 1:40 before adding to streptavidin donor bead plus lysis buffer. The mixture of 
streptavidin donor beads and biotinylated cAMP in lysis buffer was prepared 30 min 
before adding to each well. The plate was incubated overnight with gentle shaking 
on the orbital shaker. Alpha screen signals were measured by an EnVision® 
Multilabel Reader (2104-0010) from PerkinElmer. Assay reactions were performed 
for each treatment at least three times in three replicates.   The plate was covered by 
micro-plate press-on adhesive sealing film and also aluminium foil during all 
incubations procedures to avoid evaporation and light, respectively.   
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3.4.3. Determination of optimal cell density and forskolin concentration for 
cAMP Alphascreen assay in HEK cells stably expressing opioid receptors 
 
Optimization of cell density and FSK concentration for HEK-KOP was performed in 
our laboratory previously. The optimal cell numbers and FSK concentration for HEK-
KOP were 103 cells/well and 300 µM respectively (217).  
 
HEK-MOP and HEK-DOP were cultured and harvested as described in section 3.4.2. 
Cells at density of 12x102, 4x103, and 8x103 cells/µL were diluted with the acceptor 
bead working solution and the stimulation buffer containing 0.2 units/µL of anti-cAMP 
acceptor beads. The Alphascreen cAMP assay was carried out as described in 
section 3.4.2.  
 
3.4.4. Screening of selected fragments on the inhibition of forskolin-stimulated 
cAMP accumulation in HEK cells expressing opioid receptors 
 
For screening of C-terminal fragments (BE 19-31, BE 20-31, and BE 29-31) on HEK-
MOP cells, HEK-MOP cells were cultured and harvested as described in section 
3.4.2. The number of HEK-MOP cells was 2x104 cells/well and FSK concentration 
was 100 µM. Concentrations of 10 nM and 1 µM were selected for screening of C-
terminal fragments. The Alphascreen cAMP assay was performed the same as 
described in section 3.4.2. 
 
For screening of fragments of BE 1-31 (BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 
1-20), HEK cells expressing KOP receptors were cultured and harvested (as 
according to the method described in section 3.4.2) with the optimised 
concentrations of cells being 103 cells/well and FSK concentration 300 µM/well. Two 
concentrations of each opioid peptide were examined (Low concentration: 10 nM 
and high concentration: 1 µM). The Alphascreen cAMP assay was performed as 
described in section 3.4.2.  
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3.4.5. Evaluation of concentration dependent cAMP inhibition by BE 1-31, BE 
1-20, BE 1-17, BE 1-13, BE 1-11, and BE 1-9 in HEK cells expressing opioid 
receptors 
 
HEK cells stably expressing MOP and DOP were cultured and harvested as 
described in section 3.4.2. The number of cells was 2x104 cells/well for both HEK 
MOP and HEK DOP cells. The optimised final concentration of FSK/well was 50 µM 
for HEK-DOP cells and 100 µM for HEK-MOP cells. The concentration range of 
opioid peptides (BE 1-31, BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20) was 0.3 
nM to 1 µM in half log intervals/well.  The Alphascreen cAMP assay was performed 
the same as that explained in section 3.4.2. The evaluation of concentration 
dependent cAMP inhibition by fragments of BE 1-31 was not performed in HEK-KOP 
cells as this study did not progress past the screening protocol (results section 
3.4.4). 
 
3.4.6. Opioid Antagonism of BE 1-31 fragments inhibition of cAMP 
accumulation in HEK cells expressing opioid receptors 
 
Naloxone is a potent non-selective antagonist for opioid receptors. A mixture of cells 
(2x104 cells/well), anti-acceptor beads (0.2 units/ µL), and naloxone (100 µM)  (7 µL) 
was added to each well and incubated for 30 min while the plate was covered by 
aluminium foil on an orbital shaker. After the cells had completed the 30 min 
naloxone incubation, a mixture of BE 1-31 fragments (50 nM) with FSK was added to 
incubate for a further 30 min. The Alphascreen cAMP assay was performed as 
described in section 3.4.2. 
 
3.4.7 Evaluation of effect of mixture of N-terminal and C-terminal fragments in 
HEK cells expressing MOP  
 
The procedure was performed as per section 3.4.5. A mixture of high concentration 
(1 µM) of C-terminal fragments (BE 19-31, BE 20-31, and BE 29-31) and different 
concentrations (from 1 nM to 1 µM in half log intervals) of BE 1-9 and BE 1-17 were 
selected to examine the possible positive or negative effect of C-terminal fragments 
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in agonist activity of N-terminal fragments through allosteric regulatory site in opioid 
receptors. The Alphascreen cAMP assay was performed as described in section 
3.4.2. 
 
3.4.8. Statistical analysis 
 
Data calculations and statistical analysis were performed using Prism software 
(GraphPad Software Inc., CA, USA). The dose-response curves were plotted using 
one-site curve fitting in the Prism software using nonlinear regression analysis. 95% 
confidence interval was implemented for comparison of IC50 of BE 1-31 and each 
fragment. The comparison between naloxone treated and naloxone untreated groups 
were performed using one-way ANOVA followed by Bonferroni post-test. 
Significance is denoted by * (P˂ 0.05). 
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3.5 Results 
 
3.5.1 Standard curve of cAMP 
 
 The production of the signal depends on concentration of cAMP. The signal was 
higher with low concentration of cAMP. Conversion of the detected signals for each 
treatment to cAMP concentration was calculated based on a cAMP standard curve 
(Figure 3.1).  
 
 
 
 
Figure 3.1. cAMP standard curve. A serial dilution of cAMP was prepared to provide a concentration 
range of 1.5x10
-9
 to 5x10
-6
 M in half log intervals. Alpha screen signals were measured by an 
EnVision
®
 Multilabel Reader. The data is presented as mean ± SEM of three separate experiments 
(n=3). 
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3.5.2 Determination of optimal cell density and forskolin concentration for 
cAMP Alphascreen assay in HEK-MOP cells 
 
Cell densities of 3x103, 104 and 2x104 cells/well and FSK concentrations from 0 to 
2x10-3 M in half log intervals were chosen for optimisation of assay conditions 
proposed by cAMP Alphascreen assay protocol. cAMP accumulation from cells 
plated at 3x103 and 104 cells/well was lower than required for inhibition experiments. 
The accumulation of cAMP increased with increased cell density. An optimal 
condition for cAMP Alphascreen assay was determined to be 2x104 cells/well and 
100 µM FSK in HEK-MOP cells (Figure 3.2). 
 
 
 
 
Figure 3.2 cAMP accumulation in response to varying density of HEK-MOP cells and FSK. 
Concentrations of FSK between 0 and 3x10
-3
 M in half log intervals were added to each well. HEK-
MOP cells were harvested with versene and adjusted to yield 3x10
3
, 10
4
 and 2x10
4
 viable cells/well. 
The data was plotted using one-site curve fitting using nonlinear regression analysis. The data is 
presented as mean ± SEM of an experiment replicates (n=3). 
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3.5.3. Determination of optimal cell density and forskolin concentration for 
cAMP Alphascreen assay in HEK-DOP cells 
 
Cell densities of 3x103 and 2x104 cells/well; FSK concentrations from 0 to 2x10-3 M 
in half log intervals, were chosen for optimisation of assay conditions. When a cell 
density of 3x103 cells/well was used, cAMP accumulation was lower than that 
required for inhibition experiments. The accumulation of cAMP increased 
proportionally with increased cell density. Optimal conditions for cAMP Alphascreen 
assay in HEK-DOP cells were determined to be 2x104 cells/well and 50 µM FSK 
(Figure 3.3). 
 
 
Figure 3.3.  cAMP accumulation in response to varying density of HEK-DOP cells and FSK. 
Concentrations of FSK between 0 and 3x10
-3
 M in half log intervals were added to each well. HEK-
DOP cells were harvested with versene and adjusted to yield 3x10
3
 and 2x10
4
 viable cells/well. The 
data was plotted using one-site curve fitting using nonlinear regression analysis. The data represents 
mean ± SEM of an experiment replicates (n=3). 
 
. 
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3.5.4. Screening of BE 1-31, BE 1-20, BE 1-17, BE 1-13,  BE 1-11, and BE 1-9 on 
the inhibition of forskolin-stimulated cAMP accumulation in in HEK-KOP cells 
 
Low and high concentrations (10 nM and 1 μM) of BE 1-31 and fragments (BE 1-9, 
BE 1-11, BE 1-17, and BE 1-20) were examined for their modulation of the 
accumulation of cAMP in HEK-KOP (Figure 3.4). U50,488H is a full agonist of the 
KOP receptor and was used as a positive control. U50,488H at a concentration of 10 
nM reduced cAMP level up to 24 %. In comparison, the low effect of BE 1-31 and its 
fragments on the cAMP production suggest that they do not effectively activate KOP. 
The IC50 values of BE 1-9, BE 1-11, BE 1-13 were greater than 1µM. The greatest 
inhibition of production of cAMP (45%) was shown with BE 1-17, BE 1-20, BE 1-31 
at 1 μM. 
 
  
Figure 3.4 Screening of BE 1-31 and fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-
20) for activity on cAMP modulation in HEK-KOP cells. Low concentration: 10 nM and High 
concentration: 1µM. The screening of BE 1-31 and its fragments were performed using 10
3
 cells/well 
with FSK (300 µM) to investigate the effect of BE 1-31 and fragments on the modulation of KOP by 
measuring the level of cAMP with Alphascreen cAMP assay. The data was analysed  using one-way 
ANOVA, post-test Bonferroni multiple comparison test, *P <0.05. The data represents mean ± SEM 
with n = 9. 
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3.5.5. Screening of BE 19-31, BE 20-31, and BE 29-31 on the inhibition of FSK-
stimulated cAMP accumulation in in HEK-MOP cells 
 
Concentrations of 10 nM and 1 μM of C-terminal fragments (BE 19-31, BE 20-31, 
and BE 29-31) were examined on modulation of cAMP in HEK-MOP cells (Figure 
3.5). C-terminal fragments did not show significant effect on modulation of cAMP. 
 
   
Figure 3.5. Screening of C-terminal fragments of BE 1-31 (BE 19-31, BE 20-31, and BE 29-31) 
for activity on cAMP modulation in HEK-MOP cells. Low concentration: 10 nM and high 
concentration: 1µM. The screening of selected C-terminal fragments of BE 1-31 were performed using 
2x10
4
 cells/well with FSK (100 µM) to investigate the effect of C-terminal fragments on activation of 
MOP by measuring the level of cAMP with Alphascreen cAMP assay. The C-terminal fragments of BE 
1-31 displayed very low potency at MOP. The data was analysed using one-way ANOVA, post-test 
Bonferroni multiple comparison test, *P <0.05. The data represents mean ± SEM with n = 9. 
 
 
3.5.6. Evaluation of concentration dependent cAMP inhibition by BE 1-31, BE 
1-17, BE 1-13, BE 1-11, and BE 1-9 in HEK-MOP cells 
 
To determine the agonist activity of BE 1-31 fragments (BE 1-9, BE 1-11, BE 1-13, 
and BE 1-17) on MOP receptors and the inhibition of cAMP production, the cAMP 
assay was conducted on HEK-MOP cells. The concentration-dependent effects of 
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selected peptide fragments on the inhibition of cAMP accumulation (stimulated by 
FSK) in HEK 293 cells expressing MOP receptors are shown in Figure 3.6.  BE 1-9 
showed partial agonist activity at MOP, as the inhibition efficacy of BE 1-9 in the 
cAMP assay was less than those of the other N-terminal fragments tested. The IC50 
value could not be calculated for BE 1-9. The IC50 values of fragments (BE 1-11, BE 
1-13, and BE 1-17) were not significantly different to that of BE 1-31 (P<0.05).  
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Figure 3.6. The concentration dependent cAMP inhibition of BE 1-9, BE 1-11, BE 1-13, BE 1-17, 
BE 1-20, BE 1-31, and fentanyl in HEK-MOP cells, concentrations of BE 1-31 and its fragments 
start from 0.3 nM to 1 µM in half log intervals.  HEK-MOP cells (2X10
4
 cells/well) were used to 
investigate the effect of BE 1-31 and its fragments on the activation of MOP by measuring the amount 
of cAMP with Alphascreen cAMP assay. FSK (100 μM) was used to stimulate the production of 
cAMP. The dose-response curves were plotted using one-site curve fitting in nonlinear regression 
analysis tools. 95% Confidence interval was implemented for comparison of IC50 of BE 1-31 and 
each fragment. The data represents mean ± SEM with n = 9. 
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3.5.7. Opioid antagonism of BE 1-31 fragments (BE 1-11, BE 1-13, BE 1-17, and 
BE 1-20) cAMP modulation in HEK-MOP cells 
 
To confirm the effect of BE 1-31 and its fragments (BE 1-11, BE 1-13, BE 1-17, BE 
1-20) on inhibition of cAMP production was acting through the activation of MOP, 
HEK-MOP cells were pre-treated with naloxone. The effect of BE 1-31 and 
fragments (BE 1-11, BE 1-13, BE 1-17) on accumulation of cAMP was inhibited 
when cells were pre-treated with naloxone. BE 1-31 and fragments (BE 1-11, BE 1-
13, and BE 1-17) in concentration of 50 nM inhibited the production of cAMP in HEK-
MOP cells in absence of Naloxone (Figure 3.7). 
  
 
Figure 3.7. The concentration dependent cAMP inhibition of BE 1-11, BE 1-13, BE 1-17, and BE 
1-31 in HEK-MOP cells after treatment with naloxone. FSK: FSK and no opioid peptide. No FSK: 
cells in the stimulation buffer (no opioid peptide and no FSK). HEK-MOP cells (2X10
4
 cells/well) were 
incubated with naloxone (100 µM) for 30 min followed by adding 50 nM of opioid peptide and FSK 
(100 μM). An alphascreen cAMP assay was used to measure the cAMP level. cAMP levels were 
significantly higher in naloxone treated cells than those in absence of naloxone. The data was 
analysed using one-way ANOVA, post-test Bonferroni multiple comparison test, *P <0.05. The data 
represents mean ± SEM with n = 9. 
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3.5.8 Evaluation of concentration dependent cAMP inhibition by BE 1-31, BE 1-
20, BE 1-17, BE 1-13, and BE 1-11, and BE 1-9 in HEK-DOP cells 
 
The effects of a range of concentrations of BE 1-31 and fragments (BE 1-9, BE 1-11, 
BE 1-13, BE 1-17, and BE 1-20) on FSK stimulated cAMP accumulation were 
studied using HEK-DOP cells (Figure 3.8). The full DOP agonist SNC80 was used as 
a positive control. All of the selected BE1-31 fragments in concentration of 1μM or 
greater were shown to be capable of activating the DOP, as expressed in the HEK 
cell line, and significantly reduced cAMP accumulation. BE 1-9, BE 1-13, BE 1-17, 
and BE 1-20 displayed greater potency in comparison to BE 1-31. The IC50 values 
of BE 1-9, BE 1-13, BE 1-17, and BE 1-20 were not significantly different in 
comparison to each other.  
 
  
103 
 
 
Figure 3.8. The concentration dependent cAMP inhibition of BE 1-9, BE 1-11, BE 1-13, BE 1-17, 
BE 1-20, BE 1-31, and SNC80 in HEK-DOP cells, concentrations of BE 1-31 and fragments start 
from 0.3 nM to 1 µM in half log intervals. HEK -DOP cells (2x10
4
 cells/well) were used to investigate 
the effect of BE 1-31 and its fragments on activation of DOP by measuring the amount of cAMP with 
an Alphascreen cAMP assay. FSK (50 μM) was used to stimulate the production of cAMP. The dose-
response curves were plotted using one-site curve fitting in nonlinear regression analysis. A 95% 
Confidence interval was implemented for comparison of IC50 of BE 1-31 and each fragment. The 
data represents mean ± SEM with n = 9. 
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3.5.9. Opioid antagonism of BE 1-31 fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-
17, and BE 1-20) cAMP modulation in HEK-DOP cells 
 
To confirm the activity of BE 1-31 and fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-
17, BE 1-20) on DOP, the effect of BE 1-31 and selected fragments on production of 
cAMP in pre-treated cells with naloxone was compared with the effect of BE 1-31 
and its fragments on production of cAMP in absence of naloxone. Stimulation of 
DOP (inhibition of cAMP) by BE 1-31 and mentioned fragments was prevented due 
to the naloxone block of DOP. All peptides tested inhibited the accumulation of 
cAMP in absence of naloxone. The effects of naloxone on the cAMP inhibition of BE 
1-31 and its metabolites; BE 1-17, BE 1-13, and BE 1-11 are depicted in Figure 3.9.  
 
 
 
 
Figure 3.9 The concentration dependent cAMP inhibition of BE 1-9, BE 1-11, BE 1-13, BE 1-17, 
BE 1-20, and BE 1-31 in HEK-DOP cells after treatment with naloxone. FSK: FSK and no opioid 
peptide. No FSK: cells in stimulation buffer (no opioid peptide and no FSK). HEK -DOP cells (2x10
4
 
cells/well) were incubated with naloxone (100 µM) for 30 min followed by adding 50 nM of opioid 
peptide and FSK (50 μM). Alphascreen cAMP assay was used to measure the cAMP level. cAMP 
levels were significantly higher in naloxone treated cells than those in absence of naloxone. The 
graph was analysed by using one-way ANOVA, post-test Bonferroni multiple comparison test, *P 
<0.05. The data represents mean ± SEM with n = 9. 
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3.5.10. Evaluation of cAMP modulation by a combination of N-terminal and C-
terminal fragments in HEK-MOP cells 
 
C-terminal fragments did not inhibit cAMP production in HEK-MOP cells as shown in 
Figure 3.5. To evaluate the possible modulatory effect of C-terminal fragments on 
the activity of N-terminal fragments at MOP; two N-terminal fragments were selected. 
BE 1-9, which showed partial agonist activity on MOP and BE 1-17, which displayed 
high potency in modulation of cAMP in HEK-MOP cells (Figure 3.6). To examine 
positive or negative modulatory effect of C-terminal fragments on activity of BE 1-9 
and BE 1-17, the cAMP assay was performed on HEK-MOP cells. The concentration 
dependent cAMP inhibition of the combination of BE 1-9 or BE 1-17 with 1 μM of C-
terminal fragments (BE 19-31, BE 20-31, BE 29-31) in HEK-MOP cells are shown in 
Figure 3.10, A and B, respectively. If the dose-response curve was shifted to the left, 
the C-terminal fragments would be considered as a positive allosteric modulator, 
whereas if the dose-response curve was shifted to the right, the C-terminals 
fragments would be negative allosteric modulators or antagonist. The results did not 
show any difference to concentrations curves for BE 1-17 or BE 1-9 with any 
combination of C terminal fragments. In as such, the IC50’s of BE 1-17 inhibition of 
the cAMP accumulation was not significantly different from those that examined the 
combination of BE 1-17 and C-terminal fragments (BE 19-31, BE 20-31, BE 29-31) in 
HEK cells stably expressed MOP receptors. IC50’s could not be determined for BE 
1-9 due to its partial agonism. 
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Figure 3.10 The concentration dependent cAMP inhibition of BE 1-9 and BE 1-17 mixing with C-
terminal fragments (BE 19-31, BE 20-31, BE 29-31) in HEK-MOP cells, HEK-MOP cells (2x10
4
 
cells/well) were used to investigate the effect of mixture of N-terminal and C-terminal fragment on 
activation of MOP by measuring the level of cAMP with an Alphascreen cAMP assay. FSK (100 μM) 
was used to stimulate the production of cAMP. A) Concentrations of BE 1-17 (1 nM to 1 µM in half log 
intervals) were examined with 1 µM of C-terminal fragments (BE 19-31, BE 20-31, and BE 29-31). B) 
Concentrations of BE 1-9 (1 µM to 1 nM in half log intervals) were examined with 1 µM of C-terminal 
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fragments (BE 19-31, BE 20-31, and BE 29-31). The dose-response curves were plotted using one-
site curve fitting in nonlinear regression analysis. The data represents mean ± SEM with n = 9. 
 
 
3.6. Discussion 
 
BE 1-31 is an endogenous opioid peptide, that produces central and peripheral 
analgesic actions. BE 1-31 has been suggested to produce its analgesic effects 
through activation of the MOP and DOP receptors (226). Blanc et al (227) defined 
BE 1-31 with three basic structural sections, a first section is BE 1-5, a highly specific 
opiate recognition sequence at the N-terminal. The second section is BE 6-12, 
hydrophilic peptide link. Finally, the third section is BE 13-31, a potential amphiphilic 
helix in the C-terminal. Distinctive feature of BE 13-31 is its basicity and having two 
aromatic residue Phe18 and Tyr27. BE 13-31 can form α and π helical conformation in 
aqueous buffered solution which affects the speed of degradation of BE 1-31 and 
opioid activity (227). As described in Chapter 2, three different types of fragments of 
BE 1-31, classified as N-terminal fragments, C-terminal fragments, and intermediate 
fragments were produced after biotransformation of BE 1-31 in homogenised 
inflamed tissue. Studies have shown that the N-terminal Tyr in position one of BE 1-
31 is necessary for high affinity binding to classical opioid receptors in order to have 
analgesic activity (81). Five N-terminal fragments were selected from the results in 
Chapter 2, as they presented higher MRT compared to other biotransformed N-
terminal fragments. The selected fragments were examined for their potential agonist 
activity at opioid receptors in stably expressing opioid receptor transfected cell lines. 
Assessing the activity of BE 1-31 fragments on opioid receptors may provide insight 
into the better understanding of opioid pharmacological actions during inflammatory 
response. The results from this study demonstrate that selectivity for the subtype of 
the opioid receptor is determined by the length of the peptide from the N-terminal 
tyrosine, as smaller fragments of BE 1-31 display higher potency at DOP. 
 
Characterisation of the activity of opioid agonists can be measured by assessment of 
inhibition of FSK-stimulated adenylyl cyclase activity due to activation of opioid 
receptors (228, 229). Among other pathways for analgesia, inhibition of adenylyl 
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cyclase mediates the analgesic effect of opioid agonists through MOP. This enzyme 
is responsible for the formation of cAMP (230, 231). Activation of opioid receptors 
results in the activation and dissociation of heterotrimeric G proteins and inhibition of 
adenylyl cyclase and consequently a reduction in cAMP production (232). Therefore, 
the inhibition of the production of cAMP by opioid ligands could be used as an index 
for assessment of their activity as a correlate of their analgesic effect (233).  
 
The current study demonstrated that the IC50 of cAMP accumulation of BE 1-11, BE 
1-13, and BE 1-17, were not significantly different from that of BE 1-31 in HEK-MOP 
cells. However, cAMP inhibition potency of BE 1-9 was significantly less than those 
of other N-terminal fragments in the same HEK-MOP cells. BE 1-9 displayed partial 
agonist activity, as BE 1-9 did not inhibit the cAMP accumulation to the same extent 
at a concentration of 1µM is reduced to that of BE 1-31. Full agonists bond with two 
or more amino acids on the receptor, while partial agonists interact with fewer amino 
acids on the receptor (234). Feldberg showed that the analgesic power of BE 1-9 (a 
fragment of porcine lepotropin) is very weak and short lasting (235).  HEK-MOP cells 
were also incubated with naloxone to block MOPs, prior to adding peptide fragments 
to confirm the activity of BE 1-31 and the examined fragments on cAMP inhibition 
was through MOP. The activity of BE 1-31 and BE 1-31 fragments (BE 1-11, BE 1-
13, BE 1-17, BE 1-20) on inhibition of cAMP accumulation was reversed by naloxone 
pre-treatment indicating that opioid fragments modulated cAMP through agonist 
activity at MOP. The effect of BE 1-9 on cAMP accumulation is consistent with the 
studies of Jaba et al. in which they demonstrated that the peptide interaction with 
MOP varies with the length of opioid peptide and the analgesic potency of opioid 
peptides is proportional to their peptide lengths (236).  The results of this Chapter 
may suggest that amino acids from 12-31 are not required for MOP activation, 
however, that amino acids 10 and/or 11 would be essential for MOP activation. 
 
DOP is an opioid receptor that is also involved in mediating analgesia in 
inflammatory pain.  The concentration effects of BE 1-9, BE 1-11, BE 1-13, BE 1-17, 
BE 1-20, and BE 1-31 on modulation of cAMP levels in HEK-DOP cells was 
examined. All of the selected fragments displayed high potency in inhibition of 
production of cAMP at a concentration of 1 µM. The results showed that, in contrast 
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to the partial agonist activity of BE 1-9 in HEK-MOP cells, the potency of the cAMP 
inhibition increases with the mentioned fragment in HEK-DOP cells. All the assessed 
BE 1-31 fragments contain similar amino acid sequence at their N-terminal to 
Enkephalin. Enkephalins possess the amino acid sequence of Tyr-Gly-Gly-Phe-
Met/Leu with high affinity for DOP. The similarity of amino acid sequences of the BE 
1-31 fragments to enkephalins may describe their high potency at DOP.  
 
It was demonstrated that DOP agonists could prevent neuronal injury and death in 
ischemia and hypoxia. Therefore, DOP ligands are introduced as a potential 
therapeutic strategy for neural therapies. However, the underlying signalling pathway 
of DOP in neuro-protection is not fully understood (237). As all N-terminal fragments 
of BE 1-31 examined in this study were potent at DOP, it is worthy to explore their 
activity on neuronal cell lines. The inhibition of cAMP production by BE 1-31 and all 
of the assessed fragments was reversed with pre-treatment with naloxone, a non-
selective opioid antagonist. Since HEK-DOP cells only express DOPs, the results 
confirm that all of the examined N-terminal fragments of BE 1-31 reduced cAMP 
accumulation by activating DOPs. 
 
 In this study, assessed fragments of BE 1-31and BE 1-31 showed interaction with 
both MOP and DOP. Interestingly, BE 1-9 showed partial agonist activity on MOP 
and full agonist activity at DOP. DOP agonists can increase the analgesic potency of 
MOP agonists and DOP antagonists can inhibit the progress of physical dependence 
and tolerance caused by MOP agonists (238) demonstrating the importance of 
developing  ligands with mixed opioid activity for both MOP and DOP.   
 
Unlike the potent effects of BE 1-31 and its fragments on the cAMP inhibition within 
HEK-MOP and HEK-DOP cells, these fragments had marked lower efficacy in HEK-
KOP cells (1000 times less effective than a selective KOP agonist, DYN A 1-17; data 
not shown), and therefore concentration-response analysis was not performed. Low 
concentrations of DYN have been shown to regulate pain processing through KOP 
located on spinal projection neurons. Furthermore, DYN A has been shown to play a 
role in epilepsy, addiction, emotional control and psychotic disorders through 
stimulation of KOP (90). 
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An allosteric modulator of opioid receptors may also be considered as a novel 
strategy for treatment of severe pain. Identification of allosteric modulator helps in 
development of agonists and antagonists of opioid receptor.  An investigation into 
the potential role for N and C-terminal fragments in allosteric activation was 
performed using a mixture of peptide fragments. Although C-terminal fragments do 
not bind to the orthosteric sites on opioid receptors it was hypothesised that they 
may inhibit or potentiate the action of N-terminal fragments through allosteric sites on 
opioid receptors (239). C-terminal fragments alone did not modulate cAMP. The 
results of this study did not show an increase or decrease in efficacy of N-terminal 
fragments on accumulation of cAMP in combination with C-terminal fragments. 
Identification of an allosteric modulator can be used for understanding the 
mechanism of opioid action at the opioid receptor (115).  
 
Using other techniques such as radioligand binding assay (RBA) provides further 
insight into the binding properties of N-terminal and C-terminal fragments of BE 1-31 
to the opioid receptors (240) in cells expressing different types of opioid receptors. In 
this assay, a radio-opioid peptide binds to a receptor to identify the receptor 
interaction such as the affinity of ligand for the specific opioid receptor (241).  RBA 
has been used to study the interaction of C-terminal fragments of BE 1-31 with a 
putative non-opiate binding site on the terminal SC56-9 complex of human 
complement (242). In addition, the assay enables an understanding of possible 
allosteric modulatory effects of C-terminal fragments. The C-terminal fragments of 
BE 1-31 may not modulate cAMP, but they may activate other pathways assuming 
these are related to opioid activities. 
 
Opioid receptors are proposed to form both homodimers (243) and heterodimers 
(244). They can form heterodimers with other opioid receptor types, chemokine 
receptors, serotonin receptors, and other GPCRs (245, 246). HEK cells expressing 
one of MOP, DOP, and KOP are useful for assessing the activity of a compound on 
a single opioid receptor type, which may exist as a monomer or oligomer since HEK 
cells are not neuronal cells. There will be differences attributed to the density of 
expression and/or in signal pathways between HEK cells and peripheral neurons. 
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Therefore, the effects of fragments on heterodimer form of opioid receptors were not 
evaluated in this study. It has been shown that MOP and DOP form heterodimeric 
and oligomeric complexes (247, 248). Heterodimerization of DOP and MOP exhibit a 
novel mechanism for modulation of receptor function and can be used as a novel 
strategy for treatment of pain and addiction (247). Certainly, DOP and MOP exist on 
the same neuron as illustrated by North et al (249) whether they exist as 
heterodimers and function as a heterodimer is still debated. Investigation of the 
activity of fragments on heterodimer form of opioid peptide may provide further 
insights into the pharmacology of BE 1-31 and the biotransformed fragments.  
 
MOP agonists are currently the most effective analgesic for the management of 
severe pain.  In this Chapter, the selected N-terminal fragments of BE 1-31, except 
BE 1-9, displayed an inhibitory effect on the modulation of cAMP in MOP. However, 
BE 1-9 showed better potency at DOP. DOP agonists are responsible for the 
regulation of analgesia, the autonomic system and mood driven behaviours. In 
summary, the study of the activity of BE 1-31 fragments demonstrates the role of 
tissue biotransformation in the modulation of cAMP. cAMP is a second messenger 
and acts as an important regulator in the modulation of inflammation and immunity 
(250, 251). cAMP Alphascreen assay is quite a robust for identifying the mode of 
action of each fragment at a specific receptor by measuring the level of cAMP 
accumulation accurately (252).  
 
3.7. Conclusion 
 
The results here demonstrate that N-terminal fragments of BE 1-31; BE 1-11, BE 1-
13, BE 1-17, BE 1-20 are capable of inhibiting FSK stimulated cAMP in HEK-MOP 
and HEK-DOP cells. The cAMP inhibition potencies of BE 1-11, BE 1-13, BE 1-17, 
BE 1-20 are not significantly different from that of BE 1-31 in HEK-MOP cells. BE 1-9 
displayed partial agonist activity at MOP and full agonist activity at DOP. BE 1-31 
and examined fragments displayed low potency at KOP. C-terminal fragments: BE 
19-31, BE 20-31, and BE 29-31, did not modulate cAMP in HEK-MOP cells. 
Furthermore, C-terminal fragments did not inhibit or potentiate the action of BE 1-9 
and BE 1-17 through allosteric sites on opioid receptors assessed by cAMP 
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Alphascreen assay. Examined N-terminal fragments of BE 1-31 can modulate cAMP 
in MOP and DOP like BE 1-31.  
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 : Effect of selected bio-transformed fragments of Chapter 4
BE 1-31 on IL-1β release from differentiated THP-1 cells 
 
 
4.1. Foreword 
 
This chapter describes the concentration dependent action of BE 1-31 fragments 
(BE 1-9, BE 1-11, BE 1-13, BE 1-17, BE 1-20, BE 19-31, BE 20-31) on the LPS 
induced release of IL-1β from differentiated THP-1 cells. In addition, the ability of BE 
1-31 fragments to modulate IL-1β release was evaluated in the presence of the non-
selective opioid antagonist naloxone to determine whether their IL-1β modulatory 
effect is mediated through opioid receptor. 
 
4.2. Introduction 
 
Monocytes and macrophages play a crucial role in the inflammatory response to 
invading pathogens (253). Anti-inflammatory monocytes possess a CD14+CD16- 
phenotype, whereas, classical pro-inflammatory monocytes possess a CD14+CD16+ 
phenotype (254). Pro-inflammatory monocytes express more TLR-4- a type of 
Pattern recognition receptors (PRRs) which is responsible to identify pathogen-
associated molecular patterns (PAMPs)- when compared to anti-inflammatory 
monocytes. During inflammation, monocytes migrate to the site of inflammation and 
differentiate to the M1 form of macrophages (pro-inflammatory, antimicrobial), 
through direct stimulation by granulocyte macrophage-colony stimulating factor (GM-
CSF) (255). M1 macrophages can be then converted to the M2 form (alternatively 
activated) through the stimulation of IL-10 and macrophage-colony stimulating factor 
(M-CSF) (255). The M2 form of macrophages is responsible for tissue repair (256). 
IL-1β, as described in greater depth in chapter 1 section 1.5.2, is an important pro-
inflammatory cytokine, which is released from macrophages during inflammation. 
LPS induces macrophages to release pro-inflammatory cytokines including IL-1β, 
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TNF-α, IL-6 through the TLR-4 signalling pathway (257).  IL-1β is produced in an 
inactive form with a molecular mass of 31 kDa.  IL-1β is released from the cytosol in 
an active form with a molecular mass of 17 kDa (150). Casp-1 is necessary for the 
secretion and proteolytic cleavage of pro-IL-1β (153). 
 
Pro-inflammatory cytokines such as IL-1β bind to cytokine receptors on immune cells 
to release endogenous opioid peptides (BE, DYN, ENK) that subsequently activate 
opioid receptors on sensory nerves to produce an analgesic effect (as described in 
chapter 1) (258). Furthermore, agonists of TLR-4 can induce opioid peptide release 
from monocytes and macrophages to inhibit inflammatory pain (259). It is apparent 
from the literature that pro-inflammatory cytokines modulate endogenous opioid 
peptide release, but, it is not yet established whether endogenous opioid can 
mediate cytokine release. The study on production of IL-1β is completely different 
from the study of the release of IL-1β. Previous research has studied the effect of BE 
1-31 on the production of IL-1β, whereas this thesis describes the effect of BE 1-31 
and its fragments on the release of IL-1β. 
 
There is a growing body of research demonstrating that opioids modulate innate and 
acquired immune responses. These responses include modulating several functions 
in macrophages such as the expression and synthesis of cytokines (260-265), 
phagocytosis (266, 267), superoxide formation (268), and nitric oxide production 
(269). Bian et al. showed that IL-1β and TNF-α production were inhibited by 
morphine in mouse peritoneal macrophages in vitro and this effect was not blocked 
by naloxone (260).  However, Roy et al. demonstrated an increased expression of 
the pro-inflammatory cytokines IL-6 and TNF-α with morphine at a concentration of 
50 nM and alternatively reduced expression of these two cytokines with morphine at 
a concentration of 50 µM in macrophages (270). Alicea et al, showed U50,488H, a 
selective KOP agonist, at a concentration of 1 nM produced a suppressive effect on 
the production of TNF-α and IL-1β in monocytes and macrophages, implying the 
involvement of KOP in modulating the function of monocytes and macrophages 
(264). The stimulatory effect of BE 1-31 on production of superoxide in human 
polymorphonuclear leukocytes was shown by Sharp et al. (268). Furthermore, the 
effect of different concentrations of BE 1-31 was evaluated on the modulation of IL-
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1β production in the immune cells (271, 272). As demonstrated in Chapter 2, BE 1-
31 had an increased susceptibility to hydrolytic degradation in inflamed tissue. The 
aim of this study was to discover the impact of BE 1-31 and selected fragments of 
BE 1-31 on the modulation of IL-1β release from macrophages. 
 
In this chapter, the effects of BE 1-31 and its fragments (BE 1-9, BE 1-11, BE 1-13, 
BE 1-17, BE 1-20, BE 19-31, and BE 20-31) on LPS-evoked IL-1β release were 
evaluated in differentiated THP-1 cells. Differentiated THP-1 cells were used as a 
macrophage phenotype model in this chapter to explore the activity of 
biotransformed fragments of BE 1-31 on inflammatory signal processes. The THP-1 
cells are widely used as an in vitro model for studying macrophage function and 
differentiation (273). This cell line has been used to study the secretion of pro-
inflammatory cytokines such as IL-1β, TNF-α, and IL-6 (274). The release of IL-1β 
was measured by IL-1β Alpha-LISA assay bead assay. The effect of selected N-
terminal fragments on IL-1β release was examined in the presence of the opioid 
antagonist, naloxone.  
 
 4.3. Materials 
 
THP-1 cells were a gift from Dr. Marie-Odile Parat. RPMI 1640 with L-glutamine and 
FBS (Fetal Bovine Serum) were purchased from PAA Laboratories GmbH, Australia 
and also Sigma-Aldrich, Australia. Streptomycin/penicillin was purchased from 
Invitrogen, Life Technologies, Australia.  BE 1-9, BE 1-17, BE 1-20, BE 19-31, and 
BE 20-31 were supplied from Auspep. Pty. Ltd; Australia. BE 1-11, BE 1-13, and BE 
1-31 were supplied from Mimotopes Pty. Ltd; Australia. Purity was greater than 95% 
for all peptides.  Phorbol 12-myristate 13-acetate (PMA) was purchased from 
Sapphire Bioscience Pty. Ltd., Australia. Naloxone was purchased from Sigma-
Aldrich, Australia. LPS was obtained from Enzo life Sciences, INC, NY, USA. Alpha-
LISA-IL-1β kit (AL220C) was supplied from Perkin Elmer, USA.  
 
Biorad protein assay: Tris. Base (T1503), Sodium chloride (S9888), Octylphenyl-
polyethylene glycol (IGEPAL), and sodium deoxycholate (≥97%, titration) were 
obtained from Sigma-Aldrich, Australia. Bio-Rad Protein Assay Dye Reagent 
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Concentrate (cat#500-0006) was purchased from Life science Company, NSW, 
Australia. 
 
Immuno-fluorescence: Formaldehyde molecular biology reagent (F8775-25ML), 
Normal goat serum (G9023), and triton X-100 were purchased from Sigma-Aldrich, 
NSW, Australia. Phosphate buffer saline (PBS) tablets, 100 ml were purchased from 
Amersco LLC, Solon, USA. Anti-CD11b antibody [EP1345Y] an52478 (rabbit 
monoclonal) and goat anti-rabbit IgG H&L (Alexa Fluor® 555) ab 150078 (polyclonal) 
were purchased from Abcam plc, Cambridge, UK. Extracellular anti-MOP receptor 
(polyclonal antibody) (0.8 mg/mL) and control peptide (0.4 mg/mL) were obtained 
from Biomol GmbH, Hamburg, Germany. Control peptide has the following amino 
acid sequence: Cys-Ser-Pro-Ala-Pro-Gly-Ser-Trp-Leu-Asn-Leu-Ser-His-Val-Asp-Gly-
Asn, corresponding to amino acid residues 22-38 of the rat MOP. 4',6-diamidino-2-
phenylindole (DAPI) were obtained from Sapphire Bioscience Pty. Ltd., Australia. 
Corning cell-bind 96 wells plates black, clear flat bottom were used for 
immunostaining. Blocking buffer was prepared containing 10xPBS (2.5 mL), normal 
goat serum (1.25 mL) in milli-Q water (21.25 mL). Antibody dilution buffer was 
prepared containing 10x PBS (4 mL), Triton-X-100 (120 µL), and bovine serum 
albumin (0.4 g) in milli-Q water (36 mL). 
 
 
4.4. Methods 
 
4.4.1. THP-1 cell culture 
 
THP-1 cells are monocytes derived from the peripheral blood of a 1 year old male 
patient with acute monocytic leukemia.  THP-1 cells are a human monocytic cell line 
grown in suspension. When culturing, cells were split every 6-8 days or when 
approximately 80% confluent. For splitting cells, the cells were directly added to 
RPMI containing 10% FBS with streptomycin and penicillin in a ratio of 1:10. Cells 
were sub-cultured into 75 cm2 flasks at 37  ͦC in a humidified 5% CO2 incubator. For 
long term storage of cells, cells were centrifuged at speed of 200 g for 6 minutes 
supernatant was discarded and the cells were re-suspended in media containing 
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40% RPMI, 50% FBS, and 10% DMSO. The resulting cell suspension was 
transferred to -20 freezers for 1-2 h and then stored at -80 for no more than 6 
months, or moved to liquid nitrogen for long-term cryopreservation.  
 
 
4.4.2. Differentiation of THP-1 cells  
 
When THP-1 cells achieved approximately 80% confluence, they were transferred to 
centrifuge tubes and then centrifuged at 200 g for 6 minutes. The media was 
removed and replaced with fresh RPMI containing FBS (10%) and streptomycin with 
penicillin (1%). The cells were counted using a hemocytometer and live cells 
indicated by trypan blue exclusion. Cells were seeded in 96 well plates at a desired 
density depending on the experiment. PMA (50 nM, optimized from preliminary 
studies) was used to induce the differentiation of THP-1 cells to macrophages for 48 
h. The media was changed after 24 h and replaced with fresh complete media 
containing 50 nM of PMA for another 24 h. 
 
4.4.3. Evaluation of PMA-induced differentiation of THP-1 cells  
 
THP-1 cells were cultured and differentiated as described in section 4.4.2. Cells 
were seeded in 96 well black plates with clear bottoms at density of 1.5x104 
cells/well. Six wells were allocated for PMA treatment and three wells were allocated 
for non-differentiated THP-1 cells. After 48 h incubation, the media was removed 
from each well and the cells were washed with PBS three times. Cells were fixed 
with formaldehyde 4% (30 μL/well) for 15 min at room temperature. Cells were rinsed 
3 times in PBS (100 μL/well) for 5 min. Blocking buffer was added (50 μL/well) for 1h 
incubation. While blocking the cells, anti-CD11b antibody (primary antibody) was 
prepared at a 1:150 dilution.  
 
Blocking solution was aspirated and diluted primary antibody (30 μL) was applied to 
each well. The plate was wrapped in foil in a humidified chamber and incubated over 
night at 4°C. Primary antibody was removed and the cells were rinsed three times 
with PBS (50 μL per well) for 5 min each. Goat anti-rabbit IgG H&L (secondary 
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antibody) was prepared at a 1:500 dilution and added 30 μL to each well and 
incubated for 2 h at room temperature in the dark. Unbound secondary antibody was 
then removed and wells were rinsed with PBS (50 μL) three times. For nuclear 
staining, stock aliquots of DAPI were prepared to obtain a concentration of 5mg/ml. 
DAPI was prepared from stock solutions using a 1:500 solution with antibody dilution 
buffer and covered with aluminium foil. DAPI was applied to each well (30 μL). The 
plate was covered with aluminium foil and left for 10 min. Each well was rinsed with 
PBS (50 μL) twice for 5 min each. PBS (50 μL) was added into each well and 
analysis was performed using a Nikon fluorescence microscope. The images were 
captured using TRITC emission filters (568-620 nm) and DAPI emission filters (450-
475 nm).  
 
 
4.4.4. Expression of MOP in differentiated THP-1 cells  
 
To determine the expression of MOP in differentiated THP-1 cells, refer to section 
4.4.3 for detailed methods; with the exception that for the polyclonal anti-MOP 
primary antibody was used instead of the primary antibody of CD11b.  Anti-MOP 
receptor primary antibody was prepared by diluting 1:150 and goat anti-rabbit IgG 
H&L (Alexa Fluor® 555) was prepared in a 1:700 dilution. For the negative control, 
anti-MOP antibody was pre-incubated with the control peptide (1 µg peptide per 1 µg 
antibody) over night and staining was performed as for the Anti-MOP receptor 
antibody alone (positive control).  
 
 
4.4.5. IL-1β alpha-LISA assay 
 
Human IL-1β analyte standard dilutions were prepared as per table shown in 
appendix 3.ii. Standards of IL-1β were prepared in RPMI containing FBS (1%). The 
human IL-1β analyte standard curve was shown in appendix 3.iii. The mixture of 
alpha-LISA anti-IL-1β acceptor beads (5 mg/ml) with biotinylated antibody (500 nM) 
anti-IL-1β in immunoassay buffer was prepared.  The streptavidin donor beads (80 
μg/mL) were prepared in immunoassay buffer separately. Both were kept under 
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subdued laboratory lighting. Collected samples (1 μL/well) were plated in 384-well 
microplates. Acceptor beads and biotinylated antibody (4 μL/well) were added to 
incubate for 60 minutes in the dark at room temperature.  After 1 h incubation, donor 
beads (5 μL/well) were added for 30 minutes incubation in the dark at room 
temperature. The plate was read using Enspire-Alpha 2390 multi-label reader 
(Perkin Elmer, Australia). 
 
4.4.6. Comparison of two different batches of LPS on release of IL-1β   
 
To compare the effect of two batches of LPS on IL-1β release, THP-1 cells were 
cultured and differentiated as described in section 4.4.2. The media was removed 
and the cells were washed three times with RPMI alone.  Cells were incubated with 
each batch of LPS at concentrations of 0.1 µg/mL and 1 µg/mL. Supernatants were 
collected periodically (1 h, 6 h, 12 h, and 24 h). The collected samples were 
centrifuged (6000 g for 20 min at 4 °C) for isolation of pellet cell debris and the 
supernatant collected. Samples were stored in -20°C freezer for alpha-LISA assay 
as described in section 4.4.5. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
4.4.7. IL-1β release from differentiated THP-1 cells in present of BE 1-31 and 
fragments  
 
To examine the effect of BE 1-31 and its fragments on modulation of IL-1β release, 
THP-1 cells (4x104 cells/well) were cultured and differentiated as described in 
section 4.4.2. After differentiation (48 h) of the THP-1 cells, opioid peptides (10 pM, 1 
nM, 0.1 µM) and LPS (1 µg/ml) were added to cells for 24 h incubation. The samples 
were collected and centrifuged at 6000 g for 20 min at 4 °C for the isolation of pellet 
cell debris. Supernatants were stored in -20°C freezer and subsequently analysed by 
alpha-LISA assay as described in section 4.4.5. 
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4.4.8. Naloxone modulation of IL-1β release from differentiated THP-1 cells in 
the presence of BE 1-31 and its fragments  
 
THP-1 cells (4x104 cells/well) were cultured and differentiated as described in 
section 4.4.2. The mixture of naloxone (10 μM) with LPS (1 µg/ml) was added to 
differentiated THP-1 cells along with different concentrations of opioid peptide (10 
pM, 1 nM, 0.1 µM). The samples were collected and centrifuged at 6000 g for 20 min 
at 4 °C for isolation of pellet cell debris. Supernatants were stored in -20°C freezer 
and subsequently analysed by alpha-LISA assay as described in section 4.4.5. 
 
 
4.4.9. Bradford assay protocol- Assessment of total protein content for plated 
THP-1 cells in culture 
 
To assess for consistency of cell density across wells and plates, protein lysis buffer 
was added to each well to cover the entire monolayer and incubated for 5 min. The 
monolayer cells were scraped by pipette tips and then were transferred to an 
Eppendorf tubes and vortexed for 30 sec, then incubated on ice for 20 min and then 
vortexed a final time. The samples were centrifuged at 6000 g at 4 °C for 20 min. 
The supernatant was gently transferred to a fresh tube. 
 
4.4.9.1 BSA standard curve 
 
Fresh BSA standards with concentration of 0.1, 0.2, 0.3, 0.4, 0.5 µg/µL were 
prepared from a BSA working solution (1 mg/mL) as per table in appendix 3. iv. 
 
4.4.9.2. Plate preparation of supernatant of total cell extract for assessment of 
total protein content for plated THP-1 cells 
 
BSA standards or sample (10 µL) were plated in duplicate in a round-bottom 96 well 
plate. The protein lysate was diluted in 1:3 or 1:5 if required. Distilled water was used 
as blank.  Bradford protein dye was diluted in a 1:5 ratio with distilled water. Diluted 
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dye (200 µL) was added to each sample with a multi-channel pipette. The 
absorbance was measured at 595 nm wavelength on Bio-rad iMark™ Microplate 
Absorbance Reader (catalog #168-1130). 
 
4.5 Results 
 
4.5.1. Identification of the macrophage marker CD11b, in differentiated THP-1 
cells  
 
To determine the presence of CD11b, as a macrophage marker, on differentiated 
THP-1 cells, the cells were stained with the monoclonal CD11 primary antibody and 
conjugated secondary antibody for visualisation. CD11b was not observed in 
undifferentiated THP-1 cells (Figure 4.1B). However, differentiated THP-1 cells 
expressed CD11b as shown at peak emission of 568 nM using a TRITC filter, 
indicating the cells had differentiated to a macrophage phenotype after 48 h of PMA 
exposure (Figure 4.1A). 
A B
 
Figure 4.1. Fluorescence microscopy images of CD11b expression in differentiated and non-
differentiated THP-1 cells. Differentiated THP-1 cells (A) and undifferentiated THP-1 cells (B). 
Fluorescence microscopy images (10x) showing CD11b expression by differentiated THP-1 cells (A). 
Cell nuclei are stained in blue (DAPI) and CD11b antibody immunoreactivity is shown in red (emission 
568 nM). CD11b was observed only on differentiated THP-1 cells (A). Scale bar: 20 µm. 
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4.5.2. Identification of MOP in differentiated THP-1 cells  
 
To determine the presence of MOP on differentiated THP-1 cells, an extracellular 
targeting MOP polyclonal antibody was utilized. The images of DAPI and TRITC 
filters were merged using a merging channel in the NIS-element AR 3.2 software 
(Figure 4.2). These images indicate that differentiated THP-1 cells, expressed MOP 
receptors at the cell surface (Figure 4.2, B and C). For a negative control, the MOP 
antibody was incubated with peptide control prior to being added to the differentiated 
THP-1 cells. The expression of MOP was not detected in the presence of peptide 
control, indicating the specific binding of MOP (Figure 4.2, E and F).  
 
A B C
D E F
 
Figure 4.2. Fluorescence microscopy images of MOP expression in differentiated THP-1 cells 
stimulated by PMA. Fluorescent microscopy images (10x) showing MOP expression by differentiated 
THP-1 cells stimulated by PMA using anti-MOP antibody (A,B,C). Fluorescent microscopy images 
(x10) showing differentiated THP-1 cells stimulated by PMA using pre-incubated peptide control and 
anti-MOP antibody (D,E,F). Nuclei in blue (DAPI) (A and D), MOP monoclonal antibody in red (TRITC) 
(emission 568 nm) (B and E), and overlay of DAPI and TRITC (C and F). Scale bar: 25 µm. 
 
4.5.3. Comparison of two different batches of LPS on the release of IL-1β  
  
Evidence from the literature suggests that different batches of LPS can stimulate 
PMA-induced macrophages to release different amounts of superoxide (275).  PMA-
differentiated THP-1 cells were induced by LPS to produce IL-1β. To compare the 
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effect of two available batches of LPS on IL-1β release, differentiated THP-1 cells 
were incubated with two different batches of LPS at two different concentrations (0.1 
µg/mL and 1 µg/mL). Supernatants were collected at different time points (1, 6, 12 
and 24 h). The LPS induced IL-1β release was increased significantly over the 
incubation time for both batches. LPS batch 2 was more potent than batch 1 at 
causing the release of IL-1β (Figure 4.3). Batch 1 was selected for the following 
experiments and for batch 1, an LPS concentration of 1 µg/mL provided an optimal 
response allowing for both inhibitory and excitatory activity to be ascertained. 
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Figure 4.3. Comparison of the effect of two batches of LPS on IL-1β release from differentiated 
THP-1 cells. Differentiated THP-1 cells (4x10
4
 cells/well) were incubated with two concentrations of 
LPS (0.1 µg/mL and 1 µg/mL) and culture media was collected periodically (1 h, 6 h, 12 h, and 24 h). 
Treatment with LPS batch 2 evoked a greater IL-1β release from the differentiated THP-1 for the 
same concentration. 
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4.5.4. Effect of BE 1-31 and fragments on the release of IL-1β in differentiated 
THP-1 cells  
4.5.4.1. BE 1-31 and its N-terminal fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-
17, BE 1-20) 
 
To study the effect of BE 1-31 and it N-terminal fragments on the release of IL-1β, 
selected fragments of BE 1-31 were incubated with differentiated THP-1 cells 
induced by LPS (1 μg/mL) for 24 h.  
 
A significant decrease in IL-1β release was observed when differentiated THP-1 cells 
treated with 0.1 μM of BE 1-9 (Figure 4.4, A), BE 1-11 (Figure 4.4, B), and BE 1-13 
(Figure 4.4, C). However, no effect was observed with the treatment of BE 1-9 at 
concentrations of 1 nM and 10 pM on the release of IL-1β. BE 1-11 at a 
concentration of 10 pM increased the release of IL-1β (Figure 4.4, B). BE 1-13 
increased the release of IL-1β at concentrations of 10 pM and 1 nM (Figure 4.4, C).   
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Figure 4.4. Release of IL-1β from differentiated THP-1 cells by BE 1-9, BE 1-11, and BE 1-13. 
Differentiated THP-1 cells (4x10
4
 cells/well) were used to study the effect of BE 1-9, BE 1-11, and BE 
1-13 on the release of IL-1β. The alpha-LISA assay was used to measure the level of IL-1β in the 
culture media after treatment of THP-1 cells with LPS (1μg/mL) and BE 1-9 (A) BE 1-11 (B), BE 1-13 
(C) in concentration of 10 pM, 1 nM, and 0.1 µM.  The data was analysed using a one-way ANOVA, 
with a Bonferroni multiple comparison post-test, (*P <0.05). The data represents mean ± SEM of three 
independent experiments in triplicate, n=9. 
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BE 1-31 fragments, BE 1-17, BE 1-20, and BE 1-31 were incubated with 
differentiated THP-1 cells stimulated with LPS. BE 1-17 (Figure 4.5, A), BE 1-20 
(Figure 4.5, B), and BE 1-31 (Figure 4.5, C) increased the release of IL-1β at 
concentration at 0.1 μM when compared to LPS (Figure 4.5). No effect was observed 
with BE 1-17 and BE 1-20 at a concentration of 1 nM and 10 pM on the release of IL-
1β (Figure 4.5, A, B). BE 1-31 increased the release of IL-1β at 1 nM and 0.1 μM 
(Figure 4.5, C) not seen with BE 1-17 and BE 1-20. 
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Figure 4.5. Release of IL-1β from differentiated THP-1 cells by BE 1-17, BE 1-20, and BE 1-31. 
Differentiated THP-1 cells (4x10
4
 cells/well) were used to study the effect of BE 1-17, BE 1-20, and 
BE 1-31 on the release of IL-1β. The alpha-LISA assay was used to measure the level of IL-1β in the 
supernatant after treatment of THP-1 cells with LPS (1μg/mL) and BE 1-17 (A), BE 1-20 (B), BE 1-31 
(C) at concentrations of 10 pM, 1 nM, and 0.1 µM. The data was analysed using one-way ANOVA, 
post-test Bonferroni multiple comparison test, (*P <0.05). The data represents mean ± SEM of three 
independent experiments in triplicate, n=9. 
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4.5.4.2. C-terminal fragments of BE 1-31 (BE 19-31 and BE 20-31) 
 
Fragments BE 19-31 and BE 20-31 were incubated with differentiated THP-1 cells 
stimulated with LPS. Although, no significant modulation on the release of IL-1β was 
observed with BE 19-31 at a concentration of 1 nM and 10 pM, BE 19-31 decreased 
the release of IL-1β at concentration of 0.1 μM in in comparison to LPS alone  
(Figure 4.6, A). BE 20-31 showed no significant modulation on the release of IL-1β at 
any examined concentration (10 pM, 1 nM, and 0.1 µM). 
 
 
Figure 4.6. Release of IL-1β from differentiated THP-1 cells by BE 19-31 and BE 20-31. 
Differentiated THP-1 cells (4x10
4
 cells/well) were used to study the effect of BE 19-31 and BE 20-31 
on the release of IL-1β. The alpha-LISA assay was used to measure the level of IL-1β in the 
supernatant after treatment of THP-1 cells with LPS (1μg/mL) and BE 19-31 and BE 20-31 at 
concentrations of 10 pM, 1 nM, and 0.1 µM. The data was analysed using one-way ANOVA, post-test 
Bonferroni multiple comparison test, (*P <0.05). The data represents mean ± SEM of three 
independent experiments in triplicate, n=9. 
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4.5.4.3. Fentanyl 
 
Fentanyl was selected in order to assess whether a selective MOP agonist can 
modulate IL-1β release through activation of MOP. Fentanyl displayed no significant 
modulation on the release of IL-1β at any examined concentration (0.1 μM, 1 nM and 
10 pM) (Figure 4.7) displaying modulation of IL-1β release was not mediated through 
MOP. 
 
 
 
Figure 4.7. Release of IL-1β from differentiated THP-1 cells by fentanyl. Differentiated THP-1 
cells (4x10
4 
cells/well) were used to study the effect of fentanyl on the release of IL-1β. The alpha-
LISA assay was used to measure the level of IL-1β in the supernatant after treatment of THP-1 cells 
with LPS (1μg/mL) and fentanyl at concentrations of 10 pM, 1 nM, and 0.1 µM.  The data was 
analysed using one-way ANOVA, post-test Bonferroni multiple comparison test).  Values represent 
mean ± SEM of three independent experiments in triplicate, n=9. 
  
131 
 
4.5.5. Protein concentration determination of differentiated THP-1 cells 
 
Protein assay was performed using the Bradford assay on differentiated THP-1 cells 
after collecting supernatant containing treatment of LPS and opioid peptides, as an 
indirect approximation of cell numbers of per well. The results showed the protein 
concentration was similar from well to well approximately 0.28 µg/µL indicating the 
even distribution of cells from well to well. The BSA calibration curve is shown in 
Appendix 3. v.  
 
4.5.6. The effect of naloxone on IL-1β release from differentiated THP-1 cells in 
the presence of BE 1-31 and fragments 
 
To determine the effect of BE 1-31 and fragments on release of IL-1β in presence of 
the non-selective opioid antagonist, naloxone, LPS-stimulated differentiated THP-1 
cells were incubated with selected fragments of BE 1-31 with naloxone for 24 h. The 
amount of IL-1β released was measured in the supernatant. Naloxone was used to 
block opioid receptors. The amount of IL-1β release was significantly reduced when 
differentiated THP-1 cells were incubated with LPS and naloxone in comparison to 
LPS alone. Naloxone did not block the effect of the BE 1-13 on the modulation of IL-
1β release, and the modulatory trend of IL-1β release is the same. However, the 
effect of naloxone on the modulatory effect of BE 1-9 and BE 1-11 on IL-1β release 
was not evident (Figure 4.8). 
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Figure 4.8. The effect of naloxone on IL-1β release from differentiated THP-1 cells in the 
presence of BE 1-9, BE 1-11, and BE 1-13. Differentiated THP-1 cells (4x10
4
 cells/well) were 
incubated with LPS (1μg/mL), naloxone (10μM) and opioid peptide (10 pM, 1 nM, 0.1 µM) to 
investigate the effect of naloxone on the release of IL-1β in present of opioid peptide and LPS. The 
alpha-LISA assay was used to measure the level of IL-1β in supernatant. Graph was analysed by 
using one-way ANOVA, post-test Bonferroni multiple comparison test, *P <0.05). The data represents 
mean ± SEM of three independent experiments in triplicate, n=9. 
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Naloxone did not block the effect of the BE 1-17 and BE 1-20 on IL-1β release, and 
the modulatory trend of IL-1β release is the same for BE 1-17 and BE 1-20 treatment 
without using naloxone. Given the effect of naloxone on baseline of IL-1β release 
value, it is difficult to interpret the impact of naloxone on BE 1-31 effect (Figure 4.9). 
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Figure 4.9. The effect of naloxone on IL-1β release from differentiated THP-1 cells in the 
presence of BE 1-17, BE 1-20, and BE 1-31.  Differentiated THP-1 cells were (4x10
4
 cells/well) 
incubated with LPS (1μg/mL), naloxone (10 μM) and opioid peptide in a concentration of 10 pM, 1 nM, 
and 0.1 μM to investigate the effect of naloxone on release of IL-1β in present of opioid peptide and 
LPS. The alpha-LISA assay was used to measure the level of IL-1β in culture media. The data was 
analysed using one-way ANOVA, post-test Bonferroni multiple comparison test, (*P <0.05). The data 
represents mean ± SEM of three independent experiments in triplicate, n=9. 
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4.6. Discussion 
 
After differentiation, THP-1 cells gain typical macrophage like adhesive ability and 
dendritic morphology (276). The differentiation process is complex and involves the 
expression and activation of several transcription factors. For example, membrane 
expression of CD11b, CD11c, and CD54 are significantly increased in differentiated 
THP-1 cells (276).  The expression of CD11b facilitates the phagocytosis of 
complement-opsonized particles (277). CD11b was selected as a macrophage 
biomarker to evaluate the level of differentiation of PMA- stimulated THP-1 cells in 
this study. CD11b was observed only in PMA treated THP-1 cells confirming the 
differentiation of THP-1 cells to the macrophage phenotype.  
  
Macrophages are also known to express opioid receptors, the expression of KOP 
and sigma opioid receptors on THP-1 cells was also demonstrated in separate 
studies using Reverse transcription-Polymerase chain reaction (RT-PCR) (278, 279). 
In this study, an extracellular MOP antibody was selected for identification of MOP 
on differentiated THP-1 cells, which revealed a highly conserved labelling across the 
cells in culture. This would suggest that differentiated THP-1 cells like that of other 
immune cells can express MOP. In this study, it was hypothesised that BE 1-31 may 
activate MOP on immune cells to modulate release of IL-1β. For this reason, the 
expression of MOP was assessed on differentiated THP-1 cells. 
 
Monocytes and macrophages can produce IL-1β. However, the level of IL-1β 
production between monocytes and macrophages can be different. Wewers et al. 
showed that the amount of LPS evoked the release of IL-1β from alveolar 
macrophages is lower than that from monocytes (280). Thus, the limitation in IL-1β 
release from alveolar macrophages appears to be due to a decrease in the 
processing and release of the IL-1β. However, in contrast the release of pro-
inflammatory cytokines (TNF-α and IL-6) from differentiated macrophages stimulated 
with LPS was shown to be higher than that from monocytes in other studies (281). 
Possible reasons for the inconsistent findings are that different studies could have 
resulted from different differentiation protocols and LPS purities (282). LPS can be 
contaminated with highly bioactive endotoxin protein leading to the activation of TLR-
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2. It has been shown that purification of LPS by phenol extraction can remove 
contaminating proteins and eliminate this activation (283). Both TLR-2 and TLR-4 
have been shown to induce the production of pro-inflammatory cytokines in the 
spinal cord, ultimately resulting in inflammatory pain (284). In this study, the release 
of IL-1β from monocytes was not assessed as the monocytes differentiate into   
macrophages in inflamed tissue and macrophages are responsible to defend body 
against foreign stimuli. 
 
The activity of BE 1-31 and selected fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, 
BE 1-20, BE 19-31, BE 20-31) were assessed on IL-1β release in LPS stimulated-
differentiated THP-1 cells. LPS incubation results in the accumulation of IL-1β in the 
cytosol, as well as acting as a weak stimulator for the maturation and release of IL-
1β (285). Treatment with BE 1-31 resulted in an increase in IL-1β release at a 
concentration of 1 nM and 0.1 µM. This finding confirms two earlier studies: Gein et 
al. showed that BE 1-31 enhanced the production of IL-1β at a concentration of 10 
pM-0.1 µM in an unfractionated leukocyte with or without LPS induction (272). 
However, BE 1-31 did not show a significant effect on modulation of IL-1β release at 
a concentration of 10 pM in the present study. The activity of BE 1-31, on IL-1β 
production and release were also assessed in bone-marrow-derived macrophages 
(271). BE 1-31 potentiated IL-1β production and release after stimulation of 
macrophages by LPS or silica. Cytokine production in macrophages depends on the 
differentiation level and the stimulus and type of cells utilised (276, 282).  
 
BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20 were major N-terminal fragments 
detected after biotransformation of BE 1-31 as described in Chapter 2. In this study, 
incubation of differentiated THP-1 cells with BE 1-17 and BE 1-20 caused an 
increased release of IL-1β similar to BE 1-31, however, this modulatory effect of BE 
1-17 and BE 1-20 was observed only at the relatively high concentration of 0.1 µM. 
In contrast, shorter N-terminal fragments (BE 1-9, BE 1-11, BE 1-13) showed the 
opposite effect, inhibiting IL-1β release from differentiated THP-1 cells at a 
concentration of 0.1 µM. The possibility for the decreased effect on the release of IL-
1β by BE 1-9, BE 1-11 and BE 1-13 at concentration of 0.1 µM, could be due to 
agonism at DOP. Tang et al demonstrated that D-Ala2-D-Leu5-enkephalin (DADLE), 
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a synthetic DOP agonist, could protect rats from sepsis, which was associated with 
the decreases in the serum levels of IL-1β (286). However, the results of Chapter 3 
examining the efficacy of the BE 1-31 fragments at the different opioid receptors in 
the cAMP assay found that BE 1-9 was the most potent agonist at DOP, but this 
fragment showed the weakest effect on the release of IL-1β. Biotransformation of BE 
1-31 may result in a range of fragments with differential effects on inflammatory 
mechanisms, this would mean also that any effect that alters processing of BE 1-31 
may in fact alter the net influence on inflammation.  
 
BE 19-31 and BE 20-31 were two of C-terminal fragments, which reside in inflamed 
tissue longer than other fragments (section 2.5.3). These two selected C-terminal 
fragments (BE 19-31 and BE 20-31) displayed different effects on IL-1β modulation. 
Although BE 20-31 did not show any modulation of IL-1β release, BE 19-31 reduced 
IL-1β release at a concentration of 0.1 µM similar to the effect of BE 1-9, BE 1-11, 
and BE 1-13. BE 19-31 does not possess Tyr at position 1 which is known for the 
opioid nature of BE 1-31 indicating the involvement of non-classical opioid receptor 
for the modulatory effect of BE 19-31 on IL-1β release In this instance. Moreover, 
fentanyl, a MOP agonist, did not change the release of IL-1β, which also indicates 
the likelihood of a lack of involvement for MOP in the modulation of IL-1β by BE 1-31 
and fragments in differentiated THP-1 cells. However, another possibility for the 
results of fentanyl could be that ongoing stimulation of MOP resulted in fentanyl 
being unable to activate MOP any further due to desenstisation. Desensitisation is 
defined as a progressive reduction of signal transduction that occurs more or less 
rapidly after opioid receptor activation depending on the agonist and the signaling 
pathway (287). However, it is unlikely that the effect of fragments on the release of 
IL-1β is due to desensitisation of MOP, as the amount of the release of IL-1β by 
opioid peptides was measured at different time points (data not presented in this 
thesis). A greater response to BE 1-31 fragments on the release of IL-1β was seen 
during this between 4h and 6 h exposure, when differentiated THP-1 cells were 
incubated with BE 1-11 and 1-13 (0.1μM) and LPS for 4 and 6 hours. 
 
Differentiated THP-1 cells treated with naloxone and LPS resulted in a reduction of 
IL-1β release. Activation of macrophages is the first phenomena in the body’s innate 
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immune reaction (288). Monocytes and macrophages are the major supplier of 
endogenous opioid peptides at the later stages of inflammation (5). However, recent 
reports suggest that in vitro differentiated M1 and M2 macrophages do not release 
opioid peptides in response to TLR-4 stimulation. The reason for this may be the 
lower expression of TLR-4 in differentiated macrophages under in vitro culture 
conditions (259). Based on mentioned finding, the possible explanation for the effect 
of naloxone on basal LPS stimulated IL-1β release could be the blockade of the 
effects of endogenously released peptides through blockade of TLR-4. 
 
Naloxone could not block the effect of BE 1-13, BE 1-17, and BE 1-20. However, the 
effect of naloxone on the modulation of IL-1β release with BE 1-9, BE 1-11, and BE 
1-31 was indistinct and the reason for that is the complex action of naloxone, which 
is a non-selective opioid antagonist. Moreover, naloxone has been shown to block 
the activation of TLR-4 signalling induced by LPS non-stereoselectively. Both the 
opioid antagonist (-)-naloxone and the non-opioid (+)-naloxone inhibit TLR-4 
signalling (289). There is a discrepancy between different studies in regards to opioid 
or non-opioid effect of BE 1-31 on the production of IL-1β. Gein et al. demonstrated 
that the effect of BE 1-31 on IL-1β could not be blocked by naloxone and naltrindole, 
a DOP antagonist, on unfractionated leukocytes (272). However, Apte et al. showed 
that the potentiating effects of BE 1-31 on LPS-induced IL-1 production/secretion 
was prevented by naloxone in bone-marrow-derived macrophages, implying an 
involvement of opioid receptors in this instance (271). The complexity of 
differentiation state, different activation methods, cell type and potential different LPS 
purity may account for these differences. Indeed, activation methods using PMA or 
zymosan as an activator for rabbit alveolar macrophages showed different 
modulatory effects with BE 1-31 on nitrite and reactive oxygen production in (290) 
highlighting the complexity of immune function in disease. In this study, PMA was 
used for differentiation of THP-1 cells to macrophages and pure LPS was used to 
remove the effect of contaminating proteins. However, further investigation is 
required to examine the potential signalling pathway in modulation of IL-1β release 
by BE 1-31 and its fragments. In addition, the biotransformation of peptides by 
differentiated THP-1 was evaluated for this study and the des-Tyr fragment was the 
only fragment produced after 24-hour incubation of peptide with differentiated THP-1 
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cells. Differentiated THP-1 cells may have an enzyme, which separates tyrosine from 
the N-terminal side of BE fragments. This finding confirms the non-opioid modulatory 
effect of opioid peptides on the release of IL-1β. As Tyr amino acid is necessary for 
the opioid activity of opioid peptides.  As shown in Chapter 2, BE 1-31 and its 
fragments are susceptible to rapid enzymatic degradation.  Schreiter et al showed 
that using bestatin and thiorphan as inhibitors for aminopeptidase N and neutral 
endopeptidase can locally suppress pain (65). 
 
The modulation of inflammatory signals is meditated by the activation of receptors 
both opioid and non-opioid. For instance, TLRs are involved in various types of pain; 
(inflammatory, chronic, and neuropathic) and modulation of TLRs impact on the 
progression of inflammation. TLR-2 and TLR-4 are expressed on all monocytes and 
macrophages and when LPS binds to the receptors, one result is the production of 
IL-1β. LPS mediates its function through activation of TLR-2 and TLR-4 in an 
inflammatory response with a greater effect mediated by TLR-4 than TLR-2. Since 
my findings indicate the involvement of non-opioid receptors in modulation of IL-1β 
by BE 1-31 and fragments. It maybe that this modulation occurs through the 
activation of TLR signalling pathway. For example, morphine-3-glucoronide is a 
metabolite of morphine with no known opioid receptor activity, however it has been 
shown to act at TLR-4, implying that opioids or their metabolites may activate TLR 
signalling pathways and impact pain (291).  
 
Increasing the understanding of the role of BE 1-31 and its fragments on cytokine 
modulation will provide further insight into the peripheral role of opioid in treating 
inflammatory pain and highlight new avenues of treatment. In future studies, the 
mechanisms involved in the modulation of IL-1β release by bioactive BE 1-31 
fragments would be helpful to understand how the body respond to inflammation.  
 
 
 
 
 
  
140 
 
4.7. Conclusion 
 
Incubation of differentiated THP-1 cells with LPS significantly increased the release 
of IL-1β in culture supernatant in a time dependent manner compared to the THP-1 
cells not stimulated with LPS. Examined N-terminal fragments of BE 1-31 can 
modulate IL-1β release in differentiated THP-1 cells. A significant decrease in IL-1β 
release was observed when shorter fragments of BE 1-31 (BE 1-9, BE 1-11, BE 1-
13) at concentrations of 0.1 μM when added to differentiated THP-1 cells-induced by 
LPS. In contrast, at the same concentration, BE 1-17, BE 1-20, and BE 1-31 
increased the release of IL-1β in differentiated THP-1 cells-induced by LPS. The 
modulation effect of BE 1-13, BE 1-17, and BE 1-20 on IL-1β was not reversed by 
naloxone, a non-selective antagonist of opioid receptors. However, the effect of 
naloxone on the modulation of IL-1β release with BE 1-9, BE 1-11, and BE 1-31 is 
not clear. Further investigation is required to examine the potential of TLR signalling 
pathway in modulation of IL-1β release by BE 1-31 and its fragments or explore 
other potential mechanisms involved in this modulatory effect. 
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 : Effect of BE 1-31 and selected bio-transformed Chapter 5
fragments on the modulation of NF-κB translocation 
 
 
5.1 Foreword 
 
This chapter describes beta-endorphin (BE 1-31) and its fragments (BE 1-9, BE 1-
11, BE 1-13, BE 1-17, BE 1-20) concentration dependent effects on the modulation 
of NF-κB translocation in differentiated THP-1 cells induced by LPS and also in 
differentiated SHSY5Y induced by TNF-α.  
 
5.2 Introduction 
 
NF-κB transcription factors are responsible for the expression of over 150 genes in 
different cellular processes (144, 292) including inflammation, cell proliferation, 
apoptosis, and immunity. As a consequence NF-κB transcription factors can be a 
potential target for the management of several diseases such as cancer, 
autoimmune disease (293, 294), Alzheimer’s (295), cardiovascular diseases, 
arthritis, pulmonary diseases (296), neurological diseases, and type 2 diabetes 
(297). NF-κB and IL-1β participate in the development of systematic chronic 
inflammatory disease such as type 2 diabetes. 
 
Opioids can modulate inflammation through NF-κB signalling pathways in both the 
neuronal and the immune system (298). For instance, morphine modulates the 
immune system through the modulation of IL-6, TNF-α, and NF-κB signalling 
pathways (270, 299). The precise mechanism for the regulation of NF-κB proteins by 
opioids remains largely unknown (298).  
 
Multiple stimuli including oxidative stress, TNF-α, IL-1β, bacterial products, viral 
products, and UV irradiation activate NF-κB proteins (300). The activation of NF-κB 
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protein is a multistep cascade. The first step is phosphorylation of IKK complex 
resulting in the phosphorylation of I-κB and the release of NF-κB (301). 
Consequently, unbound NF-κB protein translocate from the cytoplasm to the nucleus 
to induce the transcription of pro-inflammatory genes such as TNF-α and IL-1β (see 
chapter 1 section 1.5.1 for further reading). The activation of NF-κB is studied in 
different cell lines including fibroblasts, epithelial cells, and T and B cells (302). 
There are several mechanisms to inhibit the translocation of NF-κB proteins from the 
cytoplasm to the nucleus including the inhibition of the stimulus-triggered 
degradation of I-κB. For example, cannabinoids inhibit the activation of NF-κB 
proteins via this pathway (303). The second pathway is via the induction of the 
expression of I-κB resulting in retained NF-κB in the inactive form (304, 305). 
Morphine has been shown to induce I-κB in the human neuroblastoma cell line 
(SHSY5Y cells) which results in the inhibition of NF-κB protein activity-mediated 
induction of IL-8 mRNA (306). This induction of I-κB is mainly dependent on the 
activation of the transcription factor activator protein-1 (AP-1) (306).  
 
BE 1-31 can regulate aspects of the immune system through the modulation of pro-
inflammatory cytokines as described in chapter 1, section 1.6. BE 1-31 and 
fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, BE 1-20) can modulate the release 
of IL-β as described in chapter 4. Therefore, BE 1-31 and its major N-terminal 
fragments of BE 1-31, identified in chapter 2, may modulate NF-κB translocation in 
the inflammatory response. In the present study, the effect of BE 1-31 and its 
fragments was assessed on the modulation of NF-κB translocation. Differentiated 
THP-1 cells were used to study the effect of BE 1-31 and its fragments as a model 
for immune cells and differentiated SHSY5y cells were used as a model for 
peripheral neuronal cells.  
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5.3 Material 
 
THP-1 cells were a gift from Dr. Marie-Odile Parat, School of Pharmacy, The 
University of Queensland. RPMI 1640 with L-glutamine and FBS (Fetal Bovine 
Serum) were purchased from PAA Laboratories GmbH, Australia and also Sigma-
Aldrich, Australia. Streptomycin/penicillin was purchased from Invitrogen, life 
technologies, Australia.  SHSY5Y cells were a gift of Associate Professor Lesley 
Luka, School of Biomedical Science, The University of Queensland. Dulbecco’s 
Modified Eagle Medium (DMEM) was obtained from Sigma Aldrich, Australia. BE 1-
9, BE 1-17, and BE 1-20 were supplied from Auspep Pty.Ltd, Australia. BE 1-11, BE 
1-13, and BE 1-31 were supplied from Mimotopes Pty. Ltd; Australia Purity was 
greater than 95% for all peptides. PMA (Phorbol 12-myristate 13-acetate) were 
purchased from Sapphire Bioscience Pty. Ltd., Australia. Fentanyl was obtained from 
Astra Pharmaceuticals, Australia. N-(3,5-Bis-trifluoromethylphenyl)-5-chloro-2-
hydroxybenzamide (IMD-0354), dimethyl sulfoxide (DMSO), for molecular biology, 
and retinoic acid, > 98% powder were purchased from Sigma-Aldrich, Australia.  D-
Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr--NH2; Disulfide bridge: 2 – 7; (CTAP) was 
purchased from abcamBiochemicals®, Melbourne, Australia.  
 
Material for Immuno-fluorescence: Formaldehyde molecular biology reagent (F8775-
25ML), goat serum (G9023), triton X- 100 were obtained from Sigma-Aldrich, NSW, 
Australia. Anti-p65 NF κB primary antibody (rabbit monoclonal [E379]) and goat anti-
rabbit IgG H&L (Alexa Fluor® 555) ab 150078 were purchased from Abcam plc, 
Cambridge, UK. 4',6-diamidino-2-phenylindole (DAPI) were obtained from Sapphire 
Bioscience Pty. Ltd., Australia. Phosphate buffer saline (PBS) tablets, 100 ml were 
purchased from Amersco LLC, Solon, USA. Human Tumour necrosis factor- alpha 
(TNF-α) recombinant protein was purchased from Sapphire bioscience, NSW, 
Australia. Corning cell-bind 96 wells plates (black and clear flat bottom) were used 
for imageXpress.  
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5.4 Methods 
 
5.4.1. THP-1 cells tissue culture 
 
THP-1 cells were cultured as described in section 4.4.1. 
 
5.4.2. Induction of NF-κB translocation with LPS in differentiated THP-1 cells 
 
Cells were seeded and differentiated in Corning cell-bind 96 well black plates with 
clear bottoms at a density of 1.5x104 cells/well. The media was changed after 24 h 
and replaced with fresh complete media containing 50 nM of PMA. After 48 h of 
incubation, the media was replaced with media containing 2% FBS for 12 h of 
incubation. IMD-0354 is a NF-κB blocker and was used as a positive control to check 
the reliability of the assay. For this reason, cells were treated with IMD-0354 (10 µM) 
and LPS at two different concentrations (0.1 µg/mL and 1 µg/mL) for 1 h. To 
examine the effect of BE 1-31 fragments on modulation of NF-κB translocation, cells 
were treated with opioids and BE 1-31 fragments (10 nM and 1 µM) in combination 
with LPS (1 µg/mL) for 1 h incubation. Concentration of 1 µg/mL of LPS was 
selected as an optimised concentration for NF-κB translocation experiment. 
 
 
5.4.3. Antagonism effect of CTAP on modulatory effect of BE 1-31, BE 1-11, 
and BE 1-9 in differentiated THP-1 cells 
 
Culturing and differentiation of THP-1 cells were performed as described in section 
4.4.1. 12 h prior to agonist/antagonist treatment, the media was changed to that of 
media containing 2% FBS. Then, the culture media was removed and was replaced 
with media containing BE 1-31 or BE 1-11 or BE 1-9 (10 nM), CTAP (10 µM) and 
LPS (1 µg/mL) for 1 h.  
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5.4.4. Immuno-fluorescence of differentiated THP-1 cells for evaluation of NF-
κB translocation 
 
The fixation and staining of differentiated THP-1 cells were performed as described 
in section 4.4.3.  Anti-p65 NF-κB primary antibody was optimised to a 1:300 dilution. 
Goat anti-rabbit IgG (Alexa Fluor® 555) was optimised to a 1:700 dilution. 
 
Images of stained cells were acquired using the ImageXpress automated 
epifluoresence microscope (Molecular Devices) with a 10X objective, using the 
excitation and emission wavelengths 553 nm and 568 nm for Cy3/ NF-κB and 345 
and 455 nm for DAPI, respectively. Four images per well were captured. NF-κB 
translocation percentage was calculated for each image using MetaXpress software 
(v3.1.0.83, Molecular Devices). Cells were identified by DAPI nuclear staining and 
Cy3/ NF-κB labelling using the following parameters in imageXpress: minimum width 
(100 μm), maximum width (1000 μm), and intensity above local background (60). 
Translocation percentage is calculated based on correlation coefficient. This is the 
Pearson’s correlation coefficient of the pixel intensity of the two stains in the entire 
cell region (nucleus + gap + cytoplasm). This is typically the most robust method for 
classifying translocation. The value of correlation coefficient was optimised from the 
consultation with Molecular Devices Application Scientists. 
 
5.4.5. SHSY5Y tissue culture 
 
SHSY5Y cells are a human-derived cell line taken from the bone marrow biopsy of a 
patient with neuroblastoma and well-known in vitro model for peripheral neuronal 
cells (307-310). These cell lines grow into two forms, both as suspension and 
adherent forms. They were split every 4-5 days or when approximately 70% 
confluent. For splitting, 1 mL/75 cm2 of trypsin/EDTA was added to detach the cells 
from their flasks. Cells were incubated for 2-5 minutes at 37 °C with trypsin/EDTA. 
The detached cells were diluted in 5 ml DMEM containing 10% w/v FBS. Cells were 
split in ratios of 1:6 into T-75 cm2 tissue culture flasks (Corning life sciences) and 
they were sub-cultured into T-75 cm2 tissue culture flasks and kept in a 5% 
humidified CO2 incubator at 37 °C. Passage numbers from 6 to 14 were used in all 
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experiments. For long term storage, cells were detached by adding trypsin-EDTA, 
centrifuged at 350 g for 2 minutes and re-suspended in freezing media containing 
10% DMSO to culture media with 50% FBS. The resulting cell suspension was 
stored at -80 °C for up to a few weeks and then transferred into liquid nitrogen for 
long-term cryopreservation.  
 
5.4.6. Effect of BE 1-31 and its selected fragments on modulation of NF-κB 
translocation in differentiated SHSY5Y cells  
 
When SHSY5Y cells in the culture media achieved approximately 70% confluence, 
they were transferred to a centrifuge tube and then centrifuged at 350 g for 2 
minutes. The media was removed and replaced with fresh DMEM containing FBS 
(10%). The cells were counted using a haemocytometer and live cells were indicated 
by trypan blue exclusion. Cells were seeded in 96 well plates at a density of 104 
cells/well. Retinoic acid (10 μM) was used to induce the differentiation of SHSY5Y 
cells to a more neuronal cell phenotype by incubating for 6 days. The media was 
changed after 2 days and replaced with fresh complete media containing 10 μM of 
retinoic acid (311). On day 5, the media was changed with media containing 2% FBS 
to incubate for 12 h. Cells were then pre-treated with BE 1-31 fragments (at either 10 
nM or 1 µM) for 1 h. After 1 h of incubation, the culture media was removed and 
replaced with media containing opioids (10 nM and 1 µM) and TNF-α (20 ng/mL) for 
5 h.  
 
5.4.7. Antagonism effect of CTAP on modulatory effect of BE 1-31 and BE 1-17 
in differentiated SHSY5Y cells  
 
Culturing and differentiation of SHSY5Y cells were performed as described in section 
5.4.5. 12 h prior to agonist/antagonist treatment, the media was changed to that of 
media containing 2% FBS. Cells were treated with antagonist (CTAP, 10 µM) or 
without antagonist. After 1 h incubation, the culture media was removed and was 
replaced with media containing BE 1-31 or BE 1-17 (10 nM), CTAP (10 µM) and 
TNF-α (20 ng/mL) for 5 h.  
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5.4.8. Immuno-fluorescence of differentiated SHSY5Y cells for the evaluation of 
NF-κB translocation 
 
The immune-fluorescence of differentiated SHSY5Y cells and capturing images were 
performed as described in section 5.4.3.  
 
5.4.9. Statistical analysis 
 
Data was graphed using Prism 6.0TM and analysed by using one-way ANOVA, post-
test Bonferroni multiple comparison test).  (*P <0.05), Values represent mean ± SEM 
of three independent experiments. 
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5.5. Results 
 
5.5.1. The effect of IMD-0354 on modulation of NF-κB translocation induced by 
LPS in differentiated THP-1 cells  
 
A selective NF-κB blocker, IMD-0354, was used as a positive control for a reduction 
of NF-κB translocation induced by LPS. LPS at two concentrations (0.1 μg/mL and 1 
μg/mL) were incubated with differentiated THP-1 cells in presence of IMD-0354. The 
result shows IMD-0354 could block NF-κB translocation induced by LPS (1 μg/mL) 
significantly (Figure 5.1). 
 
 
 
Figure 5. 1. Effect of IMD-0354 on modulation of NF-κB in differentiated THP-1 cells induced by 
LPS. Differentiated THP-1 cells (1.5x10
4
 cells/well) were used to study the effect of IMD-0354 on the 
modulation of NF-κB translocation. ImageXpress automated epifluoresence microscope (Molecular 
Devices) was used to measure the percentage of NF-κB translocation after treatment of THP-1 cells 
with LPS (0.1μg/mL and 1μg/mL) and IMD-0354 at a concentration of 10μM. The graph was plotted 
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based on average of NF-κB translocation values for four images per well in triplicates for three 
independent experiments.  The data was analysed using one-way ANOVA, post-test Bonferroni 
multiple comparison test, (*P <0.05). The data represents mean ± SEM of three independent 
experiments, n=36. 
 
 
5.5.2. The effect of BE 1-31 and selected N-terminal fragments of BE 1-31 on 
modulation of NF-κB translocation in differentiated THP-1 cells  
 
To assess the effect of opioids on modulation of NF-κB translocation in differentiated 
THP-1 cells, BE 1-31 or selected fragments along with LPS were added to the cells 
for 1h of incubation. The nucleus is shown in dark blue in the negative translocation 
of NF-κB (differentiated THP-1 cells with no LPS), whereas NF-κB was observed in 
the nucleus in the positive control (differentiated THP-1 cells treated with LPS) 
(Figure 5.2).      
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Figure 5.2. Translocation of NF-κB in differentiated THP-1 cells confirmed by 
immunofluorescence. Differentiated THP-1 cells (1.5x10
4
 cells/well) were used to study the effect of 
BE 1-31 and selected fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20) on the 
modulation of NF-κB translocation. LPS was used to induce the translocation of NF-κB from 
cytoplasm to the nucleus. Positive controls represent differentiated THP-1 cells with LPS (1µg/mL), 
and negative controls represents differentiated THP-1 cells without LPS. Four images were captured 
per well and the image presented a representative image of four locations per well from three 
independent experimental replicates (10x). Cells were identified by DAPI nuclear staining (blue 
colour) (emission wavelengths 455 nm) and Cy3/ NF-κB (green colour) (emission wavelengths 568).  
Scale bar: 20 µm. 
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BE 1-9, BE 1-11, and BE 1-31 (10 nM) reduced NF-κB translocation significantly 
(Figure 5.3). BE 1-31 and the other examined fragments did not display any 
significant effect on modulation of NF-κB translocation induced with LPS in 
differentiated THP-1 cells (Figure 5.3). 
 
 
 
Figure 5.3. Effect of BE 1-31 and selected fragments of BE 1-31 on NF-κB translocation in 
differentiated THP-1 cells. Differentiated THP-1 cells (1.5x10
4
 cells/well) were used to study the 
effect of BE 1-31 and selected fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, BE 1-20) on the 
modulation of NF-κB. ImageXpress automated epifluoresence microscope (Molecular Devices) was 
used to measure the percentage of NF-κB translocation after treatment of THP-1 cells with LPS 
(1μg/mL) and selected fragments in concentration of 10 nM and 1 μM. The effect of Fentanyl (10 nM 
and 1μM) was also examined. The graph was plotted based on average of NF-κB translocation values 
for four images per well in three replicates for three independent experiments. The data was analysed 
using one-way ANOVA, post-test Bonferroni multiple comparison test, (*P <0.05). The data 
represents mean ±SEM, n=36.  
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5.5.3. The effect of CTAP in the reduced effect of BE 1-9, BE 1-11, and BE 1-31 
in NF-κB translocation induced by LPS in differentiated THP-1 cells 
 
To examine whether opioid receptors are involved in the reduction of NF-κB 
translocation by BE 1-31 fragments, CTAP was used as a selective MOP antagonist. 
CTAP by itself caused a reduction in NF-κB translocation induced by LPS. When 
differentiated THP-1 cells were treated with CTAP and BE 1-9 or BE 1-11 and LPS 
(1μg/mL) a similar decrease in the translocation of NF-κB was observed, as those 
cells were treated with BE1-9 or BE 1-11 and LPS only (Figure 5.4).  
 
 
Figure 5.4. Effect of CTAP, a MOP antagonist, on effect of BE 1-9, BE 1-11, and BE 1-31 on NF-
κB translocation in differentiated THP-1 cells. Differentiated THP-1 cells (1.5x10
4
 cells/well) were 
used to study the effect of MOP antagonist, CTAP, (10 µM) on the modulation of NF- κB translocation 
by BE 1-9, BE 1-11, and BE 1-31. ImageXpress automated epifluoresence microscope (Molecular 
Devices) was used to measure the percentage of NF-κB translocation after treatment of THP-1 cells 
with LPS (1μg/mL) and selected fragments in presence of CTAP. The graph was plotted based on 
average of NF-κB translocation values for four images per well in three replicates for three 
independent experiments. The data was analysed using one-way ANOVA, post-test Bonferroni 
multiple comparison test, (*P <0.05). The data represents mean ±SEM, n=36.   
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5.5.4. The effect of BE 1-31 and its N-terminal fragments on modulation of NF-
κB translocation induced by TNF-α in differentiated SHSY5Y cells  
 
To evaluate the effect of opioid peptides on NF-κB translocation in differentiated 
SHSY5Y cells, the cells were treated with TNF-α and BE 1-31 fragments. TNF-α was 
used as an activator for NF-κB translocation. The cells were stained with p65 
antibody and conjugated secondary antibody in order to examine the translocation of 
NF-κB from the cytoplasm to the nucleus. The nucleus was shown in dark blue in 
negative translocation of NF-κB (differentiated SHSY5Y cells with no TNF-α), 
whereas NF-κB was observed in the nucleus in the positive control (differentiated 
SHSY5Y cells treated with TNF-α) (Figure 5.5).   
 
    
 
Negative control Positive Control
 
Figure 5.5. Translocation of NF-κB in differentiated SHSY5Y cells confirmed by 
immunofluorescence. Differentiated SHSY5Y cells (10
4
 cells/well) were used to study the effect of 
BE 1-31 and selected fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, BE 1-20) on the modulation of 
NF-κB translocation. ImageXpress automated epifluoresence microscope (Molecular Devices) was 
used to measure the percentage of NF- κB translocation. TNF-α was used to induce the translocation 
of NF-κB from cytoplasm to the nucleus. Positive control represents differentiated SHSY5Y cells with 
TNF-α (20 ng/ml), and negative control represents differentiated SHSY5Y cells without TNF-α. Four 
images were captured per well and the image presented a representative image of four locations per 
well from three independent experimental replicates (10x). Cells were identified by DAPI nuclear 
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staining (blue colour) (emission wavelengths 455 nm) and Cy3/ NF-κB (green colour) (emission 
wavelengths 568). White arrows indicate the translocation of NF-κB from cytoplasm to the nucleus. 
Scale bar: 20 µm. 
 
 
All the examined N-terminal fragments of BE 1-31 in for both concentrations (10 nM 
and 1 μM) displayed a significant increase in NF-κB translocation in differentiated 
SHSY5Y induced by TNF-α (P<0.05) (Figure 5.6). 
 
 
 
Figure 5.6. Effects of BE 1-31 and selected fragments of BE 1-31 on NF- κB translocation in 
differentiated SHSY5y cells. Differentiated SHSY5y cells (104 cells/well) were used to study the 
effect of BE 1-31 and selected fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, BE 1-20) on the 
modulation of NF- κB. SHSY5y cells was pre-treated with selected fragments in concentrations of 10 
nM and 1 μM for 1h, followed by treatment of cells with a mixture of fragments with TNF-α for further 5 
h incubation. ImageXpress automated epifluoresence microscope (Molecular Devices) was used to 
measure the percentage of NF-κB translocation. The effect of Fentanyl (10 nM   and 1μM) was also 
examined.  The graph was plotted based on average of NF-κB translocation values for four images 
per well in three replicates for three independent experiments.  The data was analysed using one-way 
ANOVA, post-test Bonferroni multiple comparison test, (*P <0.05). The data represents mean ± SEM, 
n=36. 
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5.5.5. The effect of CTAP on the increased effect of BE 1-17 and BE 1-31 in NF-
κB translocation in differentiated SHSY5Y cells  
 
To examine whether opioid receptors are involved in the increased of NF-κB 
translocation by BE 1-31 or BE 1-17, differentiated SHSY5Y cells were incubated 
with BE 1-31 or BE 1-17, TNF-α, and CTAP. BE 1-31 and BE 1-17 (10 nM) displayed 
a small but significant increase in NF-κB translocation in differentiated SHSY5Y 
induced by TNF-α. In the present of CTAP, BE 1-17 and BE 1-31 does not increase 
the translocation of NF-κB significantly (Figure 5.7). 
 
 
 
 
Figure 5.7. Effect of CTAP, a MOP antagonist, on effect of BE 1-31 and BE 1-17 on NF- κB 
translocation in differentiated SHSY5y cells. Differentiated SHSY5y cells (10
4
 cells/well) were used 
to study the effect of MOP antagonist, CTAP, (10 µM) on the modulation of NF- κB translocation by 
BE 1-31 or BE 1-17 (10 nM). ImageXpress automated epifluoresence microscope (Molecular 
Devices) was used to measure the percentage of NF-κB translocation. The graph was plotted based 
on average of NF-κB translocation values for four images per well in three replicates for three 
independent experiments. The data was analysed using one-way ANOVA, post-test Bonferroni 
multiple comparison test, (*P <0.05). The data represents mean ± SEM, n=36.   
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5.6. Discussion 
 
This study examined the effect of BE 1-31 and its selected fragments (BE 1-9, BE 1-
11, BE 1-13, BE 1-17, BE 1-20) on the modulation of NF-κB translocation from the 
cytoplasm to the nucleus in two model cell lines. During the inflammatory response, 
NF-κB translocation is an initial response due to the activation of TLR-4 (312) or 
Tumour Necrosis Factor Receptor-1 (TNFR1), depending on the factor inducing NF-
κB translocation during inflammation. In this study, THP-1 cells, human monocytic 
cell line, were differentiated to the macrophage phenotype model in order to study 
the activity of selected BE 1-31 fragments on the modulation of NF-κB translocation 
in the immune cells. LPS was used to stimulate the translocation of NF-κB from the 
cytoplasm to the nucleus in differentiated THP-1 cells. LPS stimulates NF-κB 
signalling pathway through the activation of TLR-4 signalling pathway (313). 
Differentiated SHSY5Y cells displayed poor viability in the presence of low 
concentrations of LPS examined in this study (results not presented). Therefore, 
TNF-α was used instead to induce the translocation of NF-κB in the differentiated 
SHSY5Y cells. The translocation of NF-κB from the cytoplasm to the nucleus was 
analysed by the ImageXpress automated epifluoresence microscope (Molecular 
Devices).   
 
BE 1-9 and BE 1-11 significantly reduced the LPS-stimulated NF-κB translocation in 
differentiated THP-1 cells. These inhibitory effects of BE 1-9 and BE 1-11 may cause 
a reduced transcription of pro-inflammatory cytokines such as IL-1β. Therefore, this 
can be consistent with the modulation of BE 1-9 and BE 1-11 on the release of IL-1β 
shown in chapter 4. However, the difference of the NF-κB translocation study in 
chapter 5 from the IL-1β release study in chapter 4 should be considered, involving 
two different experimental methodologies despite receiving similar results. NF-κB 
translocation and the release of IL-1β could have two different signalling pathways. 
In this study, longer peptides such as BE 1-13, BE 1-17, BE 1-20 did not modulate 
NF-κB translocation in differentiated THP-1 cells, whilst modulating IL-1β release. 
Perhaps highlighting the difference in the mechanisms involved in the modulation of 
IL-1β release from NF-κB translocation. These different observations may be caused 
by differential selectivity at receptor types with shorter fragments of BE 1-31 as 
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observed in Chapter 3 and this may extend to other unknown interactions or 
mechanisms. Indeed, it is possible that the lack of modulatory effect of BE 1-13, BE 
1-17, and BE 1-20 on NF-κB translocation could be that these peptides may 
modulate NF-κB translocation in the presence of other cytokines (282, 314). 
Additional cytokines such as TNF-α may also be required to act synergistically with 
LPS to stimulate NF-κB translocation (282, 315). To investigate the mechanism 
underlying the reduction of NF-κB translocation by BE 1-9, BE 1-11, and BE 1-31, a 
MOP antagonist was used. When differentiated THP-1 cells were treated with CTAP 
and selected opioid peptide (BE 1-9 or BE 1-11 or BE 1-31) a similar decrease in the 
translocation of NF-κB was observed, as those cells were treated with BE1-9 or BE 
1-11 and LPS only. However, CTAP by itself caused a reduction in NF-κB 
translocation induced by LPS, which may display the possible connection between 
TLR-4 and MOP signalling pathways (316). It was not evident whether CTAP could 
block the decreased effect of BE 1-9, BE 1-11, and BE 1-31 on NF-κB translocation. 
 
The cell line selected as a model for peripheral neurons was the differentiated 
SHSY5Y cell. TNF-α was used to induce the translocation of NF-κB from the 
cytoplasm to the nucleus (301). This pro-inflammatory cytokine activates the 
degradation of I-κB protein in neurons and as such precipitate the translocation of 
NF-κB to the nucleus. Differentiated SHSY5Y cells are known to express classical 
opioid receptors (311), with the expression ratio of MOP to DOP reported to be 5 to 1 
(229). NF-κB transcription factor is involved in neuronal survival (317). Activation of 
MOP augments neuronal survival through a Gi/o –coupled, PI3K/Akt-dependent 
signalling cascade and hence involved in the stimulation of the NF-κB signalling 
pathway (318, 319). In addition, opioids are also thought to produce their anti-
apoptotic effects through modulation of the NF-κB signalling pathway (320).  
 
The opioid peptides were tested in isolation for their effects on the cells and the NF-
κB translocation was the same as negative control i.e. no effect. In this study, all the 
BE 1-31 fragments screened increased NF-κB translocation induced by TNF-α in 
differentiated SHSY5Y cells.  NF-κB transcription factor is important for initiating the 
inflammatory response and stimulation of these pathways results in the development 
of the inflammatory response. However, Lawrence et al. demonstrated that activation 
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of NF-κB pathway during the onset on inflammation could cause the recruitment of 
leukocytes, whereas activation of the NF-κB pathway during the resolution of 
inflammation, induces the expression of anti-inflammatory genes and the induction of 
apoptosis of inflammatory cells (147). The results in this study are consistent with 
findings in similar studies examining expression or phosphorylation of NF-κB 
transcription factor. For example, Liu et al. (320) showed that [D-Ala2, N-MePhe4, 
Gly-ol]-enkephalin (DAMGO), a MOP agonist, induced the phosphorylation of IKK, 
which resulted in stimulation of NF-κB signalling pathway in neuroblastoma SHSY5Y 
cells (320). Similarly, Hou et al. showed DAMGO induced the transcription factors 
AP1 and NF-κB activity in rat cortical neurons (321). Activation of both MOP and 
DOP causes an increase in nuclear transcription factor activator protein 1 (AP-1) 
(84). 
 
The selective MOP antagonist, CTAP, was used to identify the receptor involved in 
the modulatory effect of BE 1-31 and BE 1-17 on NF-κB translocation. BE 1-31 and 
its examined fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20) 
modulated cAMP in MOP and/or DOP as described in Chapter 3. Activation of opioid 
receptors results in the inhibition of adenylyl cyclase and a decrease in the level of 
cAMP. Activation of opioid receptors also activates MAP kinases in downstream 
signalling and several phosphorylation events targeting various transcription factors 
(83) which are involved in the activation of the NF-κB signalling pathway. CTAP 
reduced the stimulatory effect of opioid peptide or/and TNF-α on the translocation of 
NF-κB, However, the reduction of NF-κB translocation was not as significant as NF-
κB translocation produced by BE 1-31 or BE 1-17. Since, CTAP is a selective MOP 
antagonist; it is not able to antagonise the effect of BE 1-31 fragments through DOP. 
The antagonism effect of naltrindole, DOP antagonist, could not be evaluated in this 
study, as naltrindole alone increased the NF-κB translocation in TNF-α-treated 
differentiated SHSY5Y cells, data not shown. Opioids have been shown in the 
literature to either increase (320, 322) or decrease NF-κB activity (183, 299), 
perhaps the consequence of complex pharmacological specificity or mechanistic 
differences in different cell systems. For example, morphine inhibited NF-κB 
signalling in neuronal cells-stimulated by TNF-α via an AP-1 mediated induction of I-
κB. This inhibitory effect of morphine on NF-κB signalling was reversed by the opioid 
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receptor antagonist (306). However, morphine in another study displayed an 
increase in HIV-1 Tat-induced cytokine production in astrocyte through NF-κB 
transcription (322). The precise mechanism underlying the regulation of NF-κB by 
opioids is largely unknown and should be interpreted carefully due to its complexity. 
 
5.7. Conclusion 
 
BE 1-31 and its fragments (BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20) 
showed different activity on NF-κB translocation in two different cell lines. 
Differentiated THP-1 cells and differentiated SHSY5Y cells were selected as immune 
cells and neuronal cells, respectively. BE 1-9, BE 1-11, and BE 1-31 reduced NF-κB 
translocation induced by LPS in differentiated THP-1 cells. To investigate the 
mechanism underlying the reduction of NF-κB translocation by BE 1-9, BE 1-11, and 
BE 1-31, a MOP antagonist was used. As, CTAP by itself caused a reduction in NF-
κB translocation induced by LPS; it was not clear whether CTAP could block the 
decreased effect of BE 1-9, BE 1-11, and BE 1-31 on NF-κB translocation.  BE 1-31 
and selected fragments increased NF-κB translocation induced by TNF-α in 
differentiated SHSY5Y cells. CTAP reduced the stimulatory effect of opioid peptide 
or/and TNF-α on the translocation of NF-κB in differentiated SHSY5Y cells. The 
mechanism underlying the modulation of NF-κB translocation needs further 
investigation. 
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 : Overall Discussion and Conclusions Chapter 6
 
 
  
Peripheral analgesia during inflammation can be elicited from the action of 
endogenous opioid peptides on opioid receptors located on sensory neurons (323). 
These opioid receptors are expressed as a family of GPCR, namely; MOP, DOP, 
KOP, and NOP. These receptors are expressed not only within the central nervous 
system but also on peripheral sensory nerve terminals (81). BE 1-31, one of the 
most prominent endogenous opioid peptides, is produced in the pituitary gland (35), 
hypothalamus (24) and leukocytes (8). This endogenous peptide is a non-selective 
agonist for opioid receptors with the highest affinity for MOP and DOP. Through 
interaction with the MOP, BE 1-31 produces peripheral and central analgesic effects. 
During inflammation, the production of BE 1-31 is increased in leukocytes and 
released within inflamed tissue through a number of receptor specific mechanisms 
(5). Released BE 1-31, although most well-known for pain inhibition, can also 
modulate immunological and inflammatory responses through the modulation of pro-
inflammatory cytokines such as IL-1β. Inflammation is best described as a harsh 
chemical environment with increased activity of some enzymes. When BE 1-31 is 
released into this environment, it is rapidly biotransformed by enzymes such as ACE, 
aminopeptidase, DPP III, DPP IV, and serine peptidase (208). This thesis explores 
the bioactive role of the major fragments produced in inflamed tissue homogenates 
to gain an insight into the role of in vivo biotransformation in disease and pain 
modulation. For this reason the hypothesis of this thesis was that major N-terminal 
biotransformed fragments of BE 1-31 may reside in inflamed tissue longer than the 
parent molecule and produce a range of effects on analgesia and inflammatory 
signalling. 
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6.1. Biotransformation of BE 1-31  
 
BE 1-31 is broken down by peptidases which are released into inflamed tissue. In 
Chapter 2, rat paw inflamed tissue was collected and homogenised in MES buffer 
mimicking the acidic inflamed environment. Rat BE 1-31 was incubated in 
homogenised inflamed tissue at 37 °C and samples were collected and analysed by 
LC-MS. Since the biotransformation study was performed in tissue homogenates, 
some of intracellular enzymes are likely to be involved in the breakdown of peptides 
in the extracellular environment. In addition, the biotransformation of BE 1-31 was 
assessed in a rat tissue model but was not evaluated in human inflamed tissue.  In 
future studies, the biotransformation pathway of BE 1-31 in human inflamed tissue 
could be examined to ascertain the biotransformation of BE 1-31. 
 
BE 1-9, BE 1-11, BE 1-13, BE 1-17, and BE 1-20 were identified as the major N-
terminal fragments produced from this in vitro biotransformation. The subsequent 
further biotransformation of BE 1-11, BE 1-13, and BE 1-17 were examined 
individually to explore the fragmentation pattern of individual fragments. BE 1-31 and 
its major N-terminal fragments were transformed to several smaller fragments in 
homogenised inflamed tissue. It is possible that some of these BE 1-31 fragments 
may also be active in producing analgesia.  
 
6.2. Evaluation of the effect of BE 1-31 and its fragments on 
modulation of cAMP 
 
BE 1-31 had low stability in homogenised inflamed tissue, therefore leading to, the 
hypothesis that the major N-terminal biotransformed fragments may contribute to 
opioid activity. This was examined by looking at the modulation of cAMP 
accumulation in HEK cells overexpressing MOP, DOP, and KOP separately. 
 
The activation of opioid receptors causes the inhibition of adenylyl cyclase, which is 
responsible for the formation of cAMP. Consequently the reduction of cAMP 
prevents neurotransmitter release at the site of inflammation, and is then implicated 
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in the production of analgesia (324). Therefore, cAMP levels were measured as a 
marker for the agonism of opioid receptors by N-terminal fragments. However, the 
inhibition of cAMP is not the only cellular mechanism by which opioids cause 
analgesia. The effect of BE 1-31 fragments on inhibition of calcium channels, 
suppression of tertrodoxin-resistant Na+ channel and transient receptor potential 
vanilloid subtype-1 (TRPV1) (82, 83) could be future direction.  
 
BE 1-31 produces peripheral and central analgesic effects through interaction with 
the MOP and DOP. In this thesis the short N-terminal fragment of BE 1-31, that is BE 
1-9, was a partial agonist at MOP with selectivity for DOP and the other N-terminal 
fragments examined (BE 1-11, BE 1-13, BE 1-17, and BE 1-20) including BE 1-31 
displayed varying selectivity for MOP and DOP. BE 1-31 and all examined fragments 
(BE 1-11, BE 1-13, BE 1-17, and BE 1-20) displayed limited potency at KOP. In 
Chapter 3 of this thesis, the effects of BE 1-31 fragments were assessed on 
homodimers or monomers of opioid receptors expressed in cell systems. It has been 
recognised that opioid receptors can also form heterodimers of opioid receptor 
subtypes such as MOP/DOP or DOP/KOP (244). In addition, a mixture of fragments 
of BE 1-31 with selective activities for a specific opioid receptor may induce a 
synergistic analgesic effect or minimise side effects (212). Therefore, the activity of a 
single or a mixture of N-terminal fragments of BE 1-31 on a heterodimer form of 
opioid receptors could potentially be investigated to provide further information 
regarding the pharmacology of BE 1-31 and its biotransformation fragments. Indeed, 
agonists for opioid receptors that selectively target heterodimers of opioid receptors 
have displayed potent analgesic activity with decreased opioid side effects (325).  
 
My findings indicate that indeed N-terminal fragments can modulate cAMP at MOP 
and DOP like the parent molecule (BE 1-31) confirming that the attributed efficacy of 
BE 1-31 during inflammation may be in part produced by N-terminal fragments of BE 
1-31. These fragments may be an additional substrate substitute in modulating 
analgesia or inflammatory signals at different stages of inflammation.  Moreover, 
these fragments may possess activity outside that of cAMP modulation, this then led 
to the hypothesis that BE 1-31 and its major N-terminal fragments might also 
regulate inflammatory signals such as IL-1β release. 
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6.3. Evaluation of the effect of BE 1-31 and its fragments on 
modulation of IL-1β release 
 
BE 1-31 is found within the immune system and the CNS. There is some evidence 
for the action of BE 1-31 on immune cells and its subsequent role in the modulation 
of inflammatory signals (242, 326). These effects have been evidenced by the 
regulation of the release and expression of cytokines including IL-1β, IL-2, IL-8, and 
TNF-α (272, 327). This thesis has demonstrated in Chapter 4, that BE 1-31 
modulates IL-1β in LPS-activated differentiated THP-1 cells. This cell line was 
utilised as a model for studying the activity of BE 1-31 and its fragments on 
inflammatory signals in macrophages. The shorter fragments of BE 1-31 (BE 1-9, BE 
1-11, and BE 1-13) showed activities on modulation of IL-1β release that were 
different from those elicited by the longer BE 1-31 fragments and the parent 
molecule itself (BE 1-17, BE 1-20, and BE1-31). In addition, the effect of fragments 
and BE 1-31 on IL-1β was concentration-dependent. This may be potentially 
important since BE 1-31 fragments are produced via enzymatic processing in a time 
and concentration dependent manner at the site of inflammation. The findings of the 
present study indicate that each of N-terminal fragments studied may be responsible 
for the modulation of inflammatory signals at different stages of the inflammatory 
process. Furthermore in seeking to understand more about the mechanisms by 
which this modulation occurred I found that naloxone, a non-selective opioid 
antagonist, did not reverse the modulation of IL-1β by BE 1-13, BE 1-17, and BE 1-
20. However, the effect of naloxone on the modulation of IL-1β release with BE 1-9, 
BE 1-11, and BE 1-31 was distinct and the reason for that is the complex action of 
naloxone. The modulatory effect of the examined fragments on IL-1β release is likely 
to occur through a non-opioid mechanism.  It has been previously considered that 
the intermediate or C-terminal fragments of BE 1-31 may be responsible for non-
opioid activity of BE 1-31. However, in my study, the N-terminal fragments of BE 1-
31 displayed modulation of IL-1β release also through a non-opioid mechanism, a 
concept worthy of further investigation. In addition to the opioid receptors (MOP, 
KOP, DOP, NOP), several other non-opioid receptors are involved in analgesia 
during inflammation such as the TLR family of receptors (284) (TLR-2 (328), TLR-3, 
TLR-4 (259), and TLR-9 (299)). For example, morphine induces defects in TLR9-NF-
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κB signalling in the early response of alveolar macrophages to Streptococcus 
pneumoniae by modulating TLR-9-NF-κB signalling (299). The mechanism of such 
modulation of inflammatory signals including IL-1β release and NF-κB translocation 
by BE 1-31 and its biotransformed fragments will necessitate further investigations to 
elucidate the implication of TLR signalling pathway or other potential pathways.  
 
As shown in Chapter 2, BE 1-31 and its fragments are susceptible to rapid enzymatic 
degradation in an inflamed environment.  In addition, the biotransformation of BE  1-
31 fragment with differentiated THP-1 cell culture was evaluated for this study, and 
the des-Tyr fragment was the only fragment produced after a 24h of incubation. 
Therefore, studying the effect of BE 1-31 and its fragments on the release of IL-1β in 
the presence of inhibitors for aminopeptidase N and neutral endopeptidase such as 
bestatin and thiorphan (65) would be a future direction. 
 
My findings in this section are in agreement with my hypothesis, as N-terminal 
fragments can modulate IL-1β release in differentiated THP-1 cells and hence may 
contribute to possible inflammation modulatory effects in vitro model; albeit a specific 
mechanism remains to be elucidated. 
 
6.4. Evaluation of effect of BE 1-31 and its fragments on the 
modulation of NF-κB translocation 
 
IL-1β is the key activator of NF-κB, which is involved, in a large number of 
pathophysiological and physiological neuronal pathways.  NF-κB translocation is one 
of the initial responses in inflammation. BE 1-31 biotransformation fragments not 
only displayed individual  effects on IL-1β but they also showed differential activity on 
NF-κB translocation in different cell lines, as shown in Chapter 5. For this study, 
differentiated SHSY5Y and THP-1 cells were selected, as model cells for peripheral 
neurons and immune cells, respectively. These two model cell lines were then used 
in the evaluation of the activities of BE 1-31 and a number of selected fragments 
against NF-κB translocation. In differentiated SHSY5Y cells, BE 1-31 and fragments 
(BE 1-13, BE 1-17, and BE 1-20) showed significantly increased NF-κB 
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translocation. It is plausible that BE 1-31 and biotransformed fragments may have 
modulated NF-κB translocation through opioid or non-opioid receptors in 
differentiated SHSY5Y cells. However, the modulatory effect of BE 1-31 and its 
fragments on NF-κB translocation was observed in differentiated THP-1 cells only for 
BE 1-31 and the fragments BE 1-9 and BE 1-11. These results identify a variability in 
activities of fragments on the modulation of NF-κB translocation in the both 
differentiated THP-1 and SHSY5Y cell lines indicating the possibility of distinct 
mechanisms for the modulation of inflammatory signals in both immune and 
neuronal cells in vitro model and highlighting the requirement of experiments to 
confirm these results in systems that more closely resemble interaction between 
immune cells and peripheral sensory neurons in vivo. The evaluation of analgesic 
activity of BE 1-31 fragments in animal model of nociception and inflammation can 
be future directions. Formalin, capsaicin, complete Freund’s adjuvant, urate crystals 
and zymosan can be used for inflammatory assays featuring behavioural responses 
(329). 
 
BE 1-31 exerts a range of other biological effects in addition to that of analgesia. It 
has been shown to produce these effects through activation of opioid or non-opioid 
mechanisms, with the consequence of altered T cell proliferation (190, 330), 
chemotaxis (189), modulation of blood pressure (331), modulation of avoidance 
behaviour (215), and suppression of plaque forming cells (PFC) (332). For example, 
the effect of the BE fragments BE 2-9, BE 2-16, and BE 2-17 on the alteration of 
avoidance behaviour has been examined previously (213) . Albeit, the study of the 
effect of major N-terminal fragments of BE 1-31 was focus of this study, the other 
intermediate and C-terminal fragments of BE 1-31 found in this study could also be 
implicate in the modulation of these types of effects and could be appropriately 
studied in this regard. Biotransformation to these bioactive fragments may explain 
some of the off-target effects produced by BE 1-31.  
 
Biologically active biotransformed fragments may potentially be used for local 
administration to act peripherally (selective targeting) to manage inflammatory pain. 
This strategy avoids central side effects that are usually observed with clinically 
available opioids including addiction, tolerance, apnoea, etc. However, to 
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successfully utilise this strategy in future studies, further biotransformation in vivo 
issues and delivery would have to be examined. 
 
6.6. Conclusion 
 
The identification of BE 1-31 fragments and understanding their roles can provide 
insights into mechanisms that are involved in inflammation and pain pathways. The 
fragments of BE 1-31 identified in this thesis may produce effects on the 
inflammatory signalling pathways at different stages of inflammation, from an initial 
stage until the final resolution of inflammation which require to be confirmed in vivo. 
In conclusion, the study of the effect of biotransformed fragments of BE 1-31 reveals 
the role of tissue biotransformation in inflammatory response and provides further 
insight into how the body manages pain and inflammation.
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Appendix 1- Mass spectra of degradation of BE in inflamed 
tissue (pH: 7.4). 
 
 
i) Mass spectra of water 
 
 
ii) Mass spectra of homogenised inflamed paw tissue 
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iii) Mass spectra of BE after incubation in inflamed tissue (pH: 7.4,  0min) 
 
 
 
iv) Mass spectra of BE after incubation in inflamed tissue (pH: 7.4,  30min) 
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v) Mass spectra of resulting BE 6-16 after incubation of BE in inflamed 
tissue (pH: 7.4). 
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vi) Mass spectra of resulting BE fragments, BE 3-16, BE 5-18 after 
incubation of BE in inflamed tissue (pH: 7.4). 
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vii) Mass spectra of resulting BE fragments, BE 6-17, BE 7-17, BE 8-17 after 
incubation of BE in inflamed tissue (pH: 7.4). 
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viii) Mass spectra of resulting BE fragments, BE 6-18, BE 7-18 and BE 8-18 
after incubation of BE in inflamed tissue (pH: 7.4). 
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Appendix-2- Mass spectra of degradation of BE 1-31 in 
inflamed tissue (pH: 5.5) 
 
 
i) Mass spectra of BE after incubation in inflamed tissue (pH: 5.5, 0min) 
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ii) Mass spectra of BE after incubation in inflamed tissue (pH: 5.5, 5min) 
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iii) Mass spectra of resulting BE 1-31 fragment, BE 20-29 after incubation of 
BE 1-31 in inflamed tissue (pH: 5.5). 
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iv) Mass spectra of resulting BE 1-31 fragment, BE 20-24 after incubation of 
BE 1-31 in inflamed tissue (pH: 5.5). 
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v) Mass spectra of resulting BE 1-31 fragment, BE 6-16 after incubation of 
BE 1-31 in inflamed tissue (pH: 5.5). 
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vi) Mass spectra of resulting BE fragment, BE 1-15 after incubation of BE in 
inflamed tissue (pH: 5.5). 
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vii) Mass spectra of resulting BE 1-31 fragment, BE 1-20 after incubation of 
BE 1-31 in inflamed tissue (pH: 5.5). 
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viii) Mass spectra of resulting BE fragment, BE 10-31 after incubation of BE 1-
31 in inflamed tissue (pH: 5.5). 
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Appendix-3- Supplementary data for preparing reagents for 
standard curves 
 
cAMP serial dilution  
 
Serially dilute 50 µM cAMP standard solution as given below to provide a 
concentration range from 5x10-6 to 5x10-11 M in ½ log intervals. Include a positive 
control (no cAMP). 
 
 
i) cAMP serial dilution for standard curve 
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Lyophilised human IL-1β (0.1 µg) was reconstitute in 100 µL H2O and standard 
dilutions was prepared as follows: 
Tube Vol of human IL-1β (µL) Vol of diluent (µl) Human IL-1β in 
standard curve(g/ml in 
5µl) 
A 5µL of reconstituted 
human IL-1β 
45 1E-08 
B 30µl of tube A 70 3E-09 
C 30µl of tube B 60 1E-09 
D 30µl of tube C 70 3E-10 
E 30µl of tube D 60 1E-10 
F 30µl of tube E 70 3E-11 
G 30µl of tube F 60 1E-11 
H 30µl of tube G 70 3E-12 
I 30µl of tube H 60 1E-12 
J 30µl of tube I 70 3E-13 
ii) Human IL-1β analyte standard dilution 
 
 
iii)  Human IL-1β analyte standard curve 
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An aliquot of the 10 mg/mL BSA stock was thawed out to prepare a 1 mg/mL BSA 
working solution. Fresh BSA standards were prepared as outlined in the following 
table: 
H2O (µl) Serial dilution 
Volumes (µl) 
Total volume (µl) Final BSA 
concentration  
(mg/ml or µg/µl) 
75 75 µl of 1mg/ml 150 0.5 
30 120 µl of 0.5mg/ml 150 0.4 
30 90 µl of 0.4mg/ml 120 0.3 
40 80 µl of 0.3mg/ml 120 0.2 
40 40 µl of 0.2mg/ml 80 0.1 
iv)   BSA standard dilution for determination of protein concentration 
 
 
 
 
v. BSA standard curve for determination of protein concentration 
 
y = 1.1196x 
R² = 0.9979 
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